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Acute lymphoblastic leukaemia (ALL) has the highest mortality rate in childhood cancer. 
Glucocorticoids (GCs) have been used as chemotherapeutic drugs for children with ALL for 
more than 50 years. GCs induce apoptosis in lymphoid cells. However, little is known about 
the molecular mechanism of GC-induced apoptosis and there are many controversial 
hypotheses about genes regulated by GCs and their gene networks. In particular, two main 
issues are investigated: (i) GC-regulated genes and (ii) the glucocorticoid receptor (GR) gene 
networks. Only few overlapping genes have been reported from previous studies. Moreover, 
GCs function by binding with their receptors. The underlying mechanisms of cell type 
specific GR gene networks are not well established.  
 
The goal of this thesis is to understand the mechanism of the GC-induced apoptosis 
mechanism. The first part of this thesis presents an identification of GC-regulated genes. This 
study uses secondary microarray data, originating from prednisolone (glucocorticoid) treated 
childhood ALL samples (Schmidt et al., 2006) (B-linage and T-linage) that were collected 
before treatment and at six and twenty four hours after treatment. We replicate the authors‘ 
original study and discover more probe sets including all the probe sets from that original 
study. This result shows the robustness of this data. Then, we extend the data analysis and 
propose new criteria based on differences between T- and B-ALL patients. The results reveal 
the proposed GC-regulated genes. These candidate genes are grouped in order to find similar 
expression patterns which lead to possible co-regulated genes, or similar function and sharing 
networks and pathways. Four emergent clustering methods are used: Self organising maps 
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(SOM), Emergent self organising maps (ESOM), the Short Time series Expression Miner 
(STEM) and Fuzzy clustering by Local Approximation of MEmbership (FLAME). These 
genes are used in the following gene expression analysis step. 
 
The second part of this thesis focuses on inferring gene networks of GC-regulated genes and 
GR. There are many tools available for inferring gene networks including mathematical 
modelling and statistical methods. Each tool has its own advantages and disadvantages. For a 
modelling method, how do we know that the model represents the true relationship or 
interaction among genes? The need to verify results from modelling still exists. Prior 
knowledge has been used for this purpose. In this study, we use literature knowledge-based 
network tools, mainly the Ingenuity Pathway Analysis software (IPA) to elucidate gene 
networks. First, we illustrated gene networks at three time intervals and identified the 
prominent genes during those time points. Second, we further elucidated GR gene networks 
using gene lists from STEM. Third, we investigated the behaviour of selected known genes 
from the apoptosis, p53 and NFB pathways and inferred gene networks from the selected 
genes. Fourth, we inferred GR gene networks using the same gene list from previous studies 
(Phillip et al., 2005). We also used another two network tools: the BiblioSphere Pathway 
Edition (BSPE), and Oncomine to enhance the reliability of the gene network. Finally, we 
propose a GR gene network.  
 
In summary, we undertook a gene to gene network of GC-induced apoptosis process based on 
childhood leukaemia patients. This study identified novel genes and their functions, and 
pinpointed possible gene networks which provide information for future research. 
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microarray; emergent self organising maps; Fuzzy clustering by Local Approximation of 
MEmbership; gene expression; glucocorticoids; glucocorticoid receptor; Ingenuity Pathway 
Analysis software, Oncomine; prednisolone; short time series clustering, Short Time series 
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    Chapter 1 
Introduction 
 
Cancer is a leading cause of death in the world human population. One of cancer treatment 
process is chemotherapy. Chemotherapeutic agents kill abnormal cells; in other words, they 
activate the cell death programme (the apoptosis process). The knowledge of this process 
plays an important role in cancer therapy and there has been intensive research into different 
aspects of apoptosis in relation to cancer including uncovering the underlying mechanism of 
the apoptosis process. This research explores the glucocorticoid-induced apoptosis 
mechanism in childhood leukaemia using short time series gene expression data. In this 
chapter, childhood leukaemia and glucocortocoids are explained in detail and microarray data 
analysis and inferring gene networks from microarray data are reviewed. The research 
objectives are outlined and an overview of the thesis chapters is presented. 
 
1.1 Childhood Leukaemia  
 
White blood cells cancer, or leukaemia, starts in the bone marrow where the white blood cells 
are produced. The underlying causes of leukaemia remain unclear; however, there are risk 
factors indicated for some types of leukaemia including radiation, chemical, genetic problems, 
and smoke. The symptoms usually vary with the type of leukaemia but there are some 
common symptoms; for example, fever, headaches, easy bruising or bleeding, pain in the 
bones or joints and weight loss. There are two main groups of leukaemia: childhood and adult 
leukaemia. Childhood leukaemia can be divided into two types: acute (rapidly growing) or 
chronic (slow growing) but most childhood leukaemia is acute. There are two groups of acute 
leukaemia: acute lymphoblastic leukaemia (ALL) and acute myelogenous leukaemia (AML). 
Within these groups there are two subgroups of ALL: T-lineage and B-lineage. Chemotherapy 
(using drugs to kill cancer cells or stop cell division) is the most common treatment for 
children with ALL. The drug and dosage combinations may vary for each child. 
Unfortunately, chemotherapy treatments may result serious short- and long-term side effects.  
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Glucocorticoids are a type of steroid hormone. Synthetic glucocorticoids such as 
dexamethasone (Dex) and prednisolone (PRD) are the most important drugs that have been 
used extensively in the treatment of children with acute lymphoblastic leukaemia because of 
their ability to induce apoptosis (cell death) in the lymphoid cells. GCs enter the cell 
membrane and bind with the glucocorticoid receptor (GR), a member of the nuclear receptor 
subfamily 3, group C, also known as NR3C1, in order to induce apoptosis. The 
glucocorticoid-GR (GC-GR) complex then translocates to the nucleus, resulting either in 
transactivation or transrepression of the target genes. Transactivation happens when the GC-
GR complex binds with glucocorticoid responsive elements (GRE) in the DNA, while in 
transrepression, it binds to transcription factors such as Nuclear Factor-B (NF-B) or 
Activator Protein-1 (AP-1). Transcriptional activation and repression cause immuno-
suppression, a stress response, or induction of apoptosis, depending on cell type (Tissing, 
Meijerink, den Boer, & Pieters, 2003). 
 
GCs regulate diverse biological processes; for example, metabolism, development, 
differentiation, cell survival and apoptosis. Apoptosis is a cell death programme which varies 
with each multicellular organism and involves multi-steps and multi-pathways. There are two 
pathways for apoptosis: extrinsic and intrinsic. The extrinsic apoptosis pathway is initiated 
directly through the cell surface receptor while the intrinsic pathway is initiated through the 
mitochondria, the energy centre of the cell.  
 
Several research groups have studied glucocorticoid-response genes in GC-induced apoptosis 
pathways using gene expression profiling. However, the GC-induced apoptosis mechanism is 
still an active research area. After reviewing the relevant literature, there are currently two 
issues which arise from the on-going research based on GCs (i) GC regulated genes and (ii) 
the glucocorticoid receptor gene network. Many studies have revealed a large number of GC-
regulated genes using gene expression profiles from different cells and samples. There are 
more than 2000 studies on GC-induced apoptosis in lympoid cells (Herr, Gassler, Friess, & 
Büchler, 2007). There are, however, only a few overlapping genes, as indicated in Chapters 2 
and 3. Therefore, there is a need to identify and verify GC-regulated genes. Before GCs 
regulate genes to induce the apoptosis process, GCs bind to the GC receptor (GR), an 
intracellular receptor, and then transactivate or transrepress specific target genes.  
 
 3 
The underlying mechanisms of cell type specific glucocorticoid receptor signals are not well 
understood. The understanding of GC‘s functional mechanisms may be enhanced by finding 
the GC-regulated genes and GR gene networks.  
 
GC-induced apoptosis has been studied using microarray technology in vivo and in vitro on 
samples consisting of GC- treated ALL cell lines, mouse thymocytes and/or ALL patients. 
However, time series GC treated childhood ALL datasets are currently extremely limited.  
Currently, Systems Biology concepts are used to maximise the value of microarray data. Gene 
expression data can be used to ascertain signalling pathways and gene networks. One 
approach to gene networks is to present the information as a graph where the nodes represent 
genes and the edges represent interactions, which include activation or repression, and 
positive or negative feedback loops. 
 
1.2 Inferring Gene Networks  
 
DNA microarray technology is a technology for accessing thousands of gene expression 
profiles per experiment from different cells/tissues/organisms (Korenberg, 2007). This 
technology is widely used and leads to possible novel cancer causing genes, gene networks, 
and the identification of targets for cancer treatment. Specifically, there are two well-known 
microarrays: cDNA, and oligonucleotide arrays (Allison, Page, Beasley, & Edwards, 2006). 
Both arrays have been used in many studies, especially cancer studies, in search of possible 
novel genes for cancer diagnosis, prognosis and therapy. 
 
DNA microarray technology has made publicly-available gene expression profiles available.  
However, the difficulties, time required and costs associated with collecting the data involved, 
mean only a few time series gene expression data are available. Time series expression data 
may play an essential role in understanding the underlying mechanisms of complex diseases 
through inferring gene networks. Studies so far are based on a wide range of biological 
systems (Bar-Joseph, 2004; Chan, Havukkala, Jain, Hu, & Kasabov, 2008; Ernst, Nau, & Bar-
Joseph, 2005; Warren Liao, 2005) including synthetic and experimental data. Many existing 
clustering tools such as hierarchical clustering have been used with time series data; however, 
these clustering tools have not always been successful. Furthermore, Kim and Kim (2007) 
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describe some of the existing method restrictions that mainly focus on the similarity of gene 
expression and not including the time series characteristics of the data. Prior knowledge is 
also needed in some methods, and similarities in each cluster do not always represent a gene 
relationship or interaction.  
 
There are two main types of time series, short and long. Most series (80%) are short time 
series, containing eight or fewer time points (Ernst et al., 2005). This presents a challenge to 
meaningful short time series data analysis.  There are specific clustering tools for these data 
including STEM - the Short Time series Expression Miner, a software program specifically 
designed for investigating short time series gene expression data (Ernst & Bar-Joseph, 2006), 
and Difference-based clustering, an algorithm using differences between the first and second 
order for each time point (Kim & Kim, 2007).  There are only limited time series data 
available for ALL, most are short time series data with only a few time points.  
 
Microarray data analysis normally has four main methods: gene selection, clustering, 
classification and pathway analysis (S. B. Cho & Won, 2003). Many mathematical modelling, 
machine learning and statistical methods have been applied to microarray data analysis, 
especially, cancer (Berkhin, 2006; S. B. Cho & Won, 2003; Dam, Abbass, Lokan, & Yao, 
2007; D. Jiang, Tang, & Zhang, 2004; Lau & Schultz, 2002; Ma, Castillo-Davis, Zhong, & 
Liu, 2006; J. Wang, Li, & Ruan, 2005; Y. Wang et al., 2005; Xu & Wunsch, 2005). 
 
Networks can be studied at different levels, but in this study a gene network is the focus. Due 
to a lack of understanding of the actual network structures, deciphering gene networks from 
rapidly growing microarray expression databases has been shown to be a very promising 
approach in cancer research. Many tools are emerging and available for inferring gene 
networks. These tools include Boolean networks, Bayesian networks, Ordinary Differential 
Equations (ODEs), and pathway analysis. Considering their complexity, it is often difficult to 
evaluate or validate the performance of the available tools (Bansal, Belcastro, Ambesi-
Impiombato, & di Bernardo, 2007; K. H. Cho et al., 2007; D‘haeseleer, Liang, & Somogyi, 
2000; de Jong, 2002; van Someren, Wessels, Backer, & Reinders, 2002). All existing tools, 
however, have their limitations and have not been able to infer whole gene networks 
(Andrecut & Kauffman, 2006). There are no conclusions about the most suitable method for 
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inferring gene networks as each tool may reveal different aspects of gene networks (van 
Someren, Wessels, Backer, & Reinders, 2002). However, inferring gene networks using gene 
expression profiles has the potential to reveal the underlying biological knowledge (Swain, 
Hunniford, Dubitzky, Mandel, & Palfreyman, 2005). In this knowledge- based era, integrating 
datasets from many experiments and existing databases is a difficult task. However, there are 
a several free tools available for non-profit use and some are licensed /commercial. This study 
infers gene networks through networks/pathways using databases. Some existing tools have 
been used for synthetic and experimental data, for example, the yeast cell cycle, however, 
they have not been applied for inferring gene networks from data of short time series of 




This thesis covers gene expression analysis and the construction of gene to gene networks of 
childhood leukaemia. Most previous medical studies have focused on gene expression 
profiling which leads to the diagnostic and subtype classification for identifying novel 
therapeutic genes for ALL. Similarly, in the computational field, specific machine learning 
studies have used leukaemia data as a test set for newly developed methods. There is still a 
need for fundamental knowledge from both medical and computational research about 
childhood leukaemia. We aim to outline the essential available information through asking 
two questions:  
(a) What is the current situation of childhood leukaemia?  
(b) What current machine learning approaches have been used to study leukaemia?  
We address this question by reviewing the existing literature using the keywords ―childhood 
leukaemia, gene expression, machine learning‖. For this review, refer to our published article, 
―Machine learning for childhood acute lymphoblastic leukaemia gene expression data: a 
review‖ (Chaiboonchoe, Samarasinghe, & Kulasiri, 2010). This review aims to serve as a 
starting point for those interested in microarray analysis, in general, and cancer research, in 
particular. In addition, Chapter 2 reviews the literature relevant to this study. 
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Our review led us to select this research topic, which focuses on childhood leukaemia 
treatment using chemotherapeutic drugs- glucocorticoids.  
The primary purpose of this thesis is to better understand and to acquire more insight 
into the complexity of how GCs kill the malignant lymphoid cells through the GC-
induced apoptosis mechanism in childhood leukaemia.  
 
As mentioned in section 1.1, there are two main GC issues: (1) GC-regulated genes, and (2) 
the GR gene network. This study focuses on both issues. The first and second specific 
objectives discuss the first issue. The third and fourth specific objectives emphasise the 
second issue. 
 
The first specific objective of this study is to identify GC-regulated candidate genes. This 
objective is accomplished by using the prominent short time series gene expression dataset 
collected by Schmidt et al. (2006). The samples were collected from childhood leukaemia 
patients treated with prednisolone. The original authors identified 22 glucocorticoid-response 
genes (also called GC-regulated genes or GC-induced apoptosis genes) using fold changes at 
early response (six hours after treatment). We start by investigating the selected data relating 
to the following three questions:  
(1) How reproducible or robust are the original authors‘ results?  We test the validity of the 
original these results by re-analysing them using the same dataset, method and gene selection 
criteria six hours after treatment. We also extend the analysis to cover 24 hours after treatment 
as well as between six and 24 hours.  
(2) Do different platforms (software) available to normalise data have an effect on the final 
gene sets? We use R software as the original authors‘ did and add two software- Matlab and 
RMAExpress to normalise the raw data.  
(3) Do leukaemia subtypes- T and B-ALL produce similar differentially expressed gene sets? 
Many studies have indicated that leukaemia subtypes-T and B-ALL have different gene 
expression profiles (Den Boer et al., 2009; Fulci et al., 2009; Mullighan et al., 2007; Yeoh et 
al., 2002). The original authors combined T and B-ALL data due to the small number of 
samples-13 patients. We aim to determine the validity of original authors‘ criteria and we 
propose a new gene expression analysis that separates T and B-ALL. This finding leads to our 
proposed GC-regulated genes. 
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The expected outcome from the first specific objective is a GC-induced apoptosis candidate 
gene set. This gene set is used throughout the thesis. We further classify GC-induced 
apoptosis genes based on their expression level before and after treatment and identify their 
cellular function This leads to our second specific objective, which is to identify group of 
GC-induced apoptosis genes that may have similar functions. This objective can be 
achieved by using clustering methods. 
 
Clustering methods have been used to cluster genes into similar groups in order to predict 
their functions. These clustered genes may be involved in similar networks and pathways. 
There are many clustering tools available and this is an on-going research area. We aim to 
understand how emergent clustering methods work with childhood leukaemia short time 
series gene expression data. We ask the following question:  
(1) Do gene clusters differ when analysed by general clustering methods as opposed to using 
clustering methods specifically designed for short time series data?  
We select four existing artificial intelligence methods: self organising maps (SOM), Emergent 
self organising maps (ESOM), Fuzzy clustering by Local Approximation of MEmbership 
(FLAME) and Short Time series Expression Miner (STEM). All gene clusters from the four 
methods are then compared and similar clusters are reported. This finding can be used by 
biologists or scientists for further investigation. Chapter 3 covers our first and second specific 
objectives. The work in this chapter has been published in the proceedings of 18th World 
IMACS Congress and MODSIM 2009. 
 
The expected outcome from the second specific objective is a group of genes that may have a 
similar cellular function. This gene group does not, however, indicate an interaction between 
genes in the group. Which genes interact with which genes? This information can be studied 
through gene network inferring methods. A gene network can be constructed based on gene 
expression level, which represents gene to gene relationships. Microarray data can be used to 
elucidate gene networks through reverse engineering or inferring approaches. Currently, this 
is an on-going research and there are many proposed methods, for example, mathematical 
modelling, Boolean networks and Bayesian networks, as well as literature-based commercial 
and non-commercial network development tools. 
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The second aspect of this thesis addresses the second GCs related issue: the GR gene network. 
GCs are mediated by binding to, and activating, the glucocorticoid receptor (GR). Therefore, 
we aim to understand the relationship between the gene network of GC-induced apoptosis 
genes and the GR gene network. The third specific objective is to construct gene networks 
of proposed GC-induced apoptosis genes. We address this objective with the following 
questions: 
(1) What are the possible gene networks before treatment and at six and 24 hours after 
treatment?  
(2) What are common genes/gene hubs between these three gene networks?  
The expected outcome from the third specific objective is a gene network of GC-induced 
apoptosis genes. Work related to this third objective is presented in Chapter 4. The Ingenuity 
Pathway Analysis software (IPA) is the main method used in this chapter.  
 
We continue data analysis with the final specific objective to elucidate the glucocorticoid 
receptor gene network. This objective is accomplished by using web-based knowledge 
network/pathway tools. It is commonly known that the apoptosis process involves two main 
pathways: the extrinsic and the intrinsic. This leads to the following question: 
(1) How do known genes from apoptosis pathways (extrinsic and intrinsic) behave in 
childhood leukaemia at different time points?  
We further considered two other relevant pathways (p53 and NFB) because apoptosis 
involves multiple processes and pathways. Generally, a biological pathway represents 
molecule relationships which are not specific to the time when the interactions take place. We 
further investigate the gene networks of known genes from three selected pathways 







Furthermore, we ask the question:  
(2) Do different tissues (blood or liver) and drugs (prednisolone or dexamethasone) produce 
different GR gene networks?  
We located three existing proposed networks from Phillip et al. (2005), Donn et al. (2007) and 
Miller et al. (2007). Networks have been proposed as literature-derived networks of biological 
relationships and signalling networks, respectively, by the two latter authors, and only Phillip 
et al. (2005) called the proposed network a regulator of GR. Phillip et al.‘s (2005) study used 
mouse liver tissues treated with dexamethosone, while Schmidt et al. (2006) (used in our 
study) used blood sampling from childhood patients treated with prednisolone. The expected 
outcome from the fourth specific objective is a GR gene network constructed from the 
childhood leukaemia patients‘ in vivo dataset. This network is then compared with the 
previous proposed networks from the three studies mentioned above.  
Next, we ask the question: 
(3) What is the GR gene network obtained from the three web-based knowledge 
network/pathway tools?  
These three tools are the Ingenuity Pathway Analysis software (IPA), the BiblioSphere 
Pathway Edition (BSPE) and Oncomine. IPA, a literature-based tool, has been used in many 
studies to construct gene networks, including the GR network, for leukaemia but not for 
childhood leukaemia. Oncomine is a well-established database for cancer, thus, it is an 
excellent source of information on genes related to cancer. Finally, we selected BSPE to 
validate the IPA network because BSPE is also a literature-based tool.  
Finally, we proposed a GR gene network by combining all output gene networks in this 





This thesis sheds some light on the understanding of GC-induced apoptosis in childhood 
leukaemia in terms of identifying GC-regulated genes, their network, and its relationship with 
the GR gene network. This work is based on the analysis of gene expression data. The results 
of the analysis are presented and, as well, future directions for research are highlighted. 
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1.4 Chapter Overview and Specific Contributions 
 
This thesis comprises six chapters.  
Chapter 1 focuses on childhood leukaemia and its chemotherapeutic drugs- glucocorticoids- 
because of their capability to induce apoptosis in lymphoid and malignant lymphoid cells. 
Then, the motivation and objectives of this thesis are described.  
Chapter 2 presents a review of the relevant literature. We address two relevant questions (i) 
the current situation of childhood leukaemia and (ii) current machine learning approaches that 
have been used to study leukaemia. The contribution from this chapter is an original and 
comprehensive published review article which provides essential basic knowledge in this 
area.  
In Chapter 3, differentially expressed genes or novel GC-induced apoptosis genes, are 
identified and grouped according to their similarities in expression by using four emergent 
clustering methods. The first and second specific objectives are addressed in this chapter. The 
specific contribution from this chapter is (i) to emphasise different subtypes, sample types 
treated with different chemotherapeutic drugs may share common response; but there may 
still be unique patterns and the final genes discovered can vary. We extend the investigation 
further from the original Schmidt et al. (2006) study and propose new criteria to select novel 
genes in B-ALL and T-ALL subtypes. More genes were found than in the original research 
that combined the two subgroups in the analysis. Most available childhood leukaemia gene 
expression is from short time series. Different clustering methods produce different final gene 
clusters from the same dataset, and there is no conclusion about the best clustering method. 
Therefore, (ii) we addressed the comparison of gene clusters from four selected clustering 
methods with short time series data and evaluated the results with gene functional groups. 
Clustering revealed possible co-regulated or co-expressed genes but not the details of 
interactions between genes in the same cluster. Therefore, the next chapter is focused on 
inferring gene networks from the differentially expressed genes. 
In Chapter 4, the gene networks of the candidate GC-induced apoptosis genes from Chapter 3 
are elucidated by using network/pathway tools. The third specific objective is addressed in 
this chapter. The contribution of this chapter is demonstrating a combination of gene networks 
from three time intervals in order to minimise the relevant genes or identify novel genes for 
further study. We select the most common gene (node) and propose GC-induced apoptosis 
gene networks for T- and B-ALL, separately.  
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In Chapter 5, a GR gene network is proposed. The fourth specific objective is addressed in 
this chapter. In order to activate apoptosis process, GCs are binding to and activating the 
glucocorticoid receptor (GR). In Chapter 4, we have already illustrated the gene network for 
GC-regulated genes; in this chapter, we add the gene network that is involved with GR. This 
leads to understanding of the whole picture of GC-induced apoptosis process. We manually 
combined three existing GR gene networks from previous studies with our three inferred gene 
networks from the selected genes using CellDesigner

. This network is a starting point for 
scientists conducting further investigations. The main contribution of our study is to present 
an approach to utilise publicly available gene expression data and pathway databases to 
identify candidate GC-regulated genes and their network which we believe expands the 
current knowledge about GC-induced apoptosis in childhood leukaemia. This network might 
lead to an understanding of the underlying mechanisms and better clinical treatment. 
Finally, in Chapter 6, an overview and the most important findings of this research, including 
its contribution to the overall understanding of GC-induced genes and mechanisms, and 
suggestions for potential future research are defined. 
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    Chapter 2 
Literature Review 
This research is part of the field called biomedical informatics which integrates different 
disciplines including medicine, genomics and informatics. As a result, this chapter provides 
an overview of the relevant background information. Section 2.1 starts with an extensive 
review of previous research on childhood leukaemia. This research focuses on 
glucocorticoids, which are used extensively in treatment of children with acute lymphoblastic 
leukaemia. Hence, section 2.2 is a discussion on how GCs kill the malignant lymphoid cells, 
as well as on GC responsive genes and pathways. To understand GC-induced cell death 
mechanism, microarray technology has been extensively used to identify the relevant genes 
and gain insight into the underlying biological process. Therefore, section 2.3 provides a 
review of microarray data analysis focusing on microarray technology and data processing. 
Furthermore, the gene sets extended from microarray data analysis are increasingly being 
used for further investigation on how genes work in particular conditions and tissues. 
Therefore, clustering techniques and networks/pathways analysis are presented in sections 2.4 
and 2.5, respectively. 
 
2.1 Childhood Leukaemia 
 
Leukaemia is a cancer of blood cells; especially the abnormal proliferation of white blood 
cells. Normal blood stem cell development takes place in the bone marrow (BM) and then it 
divides and differentiates into platelets, red blood cells, and different types of lymphoids and 
myeloid cells. Consequently, leukaemia can be divided into four groups: acute myeloid 
leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), 
and chronic lymphocytic leukaemia (CLL). The most common childhood leukaemia is acute 
lymphoblastic leukaemia (ALL), which can be further divided into two subgroups: T-lineage 




To date, many studies have focused on diagnostic and subtype classifications, identification of 
novel drug targets and identification of risk stratification for ALL patients. Golub et al. (1999) 
started the first leukaemia microarray data analysis (Golub et al., 1999), which was followed 
by many other groups (Armstrong et al., 2002; Cheok et al., 2003; Chiaretti et al., 2004; 
Chiaretti et al., 2005; Choi et al., 2007; DeAngelo, 2005; Dunphy, 2006; Moos et al., 2002; 
Mullighan et al., 2007) and work in several regions in the world including Canada and 
Europe, i.e. Germany and the United Kingdom (Herold, von Stackelberg, Hartmann, 
Eisenreich, & Henze, 2004; Ramanujachar et al., 2007; Rogers et al., 2007; Schrøder et al., 
2006). World-wide, there are at least nine well-known leukaemia research groups including 
the Boston, Austrian, Utah, Memphis, Japan, Munich, Stanford, Copenhagen and Netherland 
groups (Knudsen, 2006). An overview of some of those studies (including groups of 
investigators, methods used and outcomes achieved) that focus on childhood ALL is given in 
Tables 2.1 and 2.2. Basically, ALL research can be classified as follows: 
 
 Overview of childhood leukaemia research, treatment and future research directions 
(Bhojwani, Moskowitz, Raetz, & Carroll, 2007; Carroll, Bhojwani, Min, Moskowitz, & 
Raetz, 2005; Carroll et al., 2003; Dunphy, 2006; Howell, Ward, Austin, Young, & 
Woods, 2007; Pui, 2004; Pui, Schrappe, Ribeiro, & Niemeyer, 2004) 
  Identification and classification of leukaemia subtypes (Andersson, Edén et al., 2005; 
Andersson, Olofsson et al., 2005; Andersson et al., 2007; De Pitta et al., 2005; Moos et 
al., 2002; Ross et al., 2003; Willman, 2004; Yeoh et al., 2002). 
 Identification of genetic determinants and aberrants (Kuiper et al., 2007; Kustanovich, 
Savitskaja, Bydanov, Belevtsev, & Potapnev, 2005; Mullighan et al., 2007; Sinnett, 
Labuda, & Krajinovic, 2006). 
 Identification of novel genes that enhance the diagnosis and prognosis, drug response, 
poor drug response or relapse and effective therapies development for leukaemia 
treatment (Bhojwani et al., 2006; Estes, Lovato, Khawaja, Winter, & Larson, 2007; 
Flotho et al., 2007; Holleman et al., 2004; Holleman et al., 2006; Kirschner-Schwabe et 
al., 2006; Lugthart et al., 2005; Smedmyr & Heyman, 2006; Tissing et al., 2007; 
Willenbrock, Juncker, Schmiegelow, Knudsen, & Ryder, 2004). 
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Table 2.1: Overview of acute lymphoblastic leukaemia microarray data analysis for gene 






Authors Methods Findings 
Golub et al. (1999) 
 
Clustering: Self Organising Map (SOM)  
Classification : Neighbourhood analysis 
and weight voting 
50 informative genes which distinguish 
ALL from AML 
Moo et al. (2002) Clustering: Hierarchical clustering using  
t -test and info-score 
20 best discriminating genes for ALL vs 
AML and B-lineage vs T-lineage ALL 




Clustering: unsupervised hierarchical 
clustering  
Classification 
 Genes selection : Chi-square, t-statistics, 
and CFS (Correlation-based Feature 
Selection), and SOM/DAV (Self 
Organising Map/Discriminant   Analysis 
with Variance ) 
 Supervised learning algorithms : k-
nearest neighbours (k-NN), support 
vector machine (SVM), neural networks 
(NN), weight voting, and prediction by 
collective likelihood of emerging 
patterns (PCL) 
six distinct subgroups of ALL : T-ALL, 
BCR-ABL, E2A-PBX1, TEL-AML1, 
MLL gene rearrangement, and 
hyperdiploid>50 chromosomes  
Ross et al. (2003) This is continuation of Yeoh et al.‘s research with different Affymetrix array (HG-
U133 instead of HG-U95Av2 array). Seven distinct subgroups of ALL: T-ALL, BCR-
ABL, E2A-PBX1, TEL-AML1, MLL gene rearrangement, hyperdiploid>50 
chromosomes and other (novel, hyperdiploid, normaldiphoid and pseudodipoid). 
Comparing between top 100 selected genes; about 
 
60% of the genes were not selected 
before and,
 
thus, are new class discriminators.  An ANN supervised learning algorithm 
was used with the top 50 identified genes, 97% of overall prediction accuracy was 
achieved. 
Willman (2004) Clustering : VxInsight Software  
(http://www.cs.sandia.gov/projects/ 
VxInsight.html) 
Classification : Bayesian networks and 
support vector machines with recursive 
feature elimination (RFE) (SVM-RFE), 
VxInsight/ANOVA and TnoM ( Threshold 
number of misclassification)) 
This study uses gene expression 
profiling for class discovery and class 
prediction of ALL data. It highlights the 
possibility of finding potentially novel 
diagnostic and therapeutic targets by 
using microarray technology. 
Andersson et al. 
(2005) 
Clustering : Hierarchical clustering analyses and principal component analyses    
(PCAs) 
Classification :  k-nearest-neighbours 
This study compares normal hematopoietic and cells leukemic cells. In addition, it 
identifies the gene-expression signatures of normal subpopulations of different lineages 
and maturations. There is 77-86% of differentially expressed genes overlap when using 
ALL and AML datasets by Ross et al. (2003). A high accuracy (98.2%) was retrieved 
when using k nearest neighbours‘ classifier to predicted genetic subtype among B 
lineage ALLs. 
 
De Pitta et al. 
(2005) 
Significance analysis of Microarray 
(SAM), Predictive Analysis of Microarray 
(PAM), Principal component analysis, 
Hierarchical cluster analysis, k-means and 
profile similarity searching 
This study identified 30 genes that best 
discriminate three subtypes: T-ALL, B-
ALL and B-ALL with MLL/AF4 
rearrangement. 
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Table 2.2: Overview of acute lymphoblastic leukaemia microarray data analysis for gene 











Authors Methods Findings 
Cheok et al. 
(2003) 
Linear Discriminant Analysis 
(LDA),  ANOVA, Support Vector 
Machine (SVM), k-nearest 
neighbour, artificial neural network 
and empirical Bayesian 
Identified 124 genes that accurately discriminated 
among the four treatments 
Holleman  
et al. (2004) 
Wilcoxon rank-sum test, t-test, 
Bagging algorithms, Cox 
proportional-hazards regression, 
Fine and Gray‘s estimator 
accounting for competing events, 
Fisher‘s exact test and Hierarchical-
clustering 
124 genes were identified with resistance to four 
drugs: prednisolone, vincristine, asparaginase and 
daunorubicin. 
Willenbrock 
et al. (2004) 
Hierachical clustering, k-nearest 
neighbour, Nearest centroid, LDA, 
SVM and Maximum Likelihood 
This study shows the high percentage of 
classification accuracy (78%) achieved by using 
DNA microarray to predict relapse and treatment 
response in childhood ALL. 
Lugthart  
et al.(2005) 
Hierarchical clustering, Principal 
component analysis (PCA), 
Spearman‘s rank correlation. 
Identified 45 genes associated with cross-resistance 
to four mechanistically distinct anti-leukaemic agents 
and 139 genes significantly related to a novel 
phenotype of discordant resistance to vincristine and 
asparaginase.   
Bhojwani  
et al. (2006) 
 
Robust multiarray analysis (RMA), 
Cluster and TreeView software, 
VxInsight, Multiple supervised 
analysis and SAM 
Identified different pathways between the timing of 
disease recurrence (early and late relapse). 
Kirschmer-
Schwabe  
et al. (2006) 
 
t-test, Fisher‘s exact test, least angel 
regression and nearest shrunken 
centroid 
Identified 83 genes differentially expressed in very 
early relapsed ALL compared to late relapse. 
Schmidt et al. 
(2006) 
Fold change 22 genes as novel genes for glucocorticoids-induced 
apoptosis 
Flotho et al. 
(2007) 
Analysis-of-Variance (ANOVA), t-
test, Spearman correlation, simple 
linear regression, Kruskal-Wallis 
test and Wilcoxon Mann-Whitney 
tests 
A set of 40 genes that predicted clinical outcome and 
14 were involved in the regulation of cell 
proliferation and associated with minimal residual 
disease (MRD) during early remission induction 
therapy. 
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The review above provides a perspective on childhood leukaemia research. One of the open 
questions is how to cure the children who do not respond well to existing childhood 
leukaemia treatments.  An understanding of how chemotherapeutic drugs kill the immature 
lymphoid cells will lead to better childhood leukaemia treatment. Treatment of childhood 
acute lymphoblastic leukaemia is based on the patient‘s specific risk group. Unfortunately, it 
is difficult and expensive to identify accurately a patient‘s risk group. Therefore, gene 
expression profiling has been used to identify possible novel gene response in childhood 
leukaemia treated with chemotherapy. The most widely used therapeutic drugs for treating 
children with ALL are glucocorticoids (GCs) such as dexamethasone or prednisolone. GCs 
induce apoptosis (cell death) and inhibit proliferation in lymphoid and malignant lymphoid 
cells, as described in detail in the following section.  
 
2.2 Glucocorticoid-induced apoptosis  
 
Tumour cells are killed by induced apoptosis during chemotherapy treatment (Igney & 
Krammer, 2002). Glucocorticoids have been used as chemotherapeutic drugs for children with 
ALL. GCs induce apoptosis and G1 (Gap 1, an early stage of cell division between the 
synthesis and mitosis phases) cell cycle arrest in malignant lymphoid cells. In fact, little is 
known about the molecular mechanism of GC-induced apoptotic signal transduction pathways 
and there are many controversial hypotheses about both the genes regulated by GCs and the 
potential molecular mechanism of GC-induced apoptosis (Schmidt et al., 2006). Therefore, an 
understanding the mechanism of this drug should lead to better prognostic factors (treatment 
response), more targeted therapies and prevention of side effects. To understand the GC-
induced apoptosis mechanism, this section reviews three relevant issues: known genes, known 
pathways and the relationship between cancer, apoptosis and cell cycle arrest. 
 
Previous studies have focused on identifying genes involved in GC-induced apoptosis. A 
review by Schmidt et al. (2004) identified 31 common genes from seven previous studies 
(Schmidt et al., 2004). Each study found a different set of genes, for example, Tonko et al. 
(2001) found eight genes  that were differentially regulated: Leucine zipper, integrin alpha6 
(ITGA6), GR, ESTs, SOCS1/JAKbp, YAF2, LDH A and Arylsulfatase C. (Tonko, 
Ausserlechner, Bernhard, Helmberg, & Kofler, 2001). 
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Recent research by Schmidt et al. (2006) proposed 22 novel differentially expressed genes. In 
particular, they proposed that the GC-induced apoptosis mechanism is activated by several 
GR-induced genes. GR regulates transcription of its target genes which can be either activated 
or inhibited; for example, it activates p53 and represses AP-1, NF-B, and c-myc. Previous 
studies defined the interplay between GR, AP-1, NF-B, and c-myc (De Bosscher, Vanden 
Berghe, & Haegeman, 2003). The mechanism of GC inhibition of NF-B depends on cell 
type. A number of studies have reported that GR directly interacts with the transcription 
factors AP-1 and NF-B, as part of the GC-induced apoptosis (Greenstein, Ghias, Krett, & 
Rosen, 2002).  
 
An issue that should be taken into account when identifying the novel genes is that treatment 
with different types of glucocorticoid drugs in different clinical settings (in vivo, in vitro and 
human samples) provides different differentially expressed novel gene sets. For example, 
Cario et al.‘s (2008) study of prednisone response in childhood leukaemia found 72 out of 104 
differentially expressed genes in common with Schmidt et al. (2006) who also used 
prednisolone. The novel glucocorticoid-response genes from in vivo and in vitro prednisolone 
treated paediatric ALL studies found only five genes in common (FKBP5/FKBP51, SNF1LK, 
ZBTB16, ZFP36L2 and SOCS-1) (Tissing et al., 2007). An in vivo, gene list by Schmidt et al 
(2006) claimed 22 essential candidate genes with only three common with the 31 identified 
from numerous previous studies (FKBP5/FKBP51, DDIT4/Dig2, and SOCS-1). Tissing et 
al.‘s (2007) in vitro study highlighted 57 probe sets (51 differentially expressed genes), of 
which 22 are found in previous studies of lymphoid cell lines. Therefore, identification of the 
specific genes involved in GC-induced apoptosis mechanism is complex and is an on-going 
research issue. 
 
From the previously known GC-induced apoptosis pathways, GC-induced apoptosis is 
generally activated through the regulation of caspase by two major pathways: intrinsic and 
extrinsic. Of the possible pathways involved in GC induced cell death, Tissing et al (2007) 
pointed out the link between three pathways (MAPK pathway, NF-B signalling and 
carbohydrate metabolism) while Herr et al (2007) proposed 12 molecules and pathways: 
mitochondria, death receptor signalling, Bcl-2 family, caspases, c-myc, IB, Granzyme A, 
TDAG8, lysosomes, proteasomal degradation, stress pathway and other modulators such as 
PKC, IL-6 and T-cell receptors (Herr et al., 2007). Detailed studies of each of these pathways 
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have been conducted including TRAIL death receptor signalling (Finnberg & El-Deiry, 2008; 
Ndebele et al., 2008; Press & Reminder, 2008), lysosomes (Guicciardi, Leist, & Gores, 2004), 
and Bcl-2 family (Adams & Cory, 2007; Youle & Strasser, 2008). Furthermore, a gene 
signalling pathway of GC-regulated genes was proposed by Miller et al. (2007) who used 
CEM cell lines (human leukaemia cultured cell lines) as samples. A glucocorticoid receptor 
gene network was presented by Phillip et al. (2005) based on liver tissue. At present, no GCs 
or their relevant gene networks have been reported using patient (human) samples. There are 
studies confirming differences in gene expression profiling between cell lines corresponding 
to normal or tumour tissues, with the degree of difference varying with the type of tissue 
(Ertel, Verghese, Byers, Ochs, & Tozeren, 2006; Leupin et al., 2006). 
 
GC-induced apoptosis is a very complicated process. To understand GC-induced apoptosis, it 
is vital to understand it at a genetic level. Microarray technology enhances the possibility of 
investigating the thousands of gene expressions in one experiment. The next section describes 
microarray technology and data processing. 
 
2.3 Microarray Data Analysis 
 
In this section, an overview of microarray data analysis is presented. Section 2.3.1 explains 
DNA microarrays, focusing on Affymetrix GeneChip® HG-U133 Plus 2. Section 2.3.2 
introduces the data normalisation process with details of the Robust Multichip Average 
(RMA).  
 
Microarray technology is an essential source of data that promises to pave the way for better 
cancer prediction and diagnosis and to identify target drugs for cancer treatment. DNA 
microarray technology has been used to study human cancer including breast cancer, prostate 
cancer and leukaemia (Russo, Zegar, & Giordano, 2003). Since its initial introduction, the 
number of microarray applications has expanded. The technology involving the production 
including experimental design and preparation and image processing is beyond the scope of 
this review. The general procedure of microarray data analysis starts from experimental 
design including the design of experiments and extraction of mRNA samples. mRNA is 
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allowed to hybridise with a gene chip containing a strand of all the genes in the human 
genome (in the case of HG-U133 Plus 2). Genes represented in the sample and on the chip 
hybridise and the level of hybridisation is measured through image analysis, providing the 
raw data. Next, the raw data are further processed and normalised (more details are given in 
section 2.3.2) to be used in the next step, to identify candidate genes. This is followed by 
pattern discovery based on various clustering methods (see more details in section 2.4). The 
final microarray data analysis process is biological modelling. Reverse engineering, an 
approach used to construct biological networks from data and to get new biological insights, 
is discussed in section 2.5. Microarray experiments are expensive and generate an 
overwhelming volume of data; therefore, this has led to the creation of publicly available 
databases. A list of databases for cancer-related microarray data and gene expression data is 
given in Table 2.3. As of 30 July 2009, three selected databases were used to identify ALL 
datasets by using keyword ―acute lymphoblastic leukaemia‖. There are 97 datasets retrieved 
from Gene Expression Omnibus (GEO) (Barrett et al., 2007; Barrett et al., 2009), 85 
experiments and 11,966 assays were obtained from Array Express, for Oncomine, there are 
103 datasets from 18 studies. Specifically, 19 experiments and 1,298 assays were found in 
Array Express, there are eight datasets on GEO, and only one study was found in Oncomine 
when using the key word ―childhood acute lymphoblastic leukaemia‖.  
 
2.3.1 DNA Microarray  
 
Human organisms consist of cells with 24 chromosomes. Chromosomes constitute 
deoxyribonucleic acid (DNA), whose structure was illustrated by Jame D. Watson and 
Franscis H.C Crick in 1953 (Watson & Crick, 1953). DNA is recognised as a double helix. 
The double helix is formed by base pairs of hydrogen bonds: adenine (A) binds to thymine 
(T) and cytosine (C) binds to guanine (G). A gene is a part of DNA; its expression proceeds 
from transcription of genetic information from the DNA level to ribonucleic acid (RNA) 
level, then translation into the protein level. This process is represented as the central dogma 
of molecular biology. The regulation of gene expression may be controlled at many levels: 
RNA processing (transcription) and transport, RNA translation and post-translational 









Table 2.3: Useful URLs for accessing cancer-related data and microarray gene expression 
databases [adapted from Barnes (2007) and Gardiner-Garden & Littlejohn (2001)]. 
 































Cancer Genome Anatomy Project 
Cancer Genome Project 
National Cancer Institute Centre for 
Bioinformatics 
Gene Expression 
Stanford University/University of 
California at Berkeley, University of 
California at San Francisco (UCSF) 
European Bioinformatics Institute (EBI) 
Lund University 
Whitehead Institute for Biomedical 
Research/MIT Centre for Genome 
Research 
Johns Hopkins University 
Harvard University 
BioDiscovery 
National Cancer for Biotechnology 
Information (NCBI) 
The Jackson Laboratory 
 
UT Austin 
National Cancer Institute (NCI) 




Johns Hopkins Oncology Centre 





































The interactions between DNA, RNA and proteins are complex and can be divided into three 
broad categories: metabolic, signalling and regulatory networks (Lewin, 2008; Lodish et al., 
2003).   
 
Gene expression involves the complex process of transcription of DNA (genes) to messenger 
ribonucleic acid (mRNA) and the translation of mRNA into proteins. In gene expression, it is 
the relative amount of mRNA which represents the activity of a specific gene. The knowledge 
about gene expression, specifically, which genes are differentially expressed, where and when 
in the cell, helps in understanding the function of cells and their development at the molecular 
level in an organism. The regulation of gene expression happens via genetic regulatory 
networks consisting of the interaction of genes (DNA), RNA, proteins and small molecules 
and their mutual regulatory interaction. DNA microarrays are essential tools for the analysis 
the expression of many genes simultaneously using information at the transcriptional level. 
Microarrays can be manufactured by two major approaches: complementary DNA (cDNA) 
microarray and Oligonucleotide chips. cDNA arrays, developed by Stanford University, are 
fabricated by robotic spotting on glass slides; and oligonucleotide arrays, produced by 
Affymetrix, are fabricated by photolithographic chemistry and light-directed chemical 
synthesis on small glass plates (Allison et al., 2006).  
 
Affymetrix GeneChip high density oligonucleotide gene expression arrays (Affymetrix® and 
GeneChip®, http://www.affymetrix.com/index.affx) are one of the most well-known arrays 
and have been widely used in biomedical research. Each gene is represented on this array by 
11-20 different probe pairs called a ‗probe set‘ (Figure 2.1). Each probe consists of 25 
nucleotide bases and each probe pair has two components: perfect match (PM), which is 
designed to match the specific sequence and mismatch (MM), located at the 13
th
 base and 
intended to measure noise caused by non-specific binding (NSB) (see Figure 2.1). The 
expression level of a gene comes from the whole probe set, as the average difference between 












Figure 2.1: Schematic representation of the Affymetrix GeneChip® expression analysis 
system in use  











Specifically, the average difference is the intensity of the whole probe set and is calculated as 
the average of the differences between the intensities of perfect match and mismatch for each 
probe pair, as shown in equation 2.1. 
 







                                                           (2.1) 
 
where j  is the number of the probe pair. 
 
Many human genome arrays have been used in leukaemia research, of which the Affymetrix 
GeneChip® Human Genome U133 Plus 2 array is the focus of this study. The size of this 
array is 11 m and it comprises 11 probe pairs per probe set and more than 54,000 probe sets. 
These represent more than 47,000 transcripts corresponding to 38,500 known human genes. 
Some genes are referred to more than once on the chip. 
 
The process involved in measuring gene expression starts from GeneChip® or arrays 
containing oligonucleotide probes. Then the labelled cDNA or cRNA targets are hybridised to 
the array and washed and scanned by laser. Finally, the expression of the genes is measured in 
the form of the fluorescent intensity of the scanned image of the hybridised probes. The 
intensity levels of gene expression vary from the lowest to the highest, represented by dark 
blue, blue, light blue, green, yellow, orange, red and white (Figure 2.1). 
 
The Affymetrix GeneChip® is analysed by the Affymetrix GeneChip Operating System 
Software (GCOS), which generates the cell intensity (.CEL) file from the image data file. This 
CEL file provides information about position and intensity of each probe on GeneChip®. 
 
Microarray data (intensity images) are analysed and presented as gene expression matrices 
whose rows denote genes and columns denote samples. Gene expression represents the 
interested condition, for instance, healthy or diseased. A time series gene expression matrix is 
represented as n m  matrix where n  represents genes and m  represents time points: matrix 
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, 1,2,..., , 1,2,..., ,ijM g i n j m      where ijg  denotes the expression level of 
thi  gene at thj  
time point is shown below (Bandyopadhyay, Maulik, & Wang, 2007): 
 






















                                                      (2.2) 
 
The raw gene expression matrix retrieved from the imaging process consists of noise, missing 
values and systematic variations from biological experimental process. Therefore, data pre-
processing is needed. In the next section, data pre-processing and the identification of 
differential gene expression are discussed. 
 
2.3.2 Microarray Normalisation 
 
After the experiment has been conducted and the raw intensity data obtained, data pre-
processing needs to be carried out to reduce the systematic sources of non-biological variation 
(Amaratunga & Cabrera, 2004). Pre-processing, which amalgamates multiple probe signals 
into a single expression measure, called normalisation, is a common first step in data 
processing (Lim, Wang, Lefebvre, & Califano, 2007). 
 
Microarray normalisation is one of the current active research areas that have produced an 
increasing number of available methods. Normalisation has three main steps: (i) background 
correction, which removes background noise
 
from signal intensities, (ii) normalisation, which 
is intended to remove non-biological variability between arrays and make distributions across 
arrays identical, and (iii) summarisation,
 
which gives a single expression measure to each 
probe set on the array.  
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The most commonly used methods are MAS5.0, RMA (Robust Multichip Average) and 
GCRMA (GeneChip RMA). MAS5.0 uses MM probes to adjust the PM probes for probe-
specific nonspecific binding for background correction, uses a baseline array and scales all the 
other arrays to have the same mean intensity for normalisation and uses tukey biweights for 
summarisation (Affymetrix, 2002). RMA (Irizarry, Hobbs et al., 2003) uses a global 
correction, quantile normalisation and median polish summarisation. The GCRMA 
(GeneChip RMA) (Z. Wu & Irizarry, 2004) was developed from RMA and differs from the 
RMA in its uses of the probe sequence information for background correction. There are 
many more available pre-processing methods and new ones are being developed. Some of 
them are summarised in Table 2.4. The question now is how to select the most appropriate 
and reliable method to address a particular biological question from a specific dataset. A 
criterion has been introduced to use as an indicator; it is the capability to detect differentially 
expressed genes. It can be described in two terms: the precision (specificity/variance) and 
accuracy (sensitivity/bias) (Irizarry, Wu, & Jaffee, 2006). To help find the best method for 
each application, there is a benchmark; a web-based tool to assess several methods based on 
the same data and to obtain a summary statistical report, which helps scientists to choose the 
best pre-processing method for their tasks (Cope, Irizarry, Jaffee, Wu, & Speed, 2004).  
 
There still are many questions with regard to the normalisation process: what is the most 
important normalisation stage? One study emphasised that the main factor that makes each 
method different is background correction (Irizarry et al., 2006). In contrast, recent research 
argues that different background corrections have insignificant effects on the correlation 
between methods (N. Jiang et al., 2008).  What is the best normalisation method? Jiang et al 
(2008) indicated that GCRMA and MAS 5.0 performed poorly compared with others, while 
Wu et al (2004) concluded that GCRMA performed better for genes with lower expressions 
and RMA for higher ones. Lim et al (2007) pointed out that GCRMA and RMA show better 
performance than MAS5.0. However, GCRMA creates artificial correlations during the 
normalisation process. Recent research has indicated that the positional dependent nearest 
neighbour (PDNN) (L. Zhang, Miles, & Aldape, 2003) is the best normalisation method 
among seven different methods. They used sensitivity, reproducibility and consistency as the 
criteria to evaluate the performance of the seven normalisation methods (N. Jiang et al., 
2008). 







Table 2.4: Description of some pre-processing methods, adapted from Irizarry et al.,( 2006) 




Normalisation  Summarisation Citation 
dChip MM intensities are 
subtracted 
Spline fitted to rank 
invariant s 
A multiplicative 
model is fitted  
Li and Wong, 
2001 
GL None Loess fitted to 
subset  
As RMA Freudenberg, 
2005 
GCRMA Based on probe 
sequence 
As RMA As RMA Wu et al., 2004 
MAS5.0 Spatial effect and MM 
subtracted 





MM intensities are 
subtracted 
Invariant set Multiplicative 
model 
Li and Wong, 
2001 
MMEI None Linear mixed model  A linear mixed 
model is fitted 
Deng et al., 2005 
PDNN Model is fitted 
accounting for 
background and specific 
signal 
Quantile Specific and non-
specific binding 
effects are 
estimated using free 
energy model 
Zhange et al., 
2003 
RMA A global correction  Quantile A robust linear 
model (median 
polish) 









Another issue that needs to be taken into account is that data, which are retrieved from 
different labs using the same platform, are different (Irizarry et al., 2005). Moreover, using a 
single platform with different normalisation methods led to large variability in the results 
(Stafford & Tak, 2008). Different studies show different conclusions and there is no 
consensus at present on the most suitable method for all data. Nonetheless, all differentially 
expressed gene lists from each method are unique but significant (N. Jiang et al., 2008). 
Normalisation has a consequential effect on the final microarray data analysis results (Irizarry 
et al., 2005). Normalisation methods alter in how the correlation structure from the data is 
revealed and, in turn, affect the accuracy of inference of cellular networks (Lim et al., 2007). 
Genes that have been determined to be differentially expressed are highly dependent on the 
normalisation method (Steinhoff & Vingron, 2006). This research uses RMA, as this method 
was selected by the original authors. 
 
Robust Multichip Average (RMA) 
 
The Robust Multichip Average or Robust Multi-array Average (RMA) (Irizarry, Bolstad et 
al., 2003; Irizarry, Hobbs et al., 2003) is one of the normalisation approaches that convert 
probe level data (CEL files) into a gene expression measure. RMA starts with the background 
correction, a non-linear correction on each chip, where the background signal (BG) intensity 
(optical noise and non-specific binding) is subtracted from probe level signal- perfect-match 
(PM) values. Quantile normalisation is then applied across chips in order to equalise probe 
intensities and, finally, the summarisation process creates a single expression measure for 
each probe set. RMA uses the median polish summarisation process.  
 
The RMA algorithm can be formulated as: 
 
                              2log , 1,...,ij i j ijPM BG e i I       and 1,...,j J                        (2.2) 
 
where  i  represents array and j  represents probes, ie  denotes the log scale expression of 
array i  and j  denotes affinity probe effect and ij  denotes an independent identically 
distributed error term with mean zero. 
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For any probe-pair, perfect match (PM) intensity consists of signal and noise and is defined 
by: 
 
                                                              PM PMPM O N S                                                (2.3) 
 
where O  denotes optical noise, N  denotes Non specific binding (NSB) noise, both O  and N  
follow a log-normal distribution with mean   and standard deviation  , S  denotes signal 
component or a quantity proportional to RNA expression (the quantity of interest) in the form 
of an exponential distribution. 
 
Quantile normalisation, a non-parametric method introduced by Terry Speed‘s group with the 
basic assumption that all samples have almost the same gene abundant distribution. Each chip 
is normalised by computing the quantile value of the distribution of probe intensities and then 
transforming this value to reference the chip quantile‘s value. Equation (2.4) depicts the 
quantile transformation: 
 
                                                                   12 1normx F F x
                                               (2.4) 
 
where 1F  defines the distribution function of the actual chip intensities and 2F  defines the 
distribution function of the reference chip.  
 
Median polish is a statistical method proposed by John W. Tukey (Tukey, 1977). It is an 
additive-fit model for a two-way layout. Tukey‘s median polish decomposes data into: 
 
                                   Data = all effect + row effect +column effect + residual                   (2.5) 
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This method subtracts the median of each row from the row values as well as from each 
column from the column values and repeats this until convergence occurs (median = 0); these 
are called row effect and column effect variables.  
 
RMA can be performed through at least three available software packages: affy package 
(Bioconductor project), RMAExpress and Matlab. Affy is a software package implemented in 
R language, which can be downloaded from the Bioconductor project website 
(http://www.bioconductor.org). Bioconductor is a freely available source for users and 
developers to analyse genomic data. RMAExpress 1.0.2 release is cross-platform software to 
obtain gene expression summary values using the Robust Multichip Average expression from 
Affymetrix Genechip® CEL files. This software is open source and can be freely downloaded 
from the website (http://rmaexpress.bmbolstad.com/). Matlab, developed by the Mathworks, 
is a numerical computing environment that enables researchers to perform computationally 
intensive applications, including matrix manipulation, plotting and implementation of 
algorithms, faster than with traditional programming languages. The Bioinformatics add-on 
toolbox in Matlab provides RMA commands for pre-processing Affymetrix microarray data.  
 
After the normalisation process, the next step is to address cancer research problems by 
identifying differentially expressed genes that may likely be involved in a particular 
biological mechanism and could become targets for therapeutic intervention. The process of 
identifying differentially expressed genes can be carried out by two main steps: first, set up 
threshold criteria for identifying novel genes by using fold change and statistical methods and, 
second, cluster novel genes into similar expression patterns (clustering or classification);   this 
is explained in detail in the following section. Normally, a gene with more than two fold 
changes is considered significant or differentially expressed. Fold changes and traditional 
statistical methods have been used to identify differentially expressed genes, for example, t-
test, significance analysis of microarrays (SAM) (Chu, Narasimhan, Tibshirani, & Tusher, 
2002) analysis of variance (ANOVA) and data clustering. Identifying which method to use is 
essential because it may affect the novel gene lists. Comparisons between some of these 




In the analysis of differentially expressed genes, a subset of genes, also called a novel gene 
set, is selected from the expression matrix, which is strongly associated with the samples. 
Identification of differentially expressed genes can be undertaken through analysis of gene 
expression levels. Differentially expressed genes can be very informative but they do not 
reveal the whole underlying biological mechanism and process. Most studies focus on finding 
differential expression patterns between healthy and cancer samples, different stages of 
tumour or before and after treatment. Genes with similar expression patterns may be called 
co-regulated genes, which imply that they are regulated together and these genes may help in 
understanding the underlying biological process. Normally, there are two main basic patterns 
which are called underexpression (down-regulation) and overexpression (up-regulation). 
Overexpressed genes are genes that, on the one hand, have higher expression values when two 
samples are compared; for example, cancer (target) and healthy. On the other hand, 
underexpressed genes have lower expression values in target than reference samples 
(Dubitzky, Granzow, Downes, & Berrar, 2003).  
 
In summary, differentially expressed genes can be detected by using different pre-processing 
processes followed by traditional statistical methods but the results from each method contain 
false gene sets and true gene sets. It is difficult to produce consistent groups of differentially 
expressed genes even from the same platform but different subsamples. This issue is one of 
the limitations of high-throughput technology that should be taken into account. Gene 
expression analysis is still an on-going research field; there is no one suitable method for all 
data but a combination or evolution of existing/new statistical and clustering methods may 
help understand the global mechanisms behind biological phenomena. Understanding how 
genes work in a human cell still remains a major challenge for scientists to overcome. There 
are many ways to extract biological information from microarray data including identifying 
differentially expressed genes, identifying global patterns of gene expression and determining 
the biological meaning from each gene and their network (Santos & Liu, 2007). Therefore, in 
the next section, clustering methods are described, explaining how to identify similar patterns 






There are two main groups of gene classification processes: supervised classification and 
unsupervised clustering. Normally, clustering has been applied to find gene expression 
patterns after obtaining the set of novel genes. Clustering gene expression data helps to 
increase the understanding of gene function, gene regulation, cellular processes and subtype 
of diseases, etc. (D. Jiang et al., 2004). Clustering methods have been used in biomedical 
applications, including cancer, in several aspects: gene expression, sequences analysis, gene 
networks and protein-protein interactions. Clustering or unsupervised classification 
approaches give a cluster of distinct and highly similar genes (or co-expressed genes) but 
without a predefined cluster. Co-expressed genes may have similar functions and be active in 
the same cellular process. Furthermore, a strong correlation between gene expression patterns 
can define co-regulated genes. Clustering has four major parts including feature selection or 
extraction, clustering algorithm design or selection and implementation, cluster validation and 
interpretation of results (Xu & Wunsch, 2005).  
 
There are many reviews of previous clustering methods for microarray data (D. Jiang et al., 
2004; Kerr, Ruskin, Crane, & Doolan, 2007; Madeira & Oliveira, 2004; Shamir & Sharan, 
2001; Tibshirani et al., 1999; Xu & Wunsch, 2005; Yin, Huang, & Ni, 2007), specifically, 
there are many recently developed clustering tools including neural networks and fuzzy 
clustering (Bandyopadhyay, Mukhopadhyay, & Maulik, 2007; Herrero, Valencia, & Dopazo, 
2001; Madeira & Oliveira, 2004; Pal, Aguan, Sharma, & Amari, 2007; L. Wang, Chu, & Xie, 
2007; Y. P. Wang et al., 2008). There are many unsupervised clustering and supervised 
classification methods. Evaluation and comparison of gene clustering methods can be found 
in Chou, Zhou, Kaufmann, Paules and Bushel, (2007) and Thalamuthu, Mukhopadhyay, 
Zheng, and Tseng (2006). Thalamuthu et al. (2006) evaluated and compared six clustering 
methods including hierarchical clustering, K-Means, partitioning around medoids (PAM), self 
organising maps (SOM), model-based clustering and tight clustering (Tseng & Wong, 2005) 
for cluster synthetic and experimental datasets. They introduced the weighted Rand index as 
the criterion to evaluate the performance of the six clustering methods with simulated data 
and annotation prediction and functional prediction accuracy for a real dataset. Tight 
clustering and model-based clustering perform better than other clustering methods in 
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simulated and experimental data, whereas, hierarchical clustering and SOM perform worse 
than the other methods. 
 
Clustering methods and the distance measure used can vary the final novel gene set in each 
cluster. Different distance measures represent different aspects of rgw data. Clustering 
approaches have been applied to first microarray analysis ALL data by Golub (1999), 
specifically, who identified 50 informative genes by using SOM clustering to differentiate 
ALL from AML. In addition, identifying ALL subgroups using neural networks including 
support vector machines (Yeoh et al., 2002), identifying genes that distinct four treatment 
types (Cheok et al., 2003); predicting relapse and treatment response (Willenbrock et al., 
2004); and other studies are shown in Tables 2.1 and 2.2.  
 
The focus of the research reported in this study is on clustering methods for short time series 
gene expression data. Complex gene networks govern and orchestrate the biological systems 
of a cell. Understanding the underlying of these networks is now possible using a microarray 
time series datasets that measure at several time points. Knowledge obtained through this 
process may help to understand the underlying mechanisms of specific diseases, especially 
cancer, and may lead to the identification of novel chemotherapeutic gene targets. Previous 
studies have used time series data for particular purposes including: (i) meaningful temporal 
gene expression patterns in the data, (ii) specify genes that belong to each pattern, (iii) 
relationships between gene groups, and (iv) model development to depict gene groups‘ 
relationships (Famili et al., 2004). 
 
Time series gene expression is the measurement of gene expression of particular samples at 
particular time points. The co-expressed genes may have similar gene expression patterns 
over time. This group of genes can be used for further analysis of inferring gene networks. 
Time series data have two main attributes: order and interdependency, but these two essential 
points are normally disregarded by conventional clustering methods. Time series expression 
data can be used to enhance the understanding of the underlying biological mechanisms 
through the process of modelling gene networks. The first applications of time series 
clustering methods used the Unweighted Pair Group Method with Arithmetic Mean 
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(UPGMA) with Pearson‘s correlation to cluster gene expression in the budding yeast, 
Saccharomyces cerevisiae (Eisen, Spellman, Brown, & Botstein, 1998).  
 
Many conventional clustering methods have also been applied to time series gene expression 
analysis. Novel algorithms have also been proposed to investigate time series gene 
expression; for example, a novel pattern based clustering method by Phan et al., (2007). 
Recently, some methods have been developed especially for time series data which apply or 
modify the existing methods to analyse time series data (Corduas & Piccolo, 2008; Das, 
Kalita, & Bhattacharyya, 2009; Douzal-Chouakria, Diallo, & Giroud, 2009; Dzeroski, 
Gjorgjioski, Slavkov, & Struyf, 2007; Kriegel, Kroger, Pryakhin, Renz, & Zherdin, 2008; 
Magni, Ferrazzi, Sacchi, & Bellazzi, 2008; Savvides, Promponas, & Fokianos, 2008; Summa, 
Steyaert, Vautrain, & Weitkunat, 2007). Many clustering algorithms have been applied to 
these unique microarray time series data and they include: the Merge SOM (MSOM) 
(Hammer, Micheli, Neubauer, Sperduti, & Strickert, 2005; Strickert & Hammer, 2005), 
Growing Recurrent Self Organising Map (GRSOM) (Yeloglu, Heywood, & Malcolm, 2007) 
and Self Organising Maps and Particle Swarm Optimisation (Xiao, Dow, Eberhart, Miled, & 
Oppelt, 2003). A two-step regression-based approach called maSigPro (microarray Significant 
Profiles) has been introduced to identify differentially expressed genes in time series profiles 
(Conesa, Nueda, Ferrer, & Talon, 2006). Difference-based clustering has also been proposed 
(J. Kim & Kim, 2007). In addition, hybrid principal component and neural networks (PCA-
NN) (Ao & Ng, 2006), multi-step approaches (Amato et al., 2006), and clustering software 
such as TimeClust have been used. TimeClust is freely available to download from its website 
(Magni et al., 2008). A review of time series microarray data analysis can be found in 
Androulakis, Yang, and Almon, (2007), Bar-Joseph, (2004) and Warren Liao (2005). 
 
Analysis of short time series has recently emerged and previous clustering methods, including 
the methods that have been developed for non time series and long time series, data do not 
perform well on short time series data with limited time points (Xuewei, Ming, Zheng, & 
Chan, 2008). Most currently available methods focus on long time series data and, at the time 
of writing, only Short Time series Expression Miner or STEM was specifically designed for 
short time series data.  
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As mentioned above, there are many clustering methods with different advantages. However, 
there is no single method that is able to visualise the patterns of all data, assign one gene to 
multiple groups that is specifically designed for short time series data.  This research aims to 
extract intrinsic biological patterns underlying time series data and find meaningful biological 
knowledge from the combination of four prominent and emergent clustering methods. The 
selected clustering methods used in this research include Self organising maps (SOM), 
Emergent self organising maps (ESOM), Fuzzy clustering by Local Approximation of 
MEmbership (FLAME) and Short time series expression miner (STEM), as explained in 
detail in the next section. 
 
2.4.1 Self Organising Maps (SOM) 
 
Self organising maps were introduced by Coonan (Coonan, 1997). This method projects high 
dimensional data into a one or two-dimensional rectangular or hexagonal grids and organises 
data on similarity basis. The SOM algorithm starts with a predefined map topology 
(rectangular or hexagonal) and then input vectors (gene expression profiles each containing 
expression values of selected genes) that are linked by weights to the map topology based on 
a distance measure. Initial weights are random and are adjusted after each iteration. The 
weights of the node closest to the input vector (the winner) and its neighbours are updated 
until convergence. The principles of SOM are that weight vectors are initially set randomly 
for each neuron and, during learning, input data (gene expression profiles) are compared with 
neuron weight vectors using a distance measure such as Euclidean distance, and weights of 
the best match neuron and its neighbours are updated until nearby neurons represent genes 
with similar expression profiles. The weight of the winner neuron (with the smallest distance 
to the input) and its nearest neighbour neurons are updated after presentation of each input 
vector (or a batch of input vectors) until the map is converged when weight change is 
negligible (Samarasinghe, 2006). A disadvantage of SOM is the user needs to predefine many 






SOM algorithm (X. Liu & Kellam, 2003): 
1. Initialise the topology and size of the output map. 
2. Initialise random weight values over the interval  0,1  as well as the learning rate   and 
the neighbourhood size, r . 
3. For each input node: 
 Present new input vector, v . 
 Calculate the Euclidean distance between input vector and weight vector of each node 
in the output map. The shortest distance (minimum distance) declares the winner 
node, c . 
 







c v w j M

                                     (2.12) 
 
where N  is number of inputs (e.g. samples, patients) in the input vectors (e.g. gene 
expression profile), M  is number of nodes. 
 Modify weight. w , learning rate   and cN , the neighbourhood surrounding the winner 
node c . For each node cj N , new weight can be calculated  as follows: 
 
                                               ,new old oldj j i jw w S d t v w                                       (2.13) 
 
 Incrementally decrease both the neighbourhood size and learning rate ( )th  and repeat 





Data clusters (density of data) from SOM can be visualised by U-Matrix. U-Matrix (unified 
distance matrix) is a coloured map representing the pair wise distances between neuron 
weights; the colour of the map varies according to distance. There are two distinct areas on 
this map where the clusters are separated by a dark gap (the largest distance between neurons) 
and each light area represents a cluster (a smaller distance between neurons). SOM also can 
be visualised by maplets, whose colour represents the spectrum of values of a specific input 
variable (e.g. expression of a gene across all patients). In some program outputs, dark dots 
inside the neurons denote the number of input vectors (expression profiles) represented by 
each neuron. No dot means no input falling into that particular node. 
 
SOM have been used to analyse gene expression data (Fernandez & Balzarini, 2007; Nikkilä 
et al., 2002; Tamayo et al., 1999; Toronen, Kolehmainen, Wong, & Castren, 1999). There are 
limited numbers of public software and tools for gene expression analysis by SOM. For 
example, the SOM_PAK and SOM_Toolbox 2.0 (for Matlab) programs available at the 
Laboratory of Computer and Information Science (CIS), Department of Computer Science 
and Engineering, Helsinki University of Technology (http://www.cis.hut.fi/somtoolbox/) 
(Vesanto, Himberg, Alhoniemi, & Parhankangas, 1999). Some commercial SOM software is 
available including Matlab with its neural network toolbox and Synapse 
(http://www.peltarion.com/products/synapse/). SOM are used to extract information from 
large-scale data but SOM only represent an overview of gene expression data and, therefore, 
further investigation of the map is needed. SOM has some limitations, being restricted to a 
predefined map structure, therefore, more powerful versions of SOM have been developed, 
specifically, Emergent Self Organising Maps (ESOM) (Ultsch & Morchen, 2005). Maps in 








2.4.2 Emergent Self Organising Maps (ESOM) 
 
Emergent Self Organising Maps (ESOM) is based on the concept of emergence. ESOM 
allows the emergence of network structure making it possible to observe overall data structure 
in high level of detail. ESOM topology is a toroid map, and it is used to solve border effects 
of classical SOM. ESOM can be visualised in three patterns: distance-based visualisation (U-
Matrix), density-based visualisation (P-Matrix), and distance- and density-based visualisation 
(U*-Matrix). P-Matrix is used in this study. P-Matrix (Ultsch, 2003a, 2003b) works well for 
gradually changing density and overlapping clusters. This density-based measure represents 
the density in data space sampled using the Pareto Density Estimation (PDE) (Ultsch, 2003b).  
 
U-Matrix shows the distance relationship of the input data in the data space using the average 
distance to neighbours of each neuron. A large U denotes a larger distance to neighbouring 
neurons while a smaller U reveals shorter distances. P-Matrix is compatible with U-Matrix: 
U-Matrix uses local distances to give insights into the distance structure; in contrast, P-Matrix 
uses density values of neurons (number of input vectors represented by each neuron) to reveal 
the underlying density structures of high dimensional data. P-Matrix in ESOM uses data 
density calculated from Pareto Density Estimation (PDE) as P-value at the coordinates of 
neuron, in . Dense areas in a map contain neurons with large P-values while small P-values 
represent sparse areas. For neuron, n , the density of data space can be defined as:  
 
                                                               P = , ,n p w n X                                       (2.14) 
  
where  ,p x X  denotes an empirical density estimation at point x  (i.e  w n )  in the data 





For each neuron, P-Matrix shows the number of input vectors in a Pareto radius of 
hypersphere (Pareto sphere). Under the assumption of multivariate mutually independent 
Gaussian standard normal density distribution (MMI), for at least two clusters in the data, the 
average radius can be calculated by: 
 
                                                              2
1
2
u d ur cd p                                                     (2.15) 
 
where 2dcd  denotes the Chi-square cumulative distribution function for degrees of freedom 
d , and up  is the average probability. For one dimensional data, the 18
th
 percentile is the 
closet percentile of distance to ur . This is called the Pareto radius, pr . ―The density measured 
at point x  using the number of points inside a hypersphere with radius pr  (Pareto radius) is 
called Pareto (probability) Density Estimation PDE( x ) ‖ (p. 2, (Ultsch, 2003b)). 
 
The ESOM method is a promising knowledge discovery approach that has the potential to be 
applied to microarray data analysis. ESOM has been used for clustering real data and the 
performance is superior to traditional SOM (J. Poelmans, P. Elzinga, S. Viaene, M. M. Van 
Hulle, & G. Dedene, 2009b). For example, a study by Ultsch and Morchen (2005) applied 
ESOM with an ALL dataset by Golub et al. (1999) and concluded that ESOM discovered new 
leukaemia sub-classes. 
 
2.4.3 Fuzzy clustering by Local Approximation of MEmbership (FLAME) 
 
Most of the traditional clustering methods are hard clustering methods which allow one gene 
to belong to only one cluster. Fuzzy clustering was introduced to overcome this limitation, 
where one gene can be clustered to more than one cluster. Each gene is assigned a cluster 
membership which indicates the degree of belonging in each cluster. Well-known methods 
include Fuzzy C-Means (Bezdek & Ehrlich, 1984). Fuzzy C-Means has been shown to give 
better clustering results even when the data contained outliers and overlapping areas, when 
compared with SOM, K-Means and hierarchical clustering (Mingoti & Lima, 2006).  
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A recently developed method is Fuzzy clustering by Local Approximations of MEmberships 
(FLAME) (Fu & Medico, 2007). FLAME is implemented by Gene Expression Analysis 
Studio (GEDAS) (http://sourceforge.net/projects/gedas) software. 
 
The FLAME algorithm has three main steps (Fu & Medico, 2007): 
1. Calculating similarities of expression patterns using Pearson‘s correlation, and then 
creating a connected graph of all K-Nearest Neighbours (KNN) of each expression vector. For 
each expression pattern, density, which indicates the number of neighbours within a specified 
distance, is calculated, classifying it into one of three groups:   
(i) Cluster supporting object (CSO) which has higher density than their neighbours,  
(ii) Outlier, which has lower density than its neighbours and a predefined threshold, and  
(iii) The Rest. 
2. Starting with assigning initial memberships to each group. Each CSO, referring to a cluster, 
is given fixed and full membership to itself. All outliers making another cluster are given the 
fixed and full membership in the outlier group. The Rest are given the equivalent or same 
memberships to all cluster and the outlier groups. This step is called Local Approximations of 
Memberships.  Local Approximation of fuzzy membership of the three groups is determined 
and each object is updated by a linear combination of the fuzzy memberships of its nearest 
neighbours or Local Approximations of Memberships. A membership degree of vector, x  in 
cluster, i  is  ip x  and is given by: 
 
 
                                                   1 2: , ,..., ,Mx p x p x p x p x                                      (2.16) 
 






p x p x

    and 1csoM X  , csoX  is the set of clusters supporting 
objects with Local Maximum Density. 
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Membership vector of each object is updated by the summation of x‘s nearest neighbours‘ 
memberships, as in Equation (2.17). 
 
 





p x w p y

                                           (2.17) 
 
where  ( )tp x  fuzzy membership vector of object x  at iteration t  and xyw  is the weight 
vector between objects x  and y .  
 
Each iteration process attempts to reduce the Local (Neighbourhood) Approximation Error 
  E p , the difference between the approximation of membership vectors in the current and 
previous iterations, defined by: 
 




x X CSO Outlier y KNN x
E p p x w p y
   
                      (2.18) 
After finishing the calculation of the Local Approximation of fuzzy membership, the process 
moves to step three. 
3. Clusters can be contracted into two categories based on fuzzy memberships: one gene to 







2.4.4 Short Time series Expression Miner (STEM) 
 
STEM is a software program for analysing short time series gene expression data (Ernst & 
Bar-Joseph, 2006). Many clustering algorithms have been applied to time series data in 
general and more details can be found in Wang et al., (2008). Among available methods, the 
Short Time series Expression Miner (STEM) (Ernst & Bar-Joseph, 2006) was particularly 
created to analyse short time series gene expression data. This method uses the change in 
direction and magnitude of the inputs with time. STEM is a Java-based program; STEM 
(http://www.cs.cmu.edu/~jernst/stem/ ) version 1.3.4 was used in this study. 
 
STEM algorithm 
1. Constructing model profiles. The first step of STEM is to create reference model profiles to 
represent all possible gene expression changes over time in terms of numbers of possible units 
of change. This can be done by discrete changes between two consecutive time points, as no 
change, up or down (e.g. 1, 2, 3 etc.). The first time point is always zero, and then it can 
stay the same or increase or decrease. The maximum changing units is c . The number of all 
possible model profiles ( P ) can be then formulated as: 
 






                                                     (2.19) 
 
where n  denotes the number of time points in a profile. For three time points, n = 3, and for 
3c =  (i.e., successive time points either go up or down for a maximum of three units), there 
are 49 distinct model profiles. If the number of possible model profiles are too many to be 
viewed, for example, n= 5 and c=3 which produces 2,401 possible model profiles, in the next 
step, possible model profiles need to be reduced by selecting m  distinct profiles. The distinct 
model profile is selected, based on maximise the minimum the pair wise distance ( d ) 
between these distinct profiles as expressed in equation 2.20. 
  





p p RR P R m
d p p
 
                                            (2.20) 
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2. Enumerating statistically significant profiles. The experimental time series gene expression 
profile of each selected gene is assigned to the closet reference based on correlation distance, 
and the total (actual) number of genes represented by each reference profile is obtained. The 
number of expected genes in each profile is then calculated. The number of expected genes is 
the possible number of genes when data are random and computed by random permutations of 
the gene expression values. The actual number of genes allocated versus the number of 
expected genes is then used to identify statistical significance. 3. Clustering significant model 
profiles. After obtaining the significant gene profiles, they are grouped according to their 
similarity. The idea of grouping is based on the premise that significant profiles that should be 
grouped together could have been separated due to noise and other effects. This clustering 
step finds true and robust groups so that genes with similar gene expression profiles are 
grouped together. 
 
In conclusion, clustering results from different clustering methods on the same dataset can 
vary. Clustering methods may force the data to cluster even when there is no similar group in 
a given dataset and these create false positives and distort the structure of existing clusters. 
Therefore, clustering is only the first step in the analysis of gene expression data, and careful 
interpretation and further in-depth analysis in needed. For this purpose, using several 
approaches to clustering and comparing the results can be useful in assessing the robustness 
of gene sets. Furthermore, clusters of differentially expressed genes containing upregulated or 
downregulated genes can be used to identify complex patterns in the form of gene networks. 
Network/pathway analysis is explained in the following section in order to shed light on how 









2.5 Network/Pathway Analysis 
 
After gene expression analysis, the next question is how to extract biological meaning from 
differentially expressed genes. The apoptotic pathway is an essential pathway in 
understanding cancer treatment. There are two main mechanisms for apoptosis pathways: the 
extrinsic (death-receptor pathway) and the intrinsic (mitochondrial pathway) (Igney & 
Krammer, 2002). The extrinsic pathway is initiated when a cell responds to an external 
apoptotic signal through a death receptor, while the intrinsic pathway is initiated with a trigger 
of cellular damage or stress (e.g. DNA damage and heat shock) through the mitochondria. 
Cells are normally tightly regulated by these pathways; however, in cancer, there are many 
important malfunctioning genes in the pathway (Folarin & Bioinformatics, 2003). This is 
essential and important knowledge in a clinical study as most chemotherapy induces apoptosis 
through DNA damage; and resistance to therapy often involves resistance to apoptosis 
(Folarin & Bioinformatics, 2003). Transformation of normal cells to cancer cells is caused by 
a complex interaction series of multiple networks and pathways, in particular, apoptosis 
pathways. There are many genes and gene products involved in these pathways. Unravelling 
these pathways (identifying genes and inferring their interaction through their gene networks) 
may lead to a better understanding of cancer treatment through apoptosis pathways.  
 
How to gain a better understanding of gene networks is currently a huge challenge for 
scientists due to a lack of understanding about network structures. Microarray technology has 
had fast paced growth which, in turn, has created a large amount of publicly available data. 
Deciphering gene networks from the rapidly growing microarray expression databases has 
been shown to be a very promising approach in cancer treatment. A current research trend in 
bioinformatics is to construct ―physical‖ networks, for example, gene regulation pathways, 
from ―conceptual‖ networks; for example, co-expression information (Benson & Breitling, 
2006). These tasks require a computational systems biology approach. Pathways and 
biological gene networks can be inferred from the analysis of microarray data by grouping 
genes (also called ―modules‖ or ―gene sets‖). The concept is to find common patterns from 
similar microarray experiments. The changes in gene expression are controlled by gene 
networks. Gene networks can be identified by using time series gene expression data which 
indicates genes that are turned on or turned off at particular times in specific conditions and 
tissues. 
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Recently, inferring gene networks from gene expression profiles has become a new challenge 
for scientists. Various statistical and machine learning methods for inferring gene networks 
have been introduced only in the last decade. Therefore, it is difficult to evaluate or validate 
the performance of these approaches that have already been proposed (Bansal, Belcastro, 
Ambesi-Impiombato, & di Bernardo, 2007; K.-H. Cho et al., 2007; D‘haeseleer, Liang, & 
Somogyi, 2000; de Jong, 2002; van Someren et al., 2002). There are two main approaches to 
developing gene network inference algorithms: physical interaction, which aims to identify 
gene-to-sequence interaction (interaction between target genes and transcription factors) and 
influence interaction, which infers gene-to-gene interaction (finds the relationship among 
expressed genes) (Bansal et al., 2007). Many methods have been used to model/infer genetic 
pathways and interactions and these include Bayesian networks (Friedman, Linial, Nachman, 
& Pe'er, 2000; Schäfer & Strimmer, 2005), Dynamic Bayesian networks (Husmeier, 2003; 
Zou & Conzen, 2005), Boolean networks (Kauffman, Peterson, Samuelsson, & Troein, 2003), 
S-systems (Kimura et al., 2005), ordinary differential equations (ODEs) (Chen, Wang, Tseng, 
Huang, & Kao, 2005), Neural networks (Lee & Yang, 2008), Petri nets (Heiner, Koch, & 
Will, 2004), and Graphical Gaussian models (Toh & Horimoto, 2002). A more detailed 
overview of these methods can be found in K.-H. Cho et al., (2007), Christensen, Thakar, and 
Albert, (2007), Lee and Tzou, (2009), Markowetz and Spang, (2007), Schlitt and Brazma, 
(2007), Styczynski and Stephanopoulos, (2005) and van Someren et al., (2002). Some 
advantages and disadvantages of some selected methods are shown in Table 2.5. 
 
Apart from the methods mentioned above, there are software programs from academic 
institutions and commercial enterprises that provide complex bioinformatics tools to construct 
networks/pathways from genes of interest. There are almost 170 online pathway databases for 
a range of biological processes, which can be divided into four main categories: metabolic, 
signalling, protein interaction and gene regulation (Cary, Bader, & Sander, 2005). A pathway 
database system was created for storing, managing, analyzing, visualising and querying 
biological pathways at multiple levels of detail. Research by Krishnamurthy et al. (2003) 
separated the databases into three groups of biological pathway: metabolic and biochemical; 





Table 2.5: Advantages and disadvantages of some selected methods for modelling/inferring 
gene networks 
 
Methods Advantages Disadvantages 
Mathematical Modelling 
Boolean Networks  Computationally simple 
 Binary model assumes gene 
to be either on or off 
 Networks are inherently 
dynamic 
 Can explore large scale 
networks 
 
 Neglect intermediate 
transitions that are well-
known and proven. 
 
Bayesian Networks  Statistical reference 
 Handle noisy data 
 Used with incomplete data 
 Able to add prior 
knowledge 
 
 Increase in computational 
complexity 
 Networks are inherently 
static but can be overcome 
by dynamic Bayesian 
networks; however, limited 





 More accurate models; 
describe network in great 
detail 
 
 Lack of in vivo and in vitro 
measurement of the kinetic 
parameters in the rate 
equations 
  Implicit assumptions not 
valid at molecular level 
 
Machine Learning approaches 
Neural Networks  Handle complex problems 
from discrete to continuous  
 Handle many variables and 
non-linear interactions 
 Flexible and adaptive 
learning  
 Reliable network prediction 
 Ability to retrieve  all 
possible interactions 
between predictor variables 
 Can combine multiple  
    training algorithms 
 
 Computational cost depends 
on chosen topology and 
learning algorithms 
 Optimal network topology is 
difficult to define 
 Neural networks is implicit 
and difficult to explicitly 




Genetic Algorithms  Robust optimisers  GAs are very slow 
 Do not find the exact solution 





Examples of well-known pathway databases are: KEGG (www.genome.ad.jp/keg) (Kanehisa 
& Goto, 2000) and Biocarta (www.biocarta.com). Each database has different 
conceptualisations, and which one is the best for a problem depends on the purpose of the 
study. Network/pathway analysis software available include ASIAN (Aburatani, Goto, Saito, 
Toh, & Horimoto, 2005), Cytoscape (Shannon et al., 2003), GeneNet (Ananko et al., 2005), 
GeneNetwork (C. C. Wu, Huang, Juan, & Chen, 2004), Oncomine, The BiblioSphere 
Pathway Edition (BSPE) and Ingenuity Pathway Analysis software (IPA). The latter three are 




Oncomine (Rhodes et al., 2007; Rhodes et al., 2004) is a knowledge-based database curated 
from the existing literature of human cancer gene expression profiles and an integrated data-
mining platform. The differentially expressed genes were analysed using t-statistics and 
corrected for measure of significance using false discovery rates. As of 22 June, 2009, there 
were 41 cancer types with 392 studies and 28,880 microarray experiments available for 
further analysis with integration another 18 bioinformatics resources including GEO, SMD, 
KEGG pathways, Gene ontology and Biocarta. Oncomine (i) collects microarray data from 
the original authors‘ website or downloads from them publicly available databases and then 
(ii) all datasets are transformed to log scale and median-centred for each array and normalised 
to one standard deviation, and next (iii) stores all data in the Oncomine database by re-naming 
all datasets to FirstAuthor_TissueTypeProfiled. All data are grouped into analyses of interest, 
for example, cancer tissue versus normal tissue, several molecular subtypes and treatment 
responses. Then the t-test is used to identify differentially expressed genes for two classes of 
expression profiles, while Pearson‘s correlation is used for multiclass comparisons. Both 
statistical methods are implemented using the R statistical computing package (http://www.r-
project.org).  
 
The top 50% of genes are then selected by using average linkage hierarchical clustering to 
represent coexpressed genes. Oncomine also analyses microarray data in terms of molecular 
concept analysis. Data can be retrieved from the Oncomine website for gene signatures of the 
top 1%, 5% or 10% of overexpressed and underexpressed genes from a selected analysis. 
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Genes in those lists are ranked using p values. For interaction network analysis, cancer 
networks are identified from known protein interaction databases or Human Protein Reference 
Database (HPRD) (http://www.hprd.org). Oncomine can be freely accessed for academic 
research through the website http://www.oncomine.org. 
 
2.5.2 BiblioSphere Pathway Edition (BSPE) 
 
The BiblioSphere Pathway Edition (BSPE) (Genomatix Software, Munich, Germany, 
http://www.genomatix.de) is a software program to analyse gene relationship networks and is 
claimed to be the only software that uses curated information from literature analysis with 
proprietary genome annotation and promoter analysis. The main database for BSPE is 
PubMed, combined with other data sources including Gene Ontology, MeSH, KEGG 
Pathway and Biocarta. When a user inputs data into BSPE and all possible results are 
retrieved, a z-score is used to identify meaningful genes. The z-score indicates the over- or 
underrepresented annotation from the input gene set based on the number of observed and 
expected annotations of the specific term. 
 
The z-score defines the distance and direction of annotation term from its distribution mean 
















In BSPE, the z-score is given by: 
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                                 (2.21) 
 
where N denotes the total number of annotated genes, R  is the number of genes meeting the 
filter criterion, n  is the total number of genes in the set analysed, and r  is the number of 
genes meeting the filter criterion in the analysis set. 
 
The BiblioSphere Pathway View can be used to elucidate the optimum and relevant networks 
and pathways for the input gene set including known metabolic and transduction pathways. 
The input gene set can be viewed in its bibliographical environment, which includes input 
genes and genes co-cited with input genes. The information about relationships from the 
literature is also reported as a graphical network. Network nodes can denote genes and edges 
represent the relationships between genes. Generally, a network node can take various forms, 
for example, it can be a transcription factor, a part of a metabolic pathway or a part of a 
Genomatix signal transduction pathway. Furthermore, in the case of genes, the colour of a 
node indicates the over or under expression of a gene in Bibliosphere. Red nodes indicate 
overexpressed genes while blue nodes indicate underexpressed genes. Likewise, connections 
and relationships are described by the type of arrow head, for instance, an open arrowhead is 
regulation, a filled arrowhead is activation, a blocked arrowhead is inhibition and a red 
arrowhead is an enzymatic modification. Networks can be viewed at six levels including 
Abstract level (two genes are mentioned in the abstract of an article), Sentence level (two 
genes are mentioned in the same sentence), Function Word level (two genes are mentioned in 
the sentence with a functional term, for example, inhibit), Gene-Function Word (GFG)( two 
genes are mentioned in order in the sentences with a functional term, for example, E2F1 
activates TP53), and expert level (two genes are hand annotated from sentences by experts) 
and signal transduction associations (two genes are mentioned in the sentences with signal 
transduction information (pathway associated-term).  
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2.5.3 Ingenuity Pathway Analysis software (IPA) 
 
Ingenuity Pathway Analysis software (IPA) (Ingenuity® Systems, Redwood City, CA, USA, 
http://www.ingenuity.com) is a web-based application that integrates a systems biology 
approach to solve various biological problems. The knowledge base of IPA comes from 
journal articles, textbooks and other data sources. This software program has many 
applications; but only functional analysis of genes and their networks have been used in this 
study. The p-value defines the significance of a gene‘s function in a network as well as gene 
to gene relationships, and a p-value less than 0.05 signifies a statistically significant and non-
random association. The right-tailed Fisher Exact Test is used to calculate the p-values. IPA 
presents the relationships and connections between a gene and curated genes in Network 
explorer and Canonical Pathways features. The node shape and colour indicate the different 
types of gene function; for example, squares represent cytokines, and diamonds represent 
enzymes.  Moreover, for up-regulated genes, nodes are red while green nodes indicate down-
regulated genes. Grey means neither up nor down-regulated and white defines the non input 
genes which are added to the network through the connection with other genes. Similar to 
BSPE, IPA uses arrows to indicate relationships; for example, a filled arrowhead indicates 
acts on, an unfilled arrowhead represents translocates to and an open arrowhead represent a 
reaction.  
 
IPA uses a six step algorithm to create the networks. Step one: the focus genes are connected 
with other genes using the interconnectedness triangles concept. Step two: the networks will 
grow as the number of triangles increases. The top ranked genes (most connected) are selected 
by using a metric called ―specific connectivity‖ which is defined as follows: 
 
Number of genes in intersection of the neighbourhood and network
Specific connectivity = 
Number of genes in union of neighbourhood and network
 
 
The selected networks are added to a maximum network size of 35 connections. As a network 
grows, the overlapping genes are selected and added to the existing network. Step three: in the 
case of smaller networks, this method tries to reveal as many relationships as possible; 
therefore, small networks are merged together with ―linker‖ or common genes between those 
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networks. This step by step process continues until the network size can be displayed, 
otherwise, it continues to step four. For networks with fewer than 35 genes, this algorithm 
will add extra genes to create triangle connectivity. A gene is selected based on the highest 
gene expression value or its top rank order in the neighbourhood of genes. Step five: all 
networks are merged to one single network with roughly 35 genes. The final step: p-scores are 
used to rank networks. The P-score can be described by: 
 
 10p-score log p-value   
 
The p-value represents the probability of finding the focus genes in the global molecular 
network in the database. 
 
In summary, three network/pathway analysis tools are used in this study. IPA is the main 
network/pathway tool used in Chapter 4 and 5. BSPE was used to verify the result from IPA 
in Chapter 5 because this network/pathway tool is based on the same concept as IPA. Both 
tools use curated information from literature/journal articles. Oncomine was selected because 
it represented the knowledge-based databases from the existing literature of human cancer 
gene expression profiles. This tool is used to add information on GR expression levels in 
other existing childhood leukaemia data. 
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    Chapter 3 
Emergent Clustering Methods for the Identification of 
Glucocorticoid-induced Apoptosis Genes 
3.1 Introduction 
Glucocorticoids are the most important drug for treating leukaemia, most notably in children 
with acute lymphoblastic leukaemia. Generally, the mechanism of GCs is mediated by 
binding to the glucocorticoid receptor, a ligand-activated transcription factor that exerts a 
pivotal role in inducing apoptosis in malignant lymphoids. It is localised in the cytoplasm and 
translocated to the nucleus. The GC-GR complex activates or represses the target genes. 
There are more than 2000 studies on GC-induced apoptosis in lymphoid cells (Herr et al., 
2007), of which some studies focus on identifying GC-regulated genes by using gene 
expression profiles from different cells, drugs and samples, as shown in Table 3.1. However, 
only a few overlapping genes have been reported (Schmidt et al., 2004). The most prominent 
study by Schmidt et al. (2006), contains the only time series dataset that were collected from 
patients, defined novel GC-induced apoptosis genes from childhood ALL patients at early 
response treatment. This gene expression data still has potential for further analysis. 
 
Gene expression data can be used for four classes of analysis: class comparison, class 
prediction, class discovery and pathway analysis (Simon et al., 2003). Class discovery 
attempts to find groups in the samples (patients) or genes. Class comparison aims to identify 
differentially expressed genes between at least two groups of different biological processes; 
for instance, disease state and treatment group. Class prediction uses gene expression profiles 
to predict group membership of a sample. Pathway analysis adds information about functional 
annotation of differentially expressed genes and gives a picture of genes working as a cascade 
network. There are at least three pathway analysis methods: cluster analysis, reverse 
engineering and pathway databases and tools (Leung & Cavalieri, 2003). Pathway analysis 
can help to understand underlying mechanisms of a selected process. Therefore, the main 
focus of this chapter is on identifying GC-regulated genes, potential functional gene clusters 
and pathway analysis on the basis of differentially expressed genes clusters. A detailed 
description of gene clustering is provided in the following section.  
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Table 3.1: Differentially expressed genes involved with GC-induced apoptosis mechanism of 
childhood leukaemia treated with glucocorticoids, from previous studies (adapted from 
Schmidt et al., 2004 and Tissing et al., 2007). 
 
Genes and Criteria Drugs and Time Cell line studies, Gene chip  and 
Tools 
References 
39 up-regulated genes and 21 down-
regulated genes 
> 2.5 fold for up-regulated and > 2 
fold for down-regulated 
Dexamethasone 
24, 48, 72 and 96 
hours 
Childhood ALL cell lines-CEM 
(sensitive and  resistance clone)                                             
HG_U95Av2  
Affymetrix GeneChip suite 4.0 and 
GeneSpringTM 
Medh et al. 
(2003) 
98 genes (23 up-regulated genes and 
75 down-regulated genes 
Six criteria, including at least 2 fold 
for up-regulated and at least 0.5 fold 
for down-regulated 
Dexamethasone 
three and eight 
hours 
T-ALL cell lines: Jurkat and CEM-C7                           
Hu6800/HuGeneFL GeneChip 
Obexer et al. 
(2001) 
113 genes 
> 3 fold 
Triamcinolone 
acetonide 
four and eight hours 
697- a human pre-B leukemic cell line 
derived from childhood ALL            
HG U95A array 
Affymetrix Microarray Suite (MAS 
5.0) and the NetAffx website 
Planey et al. 
(2003) 
22 genes 
> 0.7 fold at least 6 of 13 patients and 
subtract cell cycle genes 
Prednisolone 
0,6/8 and 24 hours 
Childhood leukaemia in vivo treatment 
HG U133 Plus 2 
Affymetrix GCOS software and R 
packages  
Schmidt et al. 
(2006) 
163 GC-regulated genes and 66 
G1/G0 genes 
> 2 fold 
Dexamethasone         
0, 2 and 8 hours 
CCRF-CEM                                    
Incyte Gemomics 
Tonko et al. 
(2001) 
51 genes (39 up-regulated genes and 
12 down-regulated genes) 
p-value < 0.001 and FDR < 10% 
Prednisolone                    
three hours and 
eight hours 
In-vitro paediatric leukaemia cell lines                           
HG U133A GeneChip 
R packages 
Tissing et al. 
(2007) 
121 genes (93 up-regulated genes and 
28 down-regulated genes) 
> 3 fold, one or more time points 
Dexamethasone          




697- a pre-B ALL cell lines                
HG U95A array  
GeneChip analysis suit software 
ver.3.3 (Affymetrix) 
Yoshida et al. 
(2002) 
39 up-regulated genes and 21 down-
regulated genes  
at least 2.5 fold for up-regulated and 
at least 2 fold for down-regulated, for 
two out three experiments 
Dexamethasone                    
20 hours  
Childhood ALL cell lines-CEM 
(sensitive and  resistance clone)                                             
HG_U95Av2  
Affymetrix Microarray Suite (MAS 







Clustering or unsupervised classification approaches give a cluster of distinct and highly 
similar genes (or co-expressed genes) without a predefined cluster. ALL time series data are 
extremely limited, which leads to the key challenge of how to analyse this limited time series 
gene expression data in order to maximise the utilisation of invaluable data. As reported in 
Chapter 2, there are many techniques developed for clustering gene expression and more 
methods are being developed. Among the existing methods, three types of technique have 
been selected. (i) Neural networks, a well-known and widely used clustering method that has 
been used in cancer gene expression analysis (Golub et al., 1999). (ii) Time series clustering 
(many clustering algorithms have been applied to time series data and more details can be 
found in Wang et al., (2008). (iii) Fuzzy clustering: fuzzy clustering was introduced to 
overcome crisp clustering where one gene belongs to one cluster. Each gene is assigned a 
cluster membership which indicates the degree of belonging in each cluster. This study uses 
four specific methods: Self-Organising Map (SOM), Emergent Self Organising Maps 
(ESOM), Short Time Series Expression Miner (STEM) and Fuzzy clustering by Local 
Approximations of MEmberships (FLAME) to analyse short time series gene expression data 
extracted from prednisolone (glucocorticoid) treated childhood leukaemia patients. The 
results from this study are used to identify gene clusters responsive to GCs and to further infer 
gene networks and pathways. 
 
3.2 Data and Software 
 
The data used in this study were collected by Schmidt et al. (2006) from childhood leukaemia 
patients treated with GCs in a study investigating GC-induced apoptosis. The data were 
collected over a period of 24 hours after treatment, making the dataset excellent for 
reconstructing gene networks. 
 
Prior to gene clustering, differentially expressed genes must be identified. Our goal is to first 
verify the original authors‘ findings on differentially expressed genes, and then explore gene 
clusters to infer gene networks from short time series expression data analysis in childhood 
leukaemia. It should be noted that a common problem with microarray data is the curse of 





Raw data in the format of CEL files and normalised microarray data were obtained online 
from the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). Raw data, 
comprising gene expression measurements for 13 patients (three T-ALL patients and ten B-
ALL patients) were collected at three time points: 0 hour, 6/8 hours and 24 hours. The initial 
analysis of time series gene expression data for differentially expressed gene identification 
followed the method used by Schmidt et al. (2006). Specifically, raw data was reprocessed, 
starting from normalisation and selection of differentially expressed genes, with the same log 
ratio threshold as in the original article. All 39 files were processed and normalised by Robust 
Multi-array Average (RMA) in R as in the original study; however, our study not only used R 
as in the original article, but also additionally used RMAExpress and Matlab to calculate the 
gene expression matrix. Furthermore, our study extended the original authors‘ work to 
compare gene expression patterns at six hours and 24 hours. The original authors‘ mainly 




There are many existing software and tools for RMA calculation available from both 
commercial and free sources. This study selected three software programs: Matlab, R, and 
RMAExpress, with the following characteristics, to investigate differentially expressed genes:  
 Matlab (http://www.mathworks.com/) uses affyrma command from bioinformatics 
toolbox to calculate Robust Multi-array Average (RMA). 
 R (http://www.r-project.org/) is software for statistical computing and graphics 
developed by BioConductor Project (http://www.bioconductor.org/) which is freely 
available source for users and developers to analyse genomic data based on the R 
programming language. 
 RMAExpress (http://rmaexpress.bmbolstad.com/) is a web-based tool used to compute 
RMA normalisation of Affymetrix Genechip® data and does not require R or any 
component of the BioConductor  project and runs on Windows (and Linux). 
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Identifying patterns from time series gene expression data could provide insights into the 
underlying gene function and gene networks. Therefore, clustering methods were used in this 
research. The four selected methods are: SOM, ESOM, STEM, and FLAME. Each method 
was selected according to their strengths; they are all user friendly software that has been 
recently developed and still has potential for further development.  They have never been used 
with childhood leukaemia time series data. A summary of these methods is given below: 
 
Self organising maps (SOM), based neural networks, is a nonlinear clustering method with 
attractive features of data visualisation and dimensionality reduction. SOM can be visualised 
based on U-Matrix that indicates the distance between each neuron and it neighbours. 
Peltarion Synapse, a commercial neural networks software, was used and the trained map 
neurons were clustered using ward clustering. 
 
Emergent self organising maps (ESOM) (Ultsch & Morchen, 2005) is an extension of SOM 
which allows a map to grow from the initial map. This analysis uses P-Matrix to analyze the 
density of the gene expression data. P-Matrix is a matrix with entries denoting data density of 
neurons in their respective neighbourhoods.  A neuron with a large P is located in a dense data 
region while a small P indicates sparse data regions in the data space. Data can be analyzed by 
using publicly available ESOM software (Databionics ESOM Tool) developed by Ultsch and 
Morchen (2005). This software is available to download from http://databionic-
esom.sourceforge.net/.  
 
Short Time series Expression Miner (STEM) (Ernst & Bar-Joseph, 2006) was specifically 
created to analyse short time series gene expression data. This method uses the change in 
direction and magnitude of the inputs with time. The operation of the STEM algorithm can be 
divided into three major steps: (i) selecting reference model profiles (gene expression pattern) 
that are constructed before analysis, and use all possible gene expression log-ratio increments 
(from 1 to 3, for example) for the two time steps of 6 h and 24 h with respect to time 0 h, 
(ii) identifying significant reference model profiles that match actual gene expression patterns 
according to p-values by using a permutation method, and (iii) grouping significant profiles. 




Fuzzy clustering by Local Approximations of MEmberships (FLAME) (Fu & Medico, 
2007). This algorithm starts by calculating similarities of expression patterns using Pearson‘s 
correlation and then creating a connected graph of all K-Nearest Neighbours (KNN) of each 
expression vector.  For each expression pattern, the density, which indicates the number of 
neighbours within a specified distance, was calculated to classify it into one of three groups: 
(i) cluster supporting object (CSO), (ii) outlier, and (iii) the rest. In the next step, the local 
approximation of fuzzy membership of the three groups is determined and each object is 
updated by a linear combination of the fuzzy memberships of its nearest neighbours. Finally, 
the clusters can be contracted, based on fuzzy membership, into two categories: one gene to 
one cluster or one gene to multiple clusters. FLAME is integrated with Gene Expression Data 
Analysis Studio (GEDAS). The software is freely available to download from 
http://sourceforge.net/projects/gedas. 
 
Each program allows the user to adjust parameters. Synapse (SOM) used a map sized 1515, 
with 100,000 epochs (number of batch iterations) in training, with initial and final learning 
rates of 0.5 and 0.001, respectively, and 14,000 epochs during clustering, starting with 0.1 
learning rate that reached 0.001 at completion. It uses a Gaussian neighbourhood function 
with a linear decay function. The ESOM was trained using online learning of a map sized 
5082, 20 training epochs, a correlation distance function and a linear function with cooling 
strategy for radius and learning rate. STEM was clustered with a 0.7 minimum correlation 
coefficient and the 0.05 significance level. FLAME was used with Pearson‘s Correlation for 
10-Nearest Neighbours with 0 and 50% thresholds.  
 
The last tool used in this analysis is the Database for Annotation, Visualisation and Integrated 
Discovery (DAVID). DAVID (http://david.abcc.ncifcrf.gov/) is a web-based program for 
functional annotation and bioinformatics microarray analysis (Huang et al., 2007). DAVID 
has many functions, of which functional annotation clustering, gene functional classification 
and gene ID conversion were used in this study for validating the cluster obtained from the 
above cluster analysis. DAVID uses the EASE score or a modified Fisher Exact P-value to 
rank the biological significance of gene groups/functions. The user uploads a gene list to 
DAVID on the web and then chooses criteria for functional annotation clustering and gene 
functional classification. We used the default setting for both functions. 
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 Functional annotation clustering  
Functional annotation clustering clusters relevant annotations for an input gene list in order to 
find similar gene annotation terms, reduce redundant terms and group heterogeneous gene 
annotation. The hypothesis for clustering is that similar annotations should contain similar 
gene members. The level of common genes between two annotations can be calculated using 
Kappa statistics (a measure of the degree of agreement between two groups of data, which 
varies from 0 to 1 (weak to strong)). Then fuzzy heuristic multiple linkage clustering is used 
to cluster a group of similar annotations (similar kappa values). Users can define criteria for 
functional annotation clustering, for example, three similarity terms overlap at the 0.50 
similarity threshold with classification of three initial group memberships, three final group 
memberships and 0.50 multiple linkage thresholds. 
 Gene functional classification 
Gene function classification can help the interpretation of biological meaning from a large 
input gene list. This tool calculates a gene-to-gene similarity matrix that shares functional 
annotations. The fuzzy heuristic multiple linkage clustering method is also used in gene 
functional classification to cluster functionally related gene according to Kappa values. Users 
can define criteria for functional annotation clustering, for example, four similarity terms 
overlap at the 0.35 similarity threshold with classification of four initial group memberships, 
four final group memberships and 0.50 multiple linkage thresholds. 
 
To summarise, these steps were used in this study: 
1. Raw data in the format of CEL files were retrieved from the website of the National Centre 
for Biotechnology Information (NCBI). Raw data comprised data for 13 patients (3 T-ALL 
patients and 10 B-ALL patients) and were collected at three time points: 0 hour, 6/8 hours, 
and 24 hours. 
2. All 39 files were processed using the same approach, called Robust Multi-array Average 
(RMA), but using different software: Matlab, R and RMAExpress to calculate a gene 
expression matrix. 
3. All gene expression matrices were retrieved and then the log ratio was calculated. The 
original authors‘ gene expression matrix, called M-values, was downloaded from the NCBI 
website. 
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4. The two sets of criteria used to select differentially expressed genes in the original article 
were log ratios of more than or equal to 0.7 and 1.0 or less than or equal to -0.7 and -1.0 in at 
least six out of 13 patients. Our study also carried out the analysis with the same ratios. 
5. In our study, a further analysis for differentially expressed genes for childhood ALL 
subgroups T- and B-ALL, were considered at a fold change equal to 1.0±  with a change of at 
least five out of ten patients for B-ALL and at least two out of three patients for T-ALL.  This 
was to identify genes that differentiate the two subgroups of ALL.  
6. Then, the genes that passed the criteria were defined as differentially expressed genes and 
were clustered by the four clustering methods (SOM, ESOM, STEM and FLAME) in order to 
find similar gene expression patterns and pathway relationships. Next, DAVID was used to 
verify clusters from the selected clustering methods according to gene function. 
7. Finally, we compared the resulting gene list with that extracted by the original authors as 
well as other lists presented in previous studies and the GC-regulated genes. 
 
3.3 Results and Discussion 
3.3.1 Validation/extension of original authors’ results and identification of GC-
regulated genes 
 
The raw data from original authors‘ study were used to analyse their reproducibility or 
robustness. We re-processed this data starting from normalisation then selected differentially 
expressed genes with the same log ratio threshold as in the original article. Specifically, all 39 
files were processed and normalised by Robust Multi-array Average (RMA), as in the original 
study and using the R program. We further investigated the effect on the final gene set of 
using different platforms (software) to normalise data. We added two platforms: Matlab, and 
RMAExpress, and compared the number of differentially expressed genes with that of the 
original authors, as shown in Table 3.2. In the original paper, Schmidt et al., (2006) combined 
the data for T-ALL and B-ALL in the analysis and selected differentially expressed genes 
under two conditions: (i) log ratio of 0.7 or higher (ii) log ratio of 1.0 or higher, for at least 
six out of the thirteen patients.  
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The authors‘ results contained 62 probe sets (25 induced+37 repressed) (49 genes) for early 
response (6 hours) and 66 probe sets (28 induced+38 repressed) (55 genes) for late response 
(24 hours). (A gene is represented by a probe set that needs to be converted to a gene symbol 
and some probe sets are repeated more than once). Schmidt et al. (2006), however, mainly 
focused on 0-6 hours in their subsequent analysis. Schmidt et al. (2006) found only 32 probe 
sets (22 genes) for 0-6 hours after deleting cell cycle genes.  
 
The results in Table 3.2 show that we have found more probe sets including all the probe sets 
from the original paper. More detail of the probe sets, comparing the original authors‘ results 
with our data analysis may be found in Appendix A.1 and extra probe sets are reported in 
Appendix A.2. We re-analysed M-values, gene regulation values, and compared the number 
of genes that passed the criteria and were indicated by the original author. We found more 
differentially expressed genes from M-value (re-analysis) than the one reported in the original 
paper. R and RMAExpress are presented together because both produced the same results.  
 
We compared differentially expressed genes selected from three different methods and the 
results are shown in Figure 3.1. R/RMExpress showed the most consistency because it gave 
genes which overlap with other methods. In this study, we then used gene expression values 
retrieved from R for further analysis.  
 
We selected some probe sets that passed the criteria from each platform to illustrate the 
variation from different platforms on the final selected gene set. At early response, namely six 
hours, some selected, induced and repressed probe sets (x-axis) are presented in Figures 3.2 
and 3.3 with respect to the number of patients (y-axis). As can be seen in both figures, the 
probe sets that passed the criteria from each method varied. Matlab and R/RMAExpress 
produced similar results. Not all probe sets that passed the criteria in one platform passed 
them in the other two platforms. Sometimes only one patient made the difference between a 
pass or fail in criteria (six or five patients out of thirteen). In Figure 3.2, while eleven probe 
sets passed the criteria, when using M-values (reanalysis), these probe sets failed when using 
Matlab and R/RMAExpress. 
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Table 3.2: Lists of induced and repressed probe sets from Matlab, M-values (from original 
and reanalysis) and R/RMAExpress 
 
 6 h 24 h 
 Induced Repressed Induced Repressed 
Original  authors‘ 
(M-values) 
25 37 28 38 
Re-analysis 
M-values 
58 66 212 258 
Matlab 56 75 226 266 




      Induced genes at 6 h                           Repressed genes at 6 h 
    Matlab                                                    Matlab 
 
 
                                 1                                                             1 
 
                                         9                                          1                16 
                                 46                                                         57 
 
                    11           1                                            8                        
 
 
M-values     R/ RMAExpress                        M-values      R/RMAExpress 
 
                  Induced genes at 24 h                           Repressed genes at 24 h 
   Matlab                                                    Matlab 
          
                       
                                10                                                            7 
 
                        3             39                                             1         34 
                                174                                                         224  
            
                   35                                                              33        
    
                                
   M-values     R/RMAExpress                        M-values      R/RMAExpress 
 
 
Figure 3.1: Venn diagram of glucocorticoid induced differentially expressed genes at 6 h and 









































































































































































Figure 3.2: Some examples of induced probe sets that passed the criteria at 6 h from Matlab, 





























































































































Figure 3.3: Some example of repressed probe sets that passed the criteria at time 6.h from 






We found that combining B-ALL and T-ALL data compromised the accuracy of selection of 
differentially expressed genes in both T-ALL and B-ALL. It was possible that the selected 
differentially expressed genes came entirely from B-ALL patients, as there were only three T-
ALL patients. We looked at the 22 proposed candidate genes from the original authors and 
found that there were some genes common to both subtypes, but some genes were found only 
in one subtype, as indicated in Table 3.3. Therefore, we separated the two types of patients 
and a new set of differentially expressed genes was selected for T-ALL and B-ALL for each 
time point. The new criteria used were a log ratio of  1 or higher for at least five out of ten 
B-ALL patients and two out of three T-ALL patients. We also analysed data for early 
response (6 hours) and late response (24 hours), but we added an analysis for response 
between 6 and 24 hours because this could give more information about gene activity at 
different times. The results are shown in Table 3.3. 
 
Table 3.3 shows the number of differentially expressed genes six hours after treatment, 
between 6 hours and 24 hours and 24 hours after treatment (before and after deleting cell 
cycle genes). The final set had 237 probe sets (203 unique probe sets after removing repeats) 
for T-ALL for the combined time points and 257 probe sets (207 unique probe sets) for B-
ALL and these were then combined into one set. The final set contained 380 unique probe sets 
(24 unique probe sets were common to T-ALL and B-ALL, of which three probes were not 
found in the original paper). These were converted from probe set ID to gene symbol using 
DAVID. The cell cycle genes were then deleted from this dataset (the cell cycle gene list was 
retrieved from KEGG, Cell cycle database, and the original article). After deleting the cell 
cycle genes, T-ALL contained 222 probe sets (172 unique probe sets) and B-ALL contained 
190 probe sets (155 unique probe sets) for the combined time points. The final set had 327 
unique probe sets (304 genes) responsive to GCs (19 unique probe sets were common to T-
ALL and B-ALL). These genes were then assessed for their time of activation (0 h, 6 h, and 







Considering the possibility of activation, these patterns can be classified into four groups with 
some examples of gene lists shown in Figure 3.4 and Table 3.4. (1) Genes differentially 
expressed only at 0-6 or 0-24 h, for example, included 15 induced genes and nine repressed 
genes from T-ALL. (2) Genes differentially expressed at 0-6, 6-24 and 0-24 h, for example, 
included three induced genes from B-ALL. (3)  Genes differentially expressed at 0-6 h and 0-
24 h, for example, included nine induced genes and two repressed genes from B-ALL. (4) 
Genes differentially expressed at 6-24 and 0-24, for example, included 13 induced genes and 
seven repressed genes from T-ALL.  
 
We then compared our differentially expressed genes from T-ALL and B-ALL with Schmidt 
et al. (2006). The original authors had compared their results with those reported in a previous 
review paper of Schmidt et al. (2004) which reported genes regulated by GCs from previous 
studies. The comparison results are explained, as follows: 
 There are 31 genes reported as GC-regulated genes from different systems, from a 
previous review of Schmidt et al. (2004). None of the top seven genes (LDH-A, 
GPR65/TDAG-8, MAP2K3, GZMA, MYC/c-myc, NR3C1/GR, and BCL2L11/Bim) of 
which were found regulated more than two-fold in the Schmidt et al. (2006) study. Our 
study found two out of seven known GC-regulated genes met our new criteria for T-
ALL: NR3C1/GR and BCL2L11/Bim. Only three out of 31 genes (FKBP51, SOCS1, 
and DDIT4/Dig2) were found in the Schmidt et al. (2006) study. Altogether, our study 
found that six genes in the subtypes overlapped the genes listed in Schmidt et al. (2004). 
B-ALL had one unique gene, FKBP51, and four genes (BCL2L11/Bim, NR3C1/GR, 
TUBB, and HES1) were unique found in T-ALL. SOCS1 is the only one found in both 
patients. 
 Finally, the Schmidt et al. (2006) study proposed 22 novel GC-regulated genes as 
common to B-ALL and T-ALL. We confirmed that only 8/22 candidate genes belonged 
to both B-ALL and T-ALL, and 14/22 genes were found only in B-ALL or T-ALL, as 





Table 3.3: Differentially expressed genes 
Differentially expressed genes six hours after treatment, between six hours and 24 hours, and 24 hours after 
treatment (before and after deleting cell cycle genes) at  1 fold change 
 
 0-6 hours 6-24 hours 0-24 hours 
 Before After Before After Before After 
 
Induced Repressed Induced Repressed Induced Repressed Induced Repressed Induced Repressed Induced Repressed 
T-ALL 19 10 19 9 59 51 56 49 58 40 56 33 
B-ALL 24 23 24 9 16 13 16 9 73 108 71 61 
Common 1 1 1 1 1 5 1 4 5 13 5 9 
 
 
                            T-ALL                                                     B-ALL 
      Induced                        Repressed                 Induced                       Repressed 
15 43 39 9 42 26 12 5 51 7 3 53 
 13 13  7 7  8 8  6 6  
4  4    9  9 2  2 
      3 3 3  
 
0-6 6-24 0-24 0-6 6-24 0-24 0-6 6-24 0-24 0-6 6-24 0-24 
                         
Figure 3.4: Candidate differentially expressed GC-induced apoptosis genes in Table 3.4 
broken down into the four patterns of expression. 
 
Numbers indicate the number of genes that are turned on or off (induced and repressed after deleting cell cycle 
genes-same numbers, as indicated in Table 3.4) at three time points for both T-ALL (left hand side) and B-ALL 
(right hand side). The numbers connected with a solid line indicate that they are all the same genes active at 











Table 3.4: GC-regulated genes and their activity patterns 
 
No. Patterns Genes 
1 Genes differentially expressed (turned 
on) only at six hours or 24 hours  
EGR1, SOCS1, IGHM, LYZ, PIK3IP1 
HES1, S100A12, GNG11, BCL2L11, 
ZNF24, and 1552230_AT 
2 Genes turned on from six hours to 24 
hours  
S100A8, ZBTB16, and P2RY14 
3 Genes turned on at six hours and stay at 
same expression level at 24 hours  
GIMAP7, SLA, FKBP5, SNF1LK, 
PFKFB2, EPPK1, WFS1, C6ORF85, 
BTNL9, and TFP1 
4 Genes turned off at six hours but turned 
on at 24 hours  
STAB1, TNFSF8, KIAA0101, DTL, 
TYMS, RRM2, PPBP, FEN1, TMSL8, 














Table 3.5: Gene list found by original authors using the combined dataset and the presence or 
absence of these genes in the two sub-types of ALL from separate analysis of the subtypes 
 
Gene symbol Description T-ALL B-ALL 












 Butyrophilin-like 9 
 






 SNF1-like kinase 
 






 FK506 binding protein 51 
 










 Kinesin family member 26A 
 






















 DNA-damage-ind.transcript 4 
 






 Guanylate binding protein 4 
 






 HGFL gene 
 






 Zinc finger protein 36 
 














 Epiplakin 1 
 






 Purinergic receptor P2Y 
 






 Gardner-Rasheed v-fgr 
 














 cAMP-regulated PP21 
 






 Proteinase inhibitor, clade A 
 






 GTPase, IMAP family M7 
 






 c-myc promoter BP 
 






 Galectin 3 
 







Many previous hypotheses and studies revealed possible GC-regulated genes based on other 
systems, such as cell-lines and mouse tissues, while the dataset used in this study was 
retrieved from patients. The only concern with this set is the small number of samples. 
Another issue that needs to be included is the ambiguity surrounding the differences in drugs 
that may alter treatment results and side effects. All studies reviewed by Schmidt et al. (2004) 
used dexamethasone while we have used datasets from prednisolone. The difference between 
prednisolone and dexamethasone is still inconclusive and not clear. Some researchers have 
also compared side effects, taste and efficacy of these two drugs in several diseases, i.e., 
asthma and ALL.   
 
In addition, some studies mentioned no difference (or advantage) between dexamethasone and 
prednisolone (Igarashi et al., 2005; van Beek et al., 2006) while some do mention their 
toxicity and treatment results (Juruena et al., 2006; Kaspers et al., 1996; Mitchell et al., 2005). 
For example, dexamethasone has higher potency (16-fold antileukaemic activity) than 
prednisolone (Kaspers et al., 1996). Furthermore, prednisone is slightly different from 
prednisolone. Prednisone is rapidly converted into prednisolone by the liver.   
 
We then compared our new gene list with previous studies. As can be seen in Table 3.1, none 
of the previous studies, using the same drugs and the same times at which data were collected, 
showed similar results. Our main feature here being the use of experimental data from clinical 
samples, the most similar study is that by Tissing et al. (2007), they used same drugs but had 
a different normalisation process, the tissues were retrieved from childhood leukaemia 
patients, not cell cultures. They compared the primary childhood ALL cells treated with in 
vivo prednisolone and leukaemic cells of childhood ALL exposed to in vitro prednisolone, for 
finding early apoptosis response genes at 6/8 hours after treatment. Our differentially 
expressed 29 probe sets from T-ALL and 47 probe sets from B-ALL (Table 3.4 first two 
column) were compared with the 39 up-regulated and 12 down-regulated genes from Tissing 
et al. (2007). We found these common induced genes: BTG1 (T-ALL and Tissing), and 
FKBP5, ZBTB16, SNF1LK (B-ALL and Tissing). No common repressed gene between T- or 




We selected another study from Table 3.1, Thompson and Johnson‘s (2003), based on using 
different chemotherapeutic drugs and different time points and different tissues but with 
similar gene selection criteria. Thompson and Johnson (2003) identified 39 up-regulated 
genes and 21 down-regulated genes in CEM (a cell line derived from human lymphoid cells). 
In addition, they proposed the time frame for apoptosis gene regulation after CEM-C7 were 
exposed to dexamethasone (Thompson & Johnson, 2003). In comparing the gene sets reported 
by Thompson and Johnson (2003) with our differentially expressed genes from T-ALL and B-
ALL patients, we found a few overlapping genes, but more than those found in comparison 
with Tissing et al. (2007). T-ALL had five overlapping genes (BCL2L1, SOCS1, BTG1, 
CD69 and NR3C1) and B-ALL has four overlapping genes (SOCS1, DFNA5, WFS1 and 
SLA). Of these two sets, only BTG1 overlapped with the common genes between our T-ALL 
and the study of Tissing et al. (2007) for T-ALL. There was no gene common to B-ALL and 
Tissing et al.‘s (2007) study. 
 
In summary, the selected dataset is robust and reproducible. We reproduced the original 
authors differentially expressed genes using the same normalisation process and criteria. 
Different platforms (software) for normalisation process behaved similarly with minor 
differences. In some cases, there was only a  one patient difference dividing whether a gene 
was selected or not. Twenty two differentially expressed genes were proposed by the original 
authors as GC-regulated genes and common to T and B-ALL (Schmidt et al., 2006); however, 
our study, that separated T- and B-ALL, revealed that only some of these genes were found in 
each subtype. We also proposed 327 unique probe sets (304 genes) responsive to GCs. 
Furthermore, we extended the analysis to find differentially expressed genes between 6 and 
24 hours. This can add a temporal picture because previous studies only considered 0 and 6 
hours and 0 and 24 hours. We then identified the temporal activation pattern of the proposed 
GCs-regulated genes. Finally, we compared this gene set with two previous studies and found 
only a few common genes, possibly indicating that different chemotherapeutic agents and 
tissues may produce different results for the target gene set. 
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3.3.2 Extraction of intrinsic biological patterns with four emergent clustering 
methods applied to gene clustering 
 
After identifying GC-induced apoptosis genes, further analysis focused on finding similar 
gene expression patterns, which may indicate genes with similar function or co-regulation. 
First, we identified gene function using The Database for Annotation, Visualisation and 
Integrated Discovery (DAVID). The results from DAVID after processing our 327 probe sets 
are as follows:  
 
For functional annotation clustering, the top three annotation clusters were defence 
response (p-value 5.5 3e- ), cell cycle (7.8 4e- ) and apoptosis (3.3 3e- ). Specifically, DAVID 
reported 30 probe sets from our list were involved in apoptosis annotation. This means 30 
probe sets from our list are already known as apoptosis related genes. Those 30 probe sets 
(highlighted gene names) are shown in Table 3.6. Even though we had already deleted cell 
cycle genes, we still retrieved cell cycle function genes from DAVID. This is an ambiguous 
issue; different sources/databases can define different set of cell cycle genes.  
 
For gene functional classification, the results indicated that there were nine gene functional 
clusters (170 genes were not clustered), as presented in Table 3.7. Each cluster had many key 
biological functions, and we selected one function to represent each group. As we were 
interested in finding similar gene function from gene expression clustering methods, the nine 
gene functional clusters were used for further comparison with gene clusters from the four 
selected clustering methods: SOM, ESOM, STEM and FLAME. 
 
In this study, a temporal (time series) gene expression dataset was used. This gene set was 
collected at three time points, making it a short time series gene expression dataset. This data 
has not been used with any clustering tools. We aimed to explore the behaviour of our final 
gene set from the perspective of each of the four selected clustering methods. The results may 
shed light on to possible consistent functional grouping of genes in childhood leukaemia. 
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Table 3.6: Results on 30 probe sets found relevant to the apoptosis process from Functional 
annotation clustering function by DAVID. 
Probe sets Gene name Gene symbol 
1557257_at B-cell CLL/lymphoma 10 BCL 10 
236439_at B-cell CLL/lymphoma 6:  BCL 6 
1559975_at B-cell translocation gene 1, anti-proliferative BTG 1 
205780_at BCL2-interacting killer (apoptosis-inducing) BIK 
206665_s_at BCL2-like 1 Bcl-x/BCL2L1 
1555372_at and 
1558143_a_at 
BCL2-like 11 (apoptosis facilitator) BCL2L11/Bim 
205681_at BCL2-related protein A1 BCL2A1 
226530_at Bcl2 modifying factor BMF/FLJ00065 
1565752_at, 1553906_s_at 
and 215602_at 
FYVE, RhoGEF and PH domain containing 2 FGD2/FLJ00048/ZFYVE4 
244447_at Kruppel-like factor 10 EGRA/KIF10 
211341_at POU class 4 homeobox 1 POU4F1/FLJ13449 
232344_at RAS p21 protein activator (GTPase activating protein) 1 RASGAP 
209936_at RNA binding motif protein 5 FLJ39876/RBM5 
235412_at Rho guanine nucleotide exchange factor (GEF) 7 ARHGEF7/p50 
211899_s_at TNF receptor-associated factor 4 TRAF4 
210314_x_at TNFSF12-TNFSF13 read-through transcript; tumour necrosis factor 
(ligand) superfamily, member 12; tumour necrosis factor (ligand) 
superfamily, member 13 
TNFSF12/Tnfsf12-Tnfsf13 
202908_at Wolfram syndrome 1 (wolframin WFS1 
229958_at ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental 
retardation 
C8orf61/FLJ39417 
223556_at and 220085_at helicase, lymphoid-specific FLJ10339/SMARCA6 
207826_s_at inhibitor of DNA binding 3, dominant negative helix-loop-helix protein HEIR-1 
203949_at myeloperoxidase MPO 
32431_at nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor) 
GR/NR3C1 
204285_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 
206390_x_at platelet factor 4 MGC138298/Pf4 
1552742_at potassium voltage-gated channel, subfamily H (eag-related), member 8 ELK1 
213093_at protein kinase C, alpha PRKCA 
239504_at  similar to Bcl-2-associated transcription factor 1 (Btf); BCL2-
associated transcription factor 1 
KIAA0164/LOC731605 
241819_at and 235735_at tumor necrosis factor (ligand) superfamily, member 8 TNFSF8 
202643_s_at tumour necrosis factor, alpha-induced protein 3 TNFAIP3 
205883_at, 227762_at, 
228854_at and 244697_at 
zinc finger and BTB domain containing 16 ZBTB16/PLZF 
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Table 3.7: Gene functional classification results from DAVID 
 
Functional Group 1 (12) 
Mitosis 
Functional Group 2 (15) 
Microtubule 
Functional Group 3 (14) 
ATP binding 














































Functional Group 5 (4) 
Transcription regulatory 
activity 
Functional Group 6 (5) 
Positive regulation of 
transcription, DNA-
dependent 
Functional Group 7 (11) 
Negative regulation of 
transcription 
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Clustering with SOM 
The first clustering tool is self organising maps (SOM), which can produce a two dimensional 
picture of high dimensional gene expression data.  SOM can reveal clusters genes with similar 
expression pattern vectors across the time points. We present here some results for SOM 
clustering of GC-induced apoptosis genes for two typical patients: patient 2 (T-ALL) and 
patient 13 (B-ALL), as shown in Figure 3.5. The lighter areas in the U-Matrix map indicate 
neurons that are clustered closer to each other and reveal some cluster patterns picked by the 
algorithm on the leftmost panels for the two patients. The cluster maplet reveals two clusters 
for T-ALL and B-ALL. The last three maplets indicate the expression of genes at 0, 6 h and 
24 h. The expression of a gene at the three time points can be traversed by following the 
expression at the same location of the three maplets. The maplets for the three time points 
indicate that cluster one (red colour) mainly contains low gene expression values (less than 
about 6.0) and vice versa for cluster two. The red areas show highly up-regulated genes, 
whereas the blue areas show highly down-regulated genes.  
 
These patterns indicate that, overall, the majority of genes have similar activity patterns at the 
three time points (i.e. either high or low). However, although activity pattern across the three 
time points showed similarity, there was a general decrease in activity in T-ALL (enlarged 
blue region with increasing time) and general increase in expression in B-ALL (enlarged 
red/yellow region). But SOM works well with high dimensional inputs. Therefore, we further 
investigated SOM with the whole set of gene expression at 24 hours after treatment of 13 
patients (input dimension is 13). The results are shown in Figure 3.6, where last three panels 
indicate the last three T-ALL patients. The activity patterns of three T-ALL show differences 
compared to the eight B-ALL patients (first and second rows). The two gene clusters shown 
on the cluster maplet indicate the highly expressed and weakly expressed genes, respectively. 
This cluster pattern is dominated by the 10 B-ALL patients; however, some general 
similarities between the B-ALL and T-ALL can be found in individual maplets informing the 
two cluster structure As the same gene is shown at the same spot in the maplets, SOM can 







Figure 3.5: Self-organising map of selected T- and B-ALL patients depicting gene expression 
across the three time points 
Self-organising map (maplets from left to right: clusters, U-Matrix, time 0 h, 6 h and 24 h for two selected 




                                                                                             T-ALL 
 
Figure 3.6: Self-organising map of ALL patients at 24 hours 
Self-organising map (maplets from left to right: clusters, U-Matrix, eight B-ALL patients (patient numbers 13, 




The advantage of using SOM is we can visualise the macro picture of the three scenarios 
(time 0, 6 and 24h) for each patient simultaneously.  SOM are good to use when data analysis 
starts because they give an overview of data. However, we found a drawback in using SOM 
for clustering in that clusters from SOM may not be consistent due to the instability of neural 
gas, the method used to cluster neurons on the trained map, as it produced unclear cluster 
boundaries. 
 
Clustering with ESOM 
The second clustering method used in this study was Emergent Self organising maps 
(ESOM).  ESOM was created based on two concepts: emergence and border less map. P-
Matrix (density-based) visualisation can be used to enhance the visibility of overlapping 
clusters and the map on the right-hand side continues with the left-hand side, and bottom and 
top are continued as a torous space. The darker colour represents high density, while the 
lighter colour represents low density. In Figure 3.7, ESOM provides a better visualisation of 
separated clusters when compared with Unified dimension matrix (U-Matrix) from SOM in 
Figure 3.5. However, in ESOM the number of clusters are user-defined, so different users can 
define different numbers of clusters. In Figure 3.7, we defined at least four gene clusters for 
both the selected T- and B-ALL patients. We further tested whether the four temporal patterns 
in Table 3.5 can be separated by density clustering.  
 
We selected ten genes scattered across the four temporals from Table 3.5 and located them on 
the P-Matrix map. For patient number two (T-ALL):  only one group (group 1) from Table 
3.4 was represented by a cluster (cluster 3) on the map, the three genes in this cluster were 
S100A8, ZBTB16 and P2RY14. The other selected gene groups from Table 3.5 did not fall 
into the same clusters on the map. Likewise, only one gene group (group 4) from Table 3.5- 
correlated with one cluster (cluster 2) on the ESOM map for patient number 13 (B-ALL). 
There are many studies claiming the success of using ESOM for clustering (Drachen, 
Canossa, & Yannakakis, 2009; Haddad et al., 2009; Lehwark, Risi, & Ultsch, 2007; J. 
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Figure 3.7: ESOM: P-Matrix (density-based) plot for the two selected patients (T-ALL top 
panel and B-ALL bottom panel)  
Dots represent best match (closet) vector to each data point. Number indicates possible cluster. 
Gene Original ESOM 
T-ALL B-ALL 
EGR1 1 1 4 
SOC1 1 3 1 
P2RY14 2 3 1 
S100A8 2 3 2 
ZBTB16 2 3 1 
FKBP5 3 1 4 
GIAMP7 3 4 1 
PFKFB2 3 1 1 
KIAA0101 4 2 2 
TNFSF8 4 4 2 
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Even though ESOM has been used for unsupervised clustering, the previous studies 
mentioned above have used it for subtype clustering; for example, leukaemia subtypes: ALL 
or AML, or music types: hiphop, jazz, metal or punk and so on. For such studies, it is easy to 
evaluate the effectiveness of using ESOM for clustering. In our study, we used it for 
visualisation of genes and possible gene clustering. ESOM is good for visualising how data 
are organised in terms of density. ESOM drawbacks are that clusters need to be defined by the 
user and it produces unclear cluster boundaries as in SOM. Therefore, clusters from both 
SOM and ESOM methods were not used in further comparisons. 
 
Clustering with STEM 
We analysed the 327 probes using Short Time series Expression Miner (STEM) for each 
patient separately. STEM process starts from converting raw expression data for 6 h and 24 h 
into log-ratios with respect to the first time point (0 hour); then using reference profiles as the 
standard permutations to identify the significant model profiles that do not happen by chance. 
Finally, significant profiles are clustered. Results for three selected patients from T- and B-
ALL are shown in Figure 3.8: T-ALL (patients 2, 20 and 25) on the left-hand side and B-ALL 
(patients 13, 24 and 31) on the right- hand side. Colours indicate significant profiles. 
Significant profiles for all B-ALL and T-ALL patients were: 
 
 B-ALL: patient 13: profiles 4, 13 and 15; patient 24: profiles 8 and 13; patient 
31: profiles 2, 3, 11 and 15 (significant profiles for the rest of the B-ALL 
patients were: patient 17: profiles 2 and 13, and 15; patient 32: profiles 2, 10 and 
14; patient 33: profiles 14 and 15; patient 37: profiles 11 and 12; patient 38: 
profile 3, patient 40: profiles 2 and 8 and patient 43; profiles 2, 12, 13 and 15). 
 T-ALL: patient 2: profiles 2 and 12; patient 20: profiles 0, 2, 3 and 11 and 
patient 25: profiles 8, 12 and 13. 
 
After clustering genes for each patient, group results for T-ALL and B-ALL were assessed. 
The result across all B-ALL patients showed ten significant cluster profiles: 2, 3, 4, 8, 10, 11, 
12, 13, 14, and 15. T-ALL had seven clusters profiles: 0, 2, 3, 8, 11, 12 and 13. After 
clustering similar significant profiles, each B-ALL and T-ALL patient showed either one or 
two clusters, as shown in Table 3.8.  
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                             Patient 2     Patient 13 





                          Patient 20                                                      Patient 24 





        
                          Patient 25                                                       Patient 31 
Figure 3.8: Results from STEM for T- and B-ALL 
T-ALL (left-hand panel) for three patients (patient numbers 2, 20 and 25). B-ALL (right-hand panel) for patient 











Cluster 1 Cluster 2 Total number of 
probe sets in profiles 
B-ALL 13 4 13,15 325 
 17 2 13 95 
 24 - 8,13 163 
 31 2,3 11,12 125 
 32 2 10,14 128 
 33 - 14,15 76 
 37 - 11,12 144 
 38 3 - 119 
 40 2 8 117 
 43 2 12,13,15 184 
T-ALL 2 2 12 149 
 20 0,2,3 11 119 






Although significant profiles in the two clusters were not identical, Table 3.8 appears to 
separate increasing and decreasing temporal activity patterns into two clusters. The total 
statistically significant probe sets from STEM clusters were 141 probe sets (129 genes) for T-
ALL and 221 probe sets (208 genes) for B-ALL, with 67 probe sets (63 genes) in common. 
For some selected significant profiles, Table 3.9 shows all the probe sets represented by them. 
 
Generally, clustering methods always exhibit patterns or clusters for all input data. It is very 
difficult to validate the significance or robustness of the results. We verified our cluster results 
by comparing the significant clusters for T- and B-ALL with gene functional groups from 
Table 3.7, with the results shown in Table 3.10. 
 
From Table 3.10 most probe sets in significant profiles from B-ALL were found scattered in 
functional groups; for example, functional group 1 contains probe sets from profiles 2, 3, 4 
and 13; functional group 2 contains probe sets from profiles 2, 3, 4, 8 and 10 and functional 
group 3 contains probe sets from profiles 2, 3, 4, 10, 11, 12, 13, 14 and 15. Similarly, for T-
ALL most probe sets in significant profiles were also found scattered in functional groups; for 
example, functional group 1 contains probe sets from profiles 0, 3 and 13 and functional 
group 2 contains probe sets from profile 0, 2 and 13. We can conclude from this analysis that 
some genes from the same cluster have similar gene function (as they were found in the same 
functional cluster). But there was more than one function for each gene cluster. How to assign 










Table  3.9: List of probe sets in some examples of significant clusters from STEM for B-ALL 
patients 
 
3 4 8 10 11 12 










































































































































































































































Table 3.10: Comparison between gene functional groups (9 groups) with STEM significant 
profiles (16 profiles) for T- and B-ALL patients 
Numbers in blanket indicate number of total probe sets. Total probe sets from STEM are 159 probe sets  for T-
ALL and 450 probe sets for B-ALL and gene functional groups are comprised of 117 probe sets. 
 




































1(12) 5  1    1 5 6 4     1   
2(15) 5 1     1 5 6 4 1 1      
3(14) 1 3     1 4 1 2  1 2 2 4 2 1 
4(10)    3   1 1   6 4  6 1  3 
5(4)  1    1  1  2       1 
6(5) 1    1 1 1        1 1  
7(11) 1 1  11       5 3 3 3 1 1 1 
8(5) 1  2   1  1 1 1        








Clustering with FLAME 
The last clustering method used in this study is Fuzzy clustering by Local Approximation of 
MEmbership (FLAME). FLAME identified clusters without the need for pre-defined numbers 
of clusters while providing fuzzy clustering characteristics. However, the number of clusters 
for each patient varied, depending on the distance measure, with Peason‘s correlation 
producing a larger number of clusters than Eucledean distance, as shown below: 
 B-ALL: 
Euclidean distance: patient 13 (14 clusters), patient 17 (12), patient 24 (10), patient 
31 (12), patient 32 (13), patient 33 (12), patient 37(11), patient 38(11), patient 40 (13) 
and patient 43 (13). 
Pearson correlation coefficient: patient 13 (20 clusters), patient 17 (16), patient 24 
(16), patient 31 (21), patient 32 (18), patient 33 (18), patient 37 (18), patient 38 (18), 
patient 40 (21) and patient 43 (19). 
 T-ALL: 
Euclidean distance: patient 2 (9 clusters), patient 20 (11) and patient 25 (10). 
Pearson correlation coefficient: patient 2 (14 clusters), patient 20 (17) and patient 25 
(20). 
 
Figure 3.9 shows 14 clusters for patient 2 (T-ALL) and 20 clusters for patient 13 (B-ALL) 
from FLAME with Pearson‘s correlation coefficient. The mean number of clusters for T-ALL 
was 17 clusters and 18 clusters for B-ALL with Pearson‘s correlation coefficient and 10 
clusters for T-ALL and 12 clusters for B-ALL when using Euclidean distance. The choice of 
distance measure can influence the final numbers of output cluster. The selection of the 
distance measure should be based on prior knowledge for each application. In this study, we 
selected two distance measures to show their effect. FLAME and STEM are different in how 
they presented final results. FLAME considers that all clusters are possible while STEM only 
selects significant profiles. We aimed for consistent gene groups. Therefore, results from both 
clustering methods were compared. FLAME clusters, based on Pearson‘s correlation 
coefficient, were compared with STEM because STEM also found similarities in shape 
between two gene expression patterns (i.e. correlation). We compared STEM and FLAME for 
each patient; specifically, probe sets in all 16 profiles of STEM were compared with probe 














      
 
                                                           Outlier               
       All CSO from each cluster 
 
Figure 3.9: Clustering results from FLAME based on Pearson correlation for one selected 
patient from each subtype 
 
FLAME: for T-ALL (patient 2) - line plots of gene expression for each Cluster, Outlier and Cluster Supporting 
Object (CSO) clusters: there are 14 clusters (0 to 13) for patient 2 (T-ALL) and 20 clusters for patient 13 (B-







The patterns in each profile from STEM and clusters from FLAME showed similar 
characteristics and number of genes in each profile/cluster for the cluster from patient with 
high number of probe sets. For example, 16 profiles (325 probe sets) from STEM for patient 
number 13 (B-ALL) compared with 20 clusters (327 probe sets) from  FLAME: profile 
number one in STEM had 15 probe sets of which nine probe sets were found in cluster 
number nine in FLAME (there were nine probe sets in cluster number nine). Similarly, profile 
number 13(10/15) from STEM and cluster number four from FLAME (10/18) had ten genes 
in common. However, the patterns in each profile from STEM and cluster in FLAME were 
not correlated or were scattered for the lower number of probe sets in the cluster, for example, 
patient number 2 (T-ALL). The results of the comparison between 16 profiles (149 probe sets) 
from STEM with 13 cluster and one outlier (327 probe sets) are shown in Table 3.11. 
 
The results for each patient from FLAME cannot be combined like the results from STEM. 
For STEM, we selected only significant profiles from each patient and then combined all 
probe sets of all patients under each significant profile to represent all T-and B-ALL patients 
(see more detail in Table 3.9). Nevertheless, for FLAME, each patient had a different number 
of genes in each cluster. To address this issue, we prepared a new input dataset for FLAME 
analysis. In this dataset, each row represented expression of one gene at the three time points 
for all patients. FLAME analysis was conducted for the three T-ALL, ten B-ALL, and 13 
ALL. FLAME indentified six clusters, eight clusters, and six clusters for T-ALL, B-ALL and 
ALL, respectively. The probe sets under these clusters were used for further comparison with 
Table 3.7. 
 
The results from FLAME were similar to the results from STEM, when comparing probe sets 
of clusters with the members in each functional group (comparison between FLAME results 
and gene functional groups are shown in Table 3.12). For example, for B-ALL, functional 
group 1 can be found in clusters 2, 3, 4, 7 and 8; functional group 2 can be found in clusters 2, 








Table 3.11: Comparison of probe sets from STEM profiles (16 profiles) and FLAME cluster 
(15 clusters: 14 clusters and one outlier) for patient number 2 (T-ALL) 
Numbers in brackets indicate number of total genes. Total probe sets from STEM are 149 probe sets and 327 
probe sets from FLAME. 
 
 STEM significant profiles 
































0(7)   2     3  1       
1(23)   6 1    5  3  1   2  
2(25)   6 3 1   6  1 1    1  
3(39)  1    4 4  6   2 6 3  1 
4(14)             1    
5(33)     1           1 
6(13)      1   1       1 
7(19) 1  1        1 2   2  
8(28) 1   1 2       1     
9(25)     2        2   2 
10(41)    1        6   4  
11(12)  2    3 3      2 1   
12(24)  4    1 2  1   4 2 1   
13(22)  2   1 3 1  5   1  3  1 












Table 3.12: Comparison between gene functional groups (nine groups) with FLAME clusters 
for T- ALL (six clusters and one outlier cluster) and B-ALL (eight clusters and one outlier 
cluster) patients 
Numbers in brackets indicate number of total probe sets. Total probe sets from FLAME are 327 probe sets and 
114 probe sets from gene functional groups. 
 
 FLAME clusters 
T-ALL B-ALL 
































1(12) 1   1 9 1    1 1 7   2 1 
2(15) 2   1 10 1 1   2 1 7   3 2 
3(14)  1   9 3 1 2  1 2 3   4 2 
4(10)   9    1   1     9  
5(4)   1  3   1    2   1  
6(5) 1 1  1  2    1 1   1 2  
7(11)  1  1 1 8     1  1  9  
8(5) 1    1 3      1 1  3  







Clearly, clustering tools can give possible groups that might have similar function or co-
regulated genes. However, clustering cannot describe interactions between genes. Therefore, 
prior knowledge can help validate the output from clustering. Consequently, the next step of 
this study, which is presented in Chapter 4, used literature-based network tools to infer the 




The overall theme of the study in this chapter addressed the identification of GC-regulated 
genes. Schmidt et al (2006) claimed that they identified a novel set of glucocorticoid-response 
genes in children with acute lymphoblastic leukaemia. Their study was carried out using 
whole-genome expression profiling and then compared gene regulation with additional 
systems, such as mice, and those from previous studies, as reviewed by Schmidt et al (2004). 
We validated the original paper‘s results starting from the normalisation process. Studies by 
many researchers have shown different results from different normalisation methods. We 
compared the same pre-processing methods for gene expression analysis on different software 
platforms (Matlab (Bioinformatics toolbox), R, and RMAExpress) which resulted in slightly 
different outputs. However, R and RMAExpress produced identical gene lists. If a threshold 
of  two patients was used (i.e. 6  2 out of 13 instead of 6 out of 13), all the software 
provided almost the same gene lists. Analysis of the processed data continued with the focus 
on finding novel GC-regulated genes. A discrepancy between T-ALL and B-ALL was shown 
to exist; this led to the proposal of new and separate criteria for the two subtypes. Altogether, 
we found 327 probe sets (304 genes) differentially expressed at the three time points. These 
genes can be classified into four different gene activities occurring at the three time points: for 
example, some genes are active at a particular time point while some other genes are active at 
all times.  
 
The comparison between the GC-regulated genes reported by Schmidt et al. (2004) and our 
new set showed six out of 31 common/overlapping genes. We confirmed that only eight out 
of twenty two novel GC-regulated genes proposed by Schmidt et al. (2006) were common to 
both T- and B-ALL subtypes, while 14 out of 22 genes were only found in either T- or B-
ALL. Furthermore, considering the two previous studies [Tissing et al. (2007), and Thompson 
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& Johnson (2003)], which were compared with our final gene lists, only a few common genes 
were found. All investigations in this study lead to the conclusion that different 
chemotherapeutic drugs, sample tissues, period of data collection and gene selection criteria 
may affect the final discovery of differentially expressed gene sets.  
 
We then further analysed the data with four emergent clustering tools. Each computational 
method provided different insights into our short time series data. SOM and ESOM are 
visualisation methods for high dimensional data projected onto a map and give an overview of 
how data are organised in terms of distance and density; the drawback is that clusters from 
SOM are not consistent and ESOM require users to define the number of clusters. The SOM 
identified two clusters of expression profiles: genes that were highly expressed throughout the 
time points and genes weakly expressed throughout the time points. The more consistent and 
detailed clusters were obtained from STEM and FLAME. STEM was used to find expression 
patterns that were statistically significant and have only a very little probability of happening 
by chance.  FLAME can be used to find clusters without predefined groups and was useful to 
verify clusters from STEM. But FLAME considers all clusters as possible. Each patient had 
different cluster results from both STEM and FLAME. Since we needed to analyse groups of 
patients, the challenge was to develop data analysis tools which can analyse multiple samples 
(patients) and multiple time points at the same time. We also found the different clusters when 
applying different distance measures. Prior knowledge needs to be incorporated with the 
selection of distance measure used in clustering tools. 
 
The next stage of our study, in Chapter 4, will look into GC responsive gene networks that 
may control the gene expression patterns behind the scenes which, in turn, will help identify 
target genes for better treatment procedures. 
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    Chapter 4                                                                       
Identification of GC-induced apoptosis gene network 
4.1 Introduction 
 
To understand a complex apoptosis process, identification of differentially expressed genes 
alone is not enough. There is a need to extend the study level from the identified genes to a 
gene network. Gaining a better understanding of gene networks is currently a challenge for 
scientists. Previous work on inferring gene regulatory networks (GRN) used statistical and 
mathematical modelling. Inferring gene networks from rapidly growing microarray gene 
expression using network/pathway databases has been shown to be a very promising approach 
in cancer research. Prior biological knowledge plays an important role in inferring genes in 
the network. Taking this into account in this chapter, we present how to infer gene networks 
using time series microarray data from selected pathway databases based on prior knowledge. 
In this study, we used publicly available childhood leukaemia treated with prednisolone 
(Schmidt et al., 2006) short time series data, and this data have not been maximally leveraged 
or integrated with existing knowledge pathway databases. Therefore, in this chapter we used 
computational analysis with identified GC-regulated genes to identify their gene networks. 
We used GC-regulated genes before and after deleting cell cycle genes as an input gene list.  
 
Usually, inferred networks are the final step of gene expression analysis. The number of 
inferred networks from time series varies according to the number of time points in the input 
data. However, the scientist/biologist or clinician needs a small but essential group of genes 
for further experiment. This leads to the question of how inferred networks, specifically, from 
time series data, can be combined in order to minimise the relevant genes or identify novel 
genes for further study.  
 
The specific objective in this chapter is to infer gene networks at three time intervals and find 
the common genes which play roles in these three networks. This inferred network was then 
used to answer the questions of how networks for different time points can reduce the number 





Raw data were collected from 13 patients (three T-ALL patients and ten B-ALL patients). The 
data used in this part was the same data used in the previous chapter. Specifically, there were 
two main datasets used in this chapter, these datasets were the results from Chapter 3. (i) 
Candidate GC-regulated genes it uses, as shown in Table 4.1. These differentially expressed 
genes from three time intervals: 6 hours after treatment (0-6 hours), between 6 hours and 24 
hours (6-24 hours), and 24 hours after treatment (0-24 hours) after deleting cell cycle genes at 
 1 fold change. (ii) Statistically significant probe sets from STEM clustering method. 
 
Table 4.1: GC-regulated differentially expressed genes 
 0-6 hours 6-24 hours 0-24 hours 
 Induced Repressed Induced Repressed Induced Repressed 
T-ALL 19 9 56 49 56 33 
B-ALL 24 9 16 9 71 61 
 
4.2.2 Computational Methods 
 
Gene network analysis and recovery of key biological pathways in this study were conducted 
using Ingenuity Pathway Analysis software (IPA) (Ingenuity® Systems, Redwood City, CA, 
USA, http://www.ingenuity.com). IPA is a web-based application that integrates a systems 
biology approach to solve various biological problems. The knowledge base of IPA comes 
from journal articles, textbooks and other data sources. This software has many applications; 
only the functional analysis of genes and their networks have been used in this study. The p-
value defines the significance of gene function in a network as well as gene to gene 
relationships, and a p-value less than 0.05 signifies a statistically significant and non-random 
association. The right-tailed Fisher Exact Test was used to calculate the p-value. 
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4.3 Results and Discussion 
4.3.1 Inferring GR gene networks from GC-induced apoptosis genes 
 
Datasets containing expression values of GC-regulated genes were uploaded and analysed 
through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). 
Each gene list was an input to Ingenuity Pathway Analysis software (IPA) which maps the 
genes to pathways generating networks using an algorithm based on gene connectivity with a 
cut-off of 35 molecules per network and produces a table containing molecules in each 
network. In each table, ‗the focus molecules‘ means input genes (presented in bold letters) 
that are overlaid onto a global molecular network and networks to create algorithmically 
generated networks based on their connectivity. In each network, up-regulated genes are  in 
red and the intensity indicating the degree of up-regulation while green  denotes down-
regulated genes. An uncoloured node was not found in the uploaded dataset but 
computationally generated by the IPA on the basis of stored knowledge. Network scores and 
p-values indicate the significance of each network, process or pathway. The score tells the 
possibility of the Network Eligible Molecules happening by chance. The ‗score‘ is calculated 
by the negative exponent of the p-value. The interpretation of the score number is that if the 
score is 53, this implies that p-value was 10 53e-  that is, the higher the score the lower the p-
value. The ‗top functions‘ in each table show the three most significant functions of each 
network. Dashed lines indicate indirect interactions while solid lines indicate direct 
interaction. There are 20 possible edge labels: A (Activation), B (Binding), C (Causes/Leads 
to), CC (Chemical-Chemical interaction), CP (Chemical- Protein interaction), E (Expression 
includes metabolism/synthesis for chemicals), EC (Enzyme Catalysis), I (Inhibition), L 
(ProteoLysis includes degradation for Chemicals), LO (Localisation), M (Biochemical 
Modification), MB (Group/complex Membership), P (Phosphorylation/ Dephosphorylation), 
PD (Protein-DNA binding), PP (Protein-Protein binding), PR (Protein-RNA binding), RB 
(Regulation of Binding), RE (Reaction), T (Transcription), and TR (Translocation). 
 
The differentially expressed gene list from Table 4.1 was used for inferring the gene networks 
through the IPA software. We used the gene list after deleting cell cycle genes. For T-ALL, 
there were 28 probe sets at 0-6 hours, 105 probe sets at 6-24 hours and 89 probe sets at 0-24 
hours. Similarly, for B-ALL there were 33 probe sets at 0-6 hours, 25 probe sets at 6-24 hours 
and 132 probe sets at 0-24 hours. Results from IPA (data not shown) typically were a number 
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of networks ranking from one to seven for each time point with a maximum of 35 molecules 
in each network consisting of those genes from our list plus those given by IPA. Processing 
these networks was fairly time consuming but we manually identified common genes active 
throughout the period (at least between two time points) which can be referred to as 
predominant genes to T- and B-ALL, separately and common to both.  
 
For T-ALL patients, 48 unique genes were found for the three different time points from IPA: 
Akt, ARHGEF7, ASPM, ATAD2, BCL2L11, BMF, CKSCR1, DTL, ERK*, E2f,  FEN1, 
HBG2, hCG, hemin, HES1, Histone h3, HNF4A, IL6, JNK, KIAA0101, LDL, LYZ, 
MCM10, MAPK, MS4A1, MYC*, NFB (complex)*, PF4, PMAIP1, PKMYT1, PPBP, 
PTGDR, p38 MARK, RNF4, SEPT5, SLC2A4, STOM, S100A8, TEPI, TMSB15A, TNF*, 
TNFSF13, TRIP6, TUBB1, UHRF1, Vegf, and ZNF24. Out of these, the seven genes were 
common to both T- and B-ALL patients. The asterisks indicate four genes found active 
throughout the three time intervals. Twenty three genes were found in our gene lists and 25 
genes were added by IPA. Only four genes were found to be active at all three time points: 
ERK, MYC, NFkB (complex) and TNF. None of these genes was found in our analysis or that 
of the original author. These four genes were strongly related to cancer. ERK (Extracellular-
signal-Regulated Kinase) is an essential component and part of the mitogen-activated protein 
kinase MARK/ERK signalling pathway. This pathway plays a major role in cancer therapies. 
MYC or cMyc gene is found in many cancers. NFkB (Nuclear Factor Kappa-light-chain-
enhancer of activated B cells) is activated in the development of many types of cancer and is a 
therapeutic target for cancer treatment. TNF (Tumour Necrosis Factors) is also involved in 
cancer therapy because this protein can cause cell death. 
 
For B-ALL patients, the 47 unique genes are ANAPC5, ASPM, Beta-estradiol, BUB1, 
CCNG1, CDC2, CDC20, CDC42EP3, CDC45L, CENPA, CENPF, CEP55, Cyclin A, 
DLGAP5, E2f, FKBP5, GBP1, HNF4A, IFNG, IL13, IL4R, KIAA0101, KIF14, KIF23,  
KIF20A, LY6A, MKI67, MYC, NFB (complex), NUF2, RPL3B, PFKFB2, PRC1, 
PYH1N1, P2RY14, RIPK2, Rb, SLK1, SPARC, STAB1, S100A8, TGFB1, TOP2A, TP53, 
TXNIP, UBE2C, and WFS1. Again, the seven highlighted genes were common to both B-and 
T-ALL. From the total of 47 genes, 21 genes were from our list and 26 genes were added by 
IPA. Five genes were found to be active at all three time intervals: HNF4A, P2RY14, Rb, 
S100A8 and TOP2A. Three were from our list: P2RY14, S100A8 and TOP2A, and the rest 
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were added by IPA. HNF4A or Hepatocyte nuclear factor 4 alpha is involved in development 
of the liver, kidney, and intestines. P2RY14 is a protein encoded by P2Y purinoceptor 14 and 
is a member of the family of G-protein coupled receptors. P2RY14 is involved in the immune 
system and the regulation of stem cell compartments. Rb or retinoblastoma protein is found to 
be dysfunctional in several types of cancer. S100A8 (S100 calcium binding protein A8) plays 
an important role in inflammation-associated cancer. TOP2A or Topoisomerase 2-alpha is 
used as the target for anticancer agents.  
 
The above analysis was based on GC-induced apoptosis genes at three time points separately, 
but involved a large amount of processing of several networks for each time point. Therefore, 
in the next step, we only selected genes that were found in at least in two of three time 
intervals from our list to create gene networks for T- and B-ALL patients using the IPA 
program. For B-ALL patients, the selected genes are described as follows (the asterisk 
denotes genes that were found multiple times in the input dataset):  
 0-6 hours, 6-24 hours and 0-24 hours (3): P2RY14, S100A8 and TOP2A. 
 0-6 hours and 0-24 hours (12): BUB1, CENPF, DLGAP5, EPPK1, FKBP5, 
GBP4, HHMR*, NUF2, PFKFB2, SIK1, SLA and UBE2C. 
 6-24 hours and 0-24 hours (8): CDC42EP3, CEP55, DTL, KIAA0101, MCM10, 
RRM2, STAB1 and TYMS. 
For T-ALL patients, the selected genes are described as follows: 
 0-6 hours and 6-24 hours (5): BCL2L11, GNG11, HES1, S100A12, and ZNF24. 
 0-6 hours and 0-24 hours (1): TFPI. 
 6-24 hours and 0-24 hours (13): DEFA3, DTL, FEN1, HBG2, KIAA0101, 
MCM10, NRGN, PPBB, PMAIP1, RHOBTB3, STOM, TMSB15A and TUBB1. 
 
There were more probe sets belonging to the above time categories but since they had 
unmapped gene id or gene symbol, they were not included in the sets. With the selected, 
reduced gene list, IPA was used again to construct a network for each time point and the 
results are shown in Tables 4.2 and 4.3 where genes from our list are in bold. Others were 
added by IPA. The selected corresponding networks are shown in Figure 4.1.  
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Table 4.2: B-ALL gene network based on the reduced gene set for 0-6 hours, 6-24 hours and 
0-24 hours 
 
ID Molecules in Network Score 
Focus 
Molecules Top Functions 
0-6 hours 
 1 AP4B1, BRAP, BUB1, CCNB1, CDK1, CENPE, 
CENPF, DLGAP5, EGFR, EPPK1*, FBXO7, 
FKBP5, GBP4 (includes EG:115361), HMMR, 
HNF4A, IFNG, IL5, MIS12, NDE1, norepinephrine, 
NUF2, P2RY14, PDE4B, PFKFB2, PPME1, 
RBMS3, S100A8, SIK1, SLA, SMOC2, SPC25, 
TGFB1, TOP2A*, UBE2C, YWHAZ 
 51  16 Cell Cycle, Cellular Assembly 




 1  ASB3, CDC7, CDC2B, CDC42EP3, CDK1, 
CDK1/2, CEP55, CKAP2, DLGAP5, DTL, E2f, 
E2F1, FEN1, GRWD1, Histone h4, HNF4A, 
Immunoglobulin, KIAA0101, LATS2, MCM8, 
MCM10, ORC3L, P2RY14, PYHIN1 (includes 
EG:149628), Rb, RRM2*, RRM2B, S100A8, SHOX, 
SMOC2, STAB1, TOP2A*, TP53, TYMS, UMPS 
35  11 Cell Cycle, Genetic Disorder, 
Metabolic Disease 
0-24 hours 
 1 beta-estradiol, BUB1, CCNG1, CEP55, E2F8, FEN1, 
FKBP5, GBP4 (includes EG:115361), HELLS, 
HMMR*, IFNG, Immunoglobulin, KIAA0101, 
KLC2, MKI67, NAP1L1, NDE1, PFKFB2, POLA1, 
POLD1, POLD3, RAD51AP1, RFC3, RFC4, RPA, 
RPRM, S100A8, SIK1, SLA, STAB1, TIMM50, 
TOP2A*, TP53, TPX2, YWHAZ 
 
38  12 DNA Replication, 
Recombination, and Repair, 
Cell Cycle, Cancer 
 2 AURKB, BUB1, catechol, CDC6, CDC7, CDC45L, 
CDK1, CDK1/2, CDT1, CENPF, DLGAP5, DTL, 
E2f, E2F2, FZR1, hCG, Histone h4, hydroquinone, 
leucovorin, MCM8, MCM10, NUSAP1, ORC2L, 
ORC3L, ORC6L, PFKFB3, POLA1, Rb, RRM2*, 
SIRT2, SMOC2, TOP2A*, TYMS, UBE2A, UBE2C 
30  9 Cell Cycle, DNA Replication, 
Recombination, and Repair, 
Cancer 
 3 CCDC53, CDC42EP2, CDC42EP3, CEBPB, 
CETN3, DSN1, E2F4, EPPK1*, ERBB2, FOXO1, 
GSTK1, HNF1A, HNF4A, MAP3K3, MIS12, 
NDC80, NSL1, NUF2, P2RY14, PHB2, PLDN, RB1, 
SMAD4, SMC1A, SPC24, SPC25, TGFB1, TP53, 
TRAF6, UMPS, ZW10, ZWINT (includes EG:11130) 
9 4 Cell Cycle, Gene Expression, 















Table 4.3: List of T-ALL genes in networks based on the reduced gene set for 0-6 hours,6-24 
hours and 0-24 hours  
 
ID 
Molecules in Network Score 
Focus 
Molecules Top Functions 
0-6 hours 
 1 2-methoxyestradiol, AIFM1, BAK1, BCL2A1, 
BCL2L2, BCL2L11, Cbp, CDC6, CFD, DHFR, 
ENDOG, F9, FBXO32, FOXG1, GCLC, GSR, heparin, 
HES1, HUWE1, LTBP1, LY6A, NKX2-2, NOTCH4, 
NOV, PTMA, S100A12, SPHK2, SPN, stearic acid, 
TFPI, TNF, TNFSF13, TNFSF13B, TP53, ZNF24 
(includes EG:7572) 
13 5 Cell Death, Cellular 
Growth and Proliferation, 
Haematological System 
Development and Function 
 2 AMOTL2, G protein beta gamma, G-protein gamma, 
GNAI1, GNAI2, GNAI3, GNB1, GNB2, GNB3, 
GNB4, GNB5, GNG2, GNG3, GNG4, GNG5, GNG7, 
GNG10, GNG11, GNG12, GNG13, SMURF1, ZHX1 






 1 BCL2L2, BCL2L11, BNC1, BOK, CBFB, COL18A1, 
CTSG, D-sphingosine, DEFA3 (includes EG:1668), 
DTL, DYNC1I1, Dynein, DYNLL2, EDN1, ENDOG, 
FEN1, hCG, IL6, KIAA0101, LPA, MCM10, MYB 
(includes EG:293405), NR3C1, NRGN, PFDN1, 
PMAIP1, POLD1, PPBP, retinoic acid, RNASE2, 
S100A12, stearic acid, STOM, TCEB2, TUBB1 
31 12 Cell Signalling, Molecular 
Transport, Vitamin and 
Mineral Metabolism 
 2 AMOTL2, Ca2+, Cbp, CCND3, CTNNB1, ERK, 
FANCA, GNG11, HDAC5, HES1, ID3, JAG1, Jnk, 
KAT5, MAPK8, MMP2, MMP9, NOTCH3, NR3C1, 
NUMB, PCNA, PRKCA, PTGDS, RBL1, RUNX2, 
SMAD2, SMAD3, SMARCB1, SMURF1, TMSB15A 
(includes EG:11013), TP53, TP63, Vegf, ZHX1, 
ZNF24 (includes EG:7572) 
8 4 Cellular Development, 
Organ Development, 
Cellular Growth and 
Proliferation 




 4 HBA1, HBA2, HBB (includes EG:3043), HBE1, 
HBG1, HBG2, HBZ, hemin, SMAD5, UBQLN4 




 1 APOA2, beta-estradiol, CDC7, CDC45L, CDT1, 
COX17, CUL4A, DEFA3 (includes EG:1668), DTL, 
EDN1, FEN1, hCG, HUS1, KIAA0101, LPA, MCM5, 
MCM6, MCM10, MMP7, MMP1 (includes EG:4312), 
NRGN, PFDN1, PMAIP1, POLA1, POLD1, PPBP, 
retinoic acid, RFC4, SLC2A1, STOM, TFPI, 
TMSB15A (includes EG:11013), TP53, TUBB1, 
VLDLR 
33 12 DNA Replication, 
Recombination, and 
Repair, Cell Cycle, Cancer 




 3 HBA1, HBA2, HBB (includes EG:3043), HBE1, 
HBG1, HBG2, HBZ, hemin, SMAD5, UBQLN4 










             
   





























Figure 4.1:  B-ALL gene networks at 0-6 hours  
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Table 4.4 presents the biological functions and pathways of the same networks from Tables 
4.2 and 4.3. They indicated that T- and B-ALL patients were quite different in the Molecular 
and cellular functions, Canonical pathways and Functions, for example, molecular and 
cellular functions of T-ALL were involved more in cell death while B-ALL were more 
involved with cell cycling.  This finding may imply that (i) the apoptosis process in T-ALL 
may occur before B-ALL during the same period of treatment (ii) there are many cells 
progressing through the cell cycle (cycling cells) in B-ALL while many non-cycling cells are 
in T-ALL. Many more pathways/steps are involved in cycling cells than in non-cycling cells 
in the apoptosis process after glucocorticoid treatment (King & Cidlowski, 1998). Genes 
found in both T-and B-ALL were involved with cancers functions. 
 
We hypothesised that genes found active throughout the time period were dominant genes that 
may be needed in the GC-induced apoptosis process.  In the next step, we identified how 
these genes were connected and in what form of relationship. We manually extracted 
relationships/connections from B- and T-ALL gene networks at three time intervals. We tried 
to minimise the gene network size by minimising the number of connected genes, for 
example, B-ALL patients, we first started from the three common genes for the three time 
intervals, and then we checked what other genes were connected to these genes; for example, 
TP53 interacts with HNF4A, and HNF4A interacts with DTL and P2RY14, and so on. We 
continued to add more connections between these genes.  
 
Finally, we drew the possible gene relationships with the selected genes, as shown in Figures 
4.2 and 4.3. For B-ALL patients, we started with the three common genes and extended to the 
others (Figure 4.3). For T-ALL patients, common genes were found for only two sets of time 
intervals (0-6 h and 6-24 h, and 6-24 h and 0-24 h); therefore, we started with these common 
genes separately and continued adding connections in the same way as for B-ALL; the results 
are shown in Figure 4.3 (a) and (b). For the two resulting networks, we then found four hub 
genes linking the two networks. These hub genes were BCL2L11, S100A12, TEPI and TP53. 
Obviously, from both curated B-and T-ALL gene networks, TP53 is the most intensive node 
which has many connections with other genes. The glucocorticoid receptor (GR/NR3C1) was 
found in the T-ALL gene network but not in the B-ALL gene network. 
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Table 4.4: List of top three activities of the selected genes from Tables 4.2 and 4.3 in 
molecular and cellular functions, canonical pathways and functions for T- and B-ALL patients 
at three time intervals by IPA 
 
B-ALL T-ALL 
0-6 6-24 0-24 0-6 6-24 0-24 
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Figure 4.2: Proposed B-ALL GC-induced apoptosis gene network for all genes active in at 
least one time interval (0-6 hours, 6-24 hours and 0-24 hours)  
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Figure 4.3:  Proposed T-ALL GC-induced apoptosis gene network for all genes active in at 
least one time interval (0-6 hours, 6-24 hours and 0-24 hours)  
 
Gene found in our study are highlighted in bold.  
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In summary, we elucidated gene networks for the three intervals using candidate GC-induced 
apoptosis genes. The number of inferred networks varied according to number of input genes. 
We used two input sizes in this study: (i) the whole gene set found differentially expressed at 
each time interval and (ii) genes found in at least two out of three time intervals. Different 
input gene sets produce many possible inferred networks; therefore, many genes appearing in 
these networks need further study. The question we try to answer after inferring gene 
networks from time series data is how to reduce the number of genes that need further study. 
We emphasised common genes (strong genes or prominent genes) because if they appeared 
more than once in a network, there was a high chance that this common gene needs to be 
activated in our input gene list.  
 
We identified common genes by manually extracting connections from inferred gene 
networks for each time interval. In addition, results from IPA showed the different Molecule 
and cellular functions, Canonical pathways and Functions between T- and B-ALL. T-ALL is 
more involved with cell death while B-ALL is more involved with cell cycle. We proposed 
GC-induced apoptosis gene networks for T- and B-ALL separately. This network still needs 
further study because the networks were retrieved from relationships already mentioned in the 
literature from studies on different cells, tissues or diseases.  
 
In the next section, we focus on elucidating the relationship between GC-induced apoptosis 
genes and GR/NR3C1 using genes found statistically significant probe sets from our STEM 



















4.3.2 Inferring GR gene networks from selected genes from STEM 
 
As shown in the previous section, genes extracted for the time intervals resulted in several 
possible inferred gene networks. Therefore, using Short Time series Expression Miner 
(STEM) to cluster genes before inferring networks can help reduce the number of networks as 
the attention here is on the temporal characteristics of data as a time series. The hypothesis 
behind clustering methods is that they cluster gene groups with similar gene expression 
patterns; these genes may have similar gene function or co-regulation. Therefore, we further 
analysed gene networks from the set of GC-regulated genes that were identified by the STEM 
clustering method and reported in Chapter 3 (327 probes were analysed for each patient 
separately). The 141 probe sets for T-ALL and 221 probe sets for B-ALL were used to 
construct gene networks.  The networks were generated through the use of Ingenuity Pathway 
Analysis (Ingenuity System, www.ingenuity.com). The list of genes above did not include 
the glucocorticoid receptor (GR) or NR3C1 gene for B-ALL even 2 patients would not have 
made NR3C1 pass the criteria. However, according to the literature, GCs mediated their 
function by binding with their receptor (glucocorticoid receptor: GR/NR3C1). Therefore, we 
aimed to understand the relationships between GC-regulated genes and GR/NR3C1 in the 
apoptosis process. Thus, we added gene expression of NR3C1 into the list of B-ALL patients 
as input into IPA.  
 
Tables 4.5 and 4.6 which report all genes that form the gene networks and the selected gene 
networks are shown in Figures 4.4 and 4.5 for B-ALL and T-ALL, respectively. In Tables 4.5 
and 4.6, the top three functions from B- and T-ALL still show that gene listed from B-ALL is 
involved in cell cycles and cancer whereas those from T-ALL are involved in cell death 
functions. Of all the networks for B-ALL in Table 4.5, only network 1 had NR3C1 and, for T-
ALL in Table 4.6, only networks 2 and 5 had NR3C1. Figures 4.4 and 4.5 show networks for 
each time interval with focus on NR3C1 or GR gene from network number one of B-ALL 
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Table 4.5: List of B-ALL gene networks based on gene list including GR from STEM 
clustering method 
 
ID Molecules in Network Score 
Focus  
Molecules Top Functions 
 1 
BCL2A1, CDK6, Cyclin A, E2f, E2F7, E2F8, 
ELL2, FCER1G, FKBP5, Histone h4, Hsp90, 
IGHM, IL12 (complex), IL18R1, IL27RA, 
Interferon alpha, KIF15, LEF1, MCM10, 
NFkB (complex), NR3C1, NUSAP1, OIP5, 
Pias, PRDM1, RAG2, Rb, RBMS3, RRM2, 
SOCS1, STAT5a/b, TPX2, TYMS, tyrosine 
kinase, ZBTB16 
 53  24 
Haematological System 
Development and Function, 
Haematopoiesis, Cancer 
 2 
ACP5, ACPP, AGTR2, AP1B1, ASPM, beta-
estradiol, BUB1, BUB1B, BYSL, CCR1, 
CCR3, CDC42EP3, CTSH, DFNA5, ERG, 
FABP5, ICAM2, IGF2R, KIF4A, KLF9, Mhc 
ii, MKI67, NCAPD2, NCAPG (includes 
EG:64151), NCAPH, PRC1, SMC2, SMC4, 
SPARC, STAB1, TGFB1, TRO, TXNIP, 
WFS1, ZWINT (includes EG:11130) 
 29  15 
DNA Replication, 
Recombination, and Repair, 
Cell Cycle, Cellular 
Assembly and Organisation 
 3 
 BCAT1, CEP55, CTNN&beta;-LEF1, 
CTNNB1, DEPDC1, DGKE, DPM1, DSN1, 
FZD8, GINS2, GSTM4, HELLS, HNF4A, 
HSPH1, LY6A, MIR124-1, MIS12, MYC, 
NUF2, P2RY14, PAICS, PDE4B, PFKFB2, 
PHB2, PP2A, PSAT1, SNX9 (includes 
EG:51429), SOX17, SPN, Tcf/lef, TCF7L2 
(includes EG:6934), TP53, TPX2, UBE2T, 
VPS37C 
 24  14 
Cell Cycle, Cellular 
Assembly and Organisation, 
DNA Replication, 
Recombination, and Repair 
 4 
ANAPC5, ATAD2, ATP, BUB3, CDKN2A, 
CDKN2D, DEFA3 (includes EG:1668), DTL, 
EPPK1, GFRA1, GINS1, ICAM3, IL6, 
KIAA0101, KIF11, MELK, Na+,K+ -ATPase, 
Oas, OAS1, OAS2, ORC4L, P2RX1, P2RX2, 
P2RX3, P2RX4, P2RX5, P2RX6, PHB2, 
retinoic acid, SHC1, SHCBP1, TARSL2, 
TMEM97, TRAF6, UBA1 
 21  12 
Protein Synthesis, 
Cardiovascular System 
Development and Function, 
Cell Morphology 
 5 
ARPP-21, CASP3, CCL6, CCL23, CD24, 
CD8A, CSF1R, CTSH, CTSL2, DARC, 
FAM171A1, FEZ1, FGD2, FGL2, GRIN1, 
HLA-F, HLA-G, HTT, IFNG, IFNGR1, IL13, 
KIF18A, LILRB2, MS4A4A, neuroprotectin 
D1, NFKBIB, PAPPA, PDE4B, PRTN3, 
RAB27A, RPS6KA2, S100A8, SERPINF1, 
SHANK1, SIK1 
 19  11 
Cellular Movement, Immune 
Cell Trafficking, Organismal 
Injury and Abnormalities 
 6 
Akt, ANXA7, Ap1, CD3E, CFLAR, CYP8B1, 
ERK, ERK1/2, FCGR1A/2A/3A, FGR, FSH, 
HSP90AA2, HSP90AB1, Ige, IGHE, IL31, 
IRS1/2, LGALS3, MGST1, MMP12, P38 
MAPK, PDE4B, PDGF BB, PI3K, PIK3IP1, 
Proteasome, PRSS3 (includes EG:5646), 
RAD51AP1, RNA polymerase II, SERPINA1, 
SHB, SLA, SPHK1, SRC, TCR 
 13  8 
Cellular Movement, 
Haematological System 
Development and Function, 

















































Figure 4.4: Glucocorticoid receptor gene networks for B-ALL at 0-6 hours  
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ID Molecules in Network Score 
Focus 
Molecules Top Functions 
 1 
ARHGEF7, BCL2L11, DTL, E2f, ERAF, 
hCG, HES1, Histone h3, Histone h4, HLA-
DQB1, HLA-DR, HLA-DRA, ID3, Ifn gamma, 
ITPKB, MCM10, MHC Class II, NFkB 
(complex), NRGN, PF4, PMAIP1, PPBP, 
Proteasome, PTGDR, Rb, RNA polymerase II, 
RUNX2, SMARCC2 (includes EG:6601), 
SOCS1, TPX2, TYMS, tyrosine kinase, 
UHRF1, Vegf, ZNF24 (includes EG:7572) 
 49  22 
Cell Death, Haematological 
System Development and 
Function, Cell-To-Cell 
Signalling and Interaction 
 2 
Akt, Ap1, ARNTL, ASB3, BMF, CAMP, 
CCR7, Collagen(s), CTF1, CTSG, DEFA3 
(includes EG:1668), ERK, GLP2R, IL1, IL1F9, 
IRS1/2, Jnk, LRRK1, LYZ, Mapk, MPO, 
NR3C1, P38 MAPK, PDGF BB, PI3K, 
PIK3IP1, Pkc(s), PRKCA, PSMC3IP, S100A8, 
S100A9, SPARC, STOM, Tgf beta, TNFSF8 
 30  15 




AHSG, ANKZF1, ARPC5, ATN1, C4A, CA2, 
CA1 (includes EG:759), CLTCL1, CREB1, 
CYP11A1, DBT, EDN1, ELL, EP300, FEN1, 
Fgfr, FRMD6, GHRHR, HNF4A, IFNAR1, 
ING4, KIAA0101, L-triiodothyronine, LPIN1, 
MEGF11, Na+,K+ -ATPase, PHKB, SCAND1, 
SIK1, SLC18A2, SNX5, SRC, TUBB1, WASL 
(includes EG:8976), ZYX 
 20  11 
Cellular Development, 
Connective Tissue 
Development and Function, 
Cell Morphology 
 4 
ASPM, ATAD2, BRE, Ca2+, CCR7, CD27, 
CSGALNACT1, CTF1, CXCL9, DAD1, 
EIF5A, ETHE1, GNB1, GNG11, GSR, ING4, 
IRAK3, IRF2, IRF9, NOTCH3, PIM2 (includes 
EG:11040), PMAIP1, PPP1R13L, PRMT2, 
PRNP, RAD51AP1, RELA, RPL5 (includes 
EG:6125), S100A12, S100P, SLC2A4, SPI1, 
TMSB15A (includes EG:11013), TNFSF9, 
TP53 
 20  11 
Cellular Development, 
Cellular Growth and 
Proliferation, Cell Death 
 5 
AKT1, BCL2, BIRC2, CBL, CCNB1, CCND1, 
CCND2, CCND3, CDC34 (includes EG:997), 
CDKN1A, CDKN1B, CHEK1, CTNNB1, 
CUL1, DLGAP5, EGFR, ELF4, FBXL3, 
FBXO7, HNRNPU, HSPD1, MLF1, NR3C1, 
PFKFB2, RBL1, RBX1 (includes EG:9978), 
SKP1, SMAD3, SMAD4, TNF, YWHAG, 
YWHAH, YWHAQ (includes EG:10971), 
YWHAZ, ZFP36 
 5  4 














Figure 4.5: Glucocorticoid receptor gene networks for T-ALL at 0-6 hours 
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In Figure 4.4, the B-ALL gene network containing NR3C1 found connections with FCER1G, 
FKBP5, Histone h4, Hsp90, NFkB, Pias, RBMS3, STAT5a/b, SOCS1, tyrosine kinase and 
ZBTB16. From Figure 4.5, the T-ALL gene network containing NR3C1 found connections 
with Akt, BMF, ERK, GLP2R, IL1, Jnk , LIF9, Mapk, PSMC3P, STOM and Tgf beta. These 
two GR gene networks from B- and T-ALL will be used to combine with the relevant 
pathway networks and existing GR gene networks selected from literature which will be used 




After identifying the set GC-regulated genes in Chapter 3, in this chapter, we focused on 
finding the gene networks of GC-regulated genes in childhood leukaemia. First, the GC-
regulated genes from Chapter 3 were used to infer gene networks at three interval time points: 
before treatment and six hours after treatment (0-6 hours), six and 24 hours after treatment (6-
24 hours) and before treatment and 24 hours after treatment (0-24 hours)). We inferred 
networks from two different sizes of input dataset with the focus on finding prominent or 
predominant genes through common genes. We manually extracted gene connections from 
the inferred networks at three time intervals and proposed GC-induced apoptosis gene 
networks for T- and B-ALL (Figures 4.2 and 4.3). The major finding of this study from 
inferring gene networks using IPA software was that we found a set of three genes (P2RY14, 
S100A8 and TOP2A) that remained active after treatment for the whole 24 hour period for B-
ALL but none for T-ALL. Seven more common genes (ASPM, E2f, HNF4A, KIAA0101, 
MYC, NFB (complex) and S100A8 were added by IPA to both T- and B-ALL networks 
with other two extra genes (HNF4A and Rb) added to B-ALL.  
 
Next, GCs activate by binding to the glucocorticoid receptor (GR). To understand the 
relationship between GR and gene network of GC-induced apoptosis genes, we then focused 
on finding the connection between gene networks of GC-induced apoptosis genes with the GR 
gene network. The GR gene network was created from a gene set selected by the STEM 
clustering method from Chapter 3. Inferred gene networks from gene clusters by STEM added 
more connected genes to NR3C1. For B-ALL (Figure 4.4), NR3C1 found connections with 
FCER1G, FKBP5, Histone h4, Hsp90, NFkB, Pias, RBMS3, STAT5a/b, SOCS1, tyrosine 
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kinase and ZBTB16. In addition, for T-ALL (Figure 4.5), NR3C1 found connections with 
Akt, BMF, ERK, GLP2R, IL1, Jnk , LIF9, Mapk, PSMC3P, STOM and Tgf beta. 
 
The next step of our study, in Chapter 5 will investigate GR gene networks that may control 
the GC-induced apoptosis mechanism which, in turn, will help to better understand the GCs-
induced apoptosis process. 
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    Chapter 5 
Inferring Gene  Networks from  Microarray data and 
Pathway Databases 
5.1 Introduction 
Systems Biology, the concept of multi-disciplinary, systematic and holistic study of biological 
systems, is now becoming rooted in the biomedical field. The integration of available 
information (from genes to gene networks/pathways) leads to better understanding of complex 
biological systems including human response to treatment. The biological system of gene 
expression and their products can be classified as transcriptional regulatory, protein 
interaction, metabolic and signal transduction networks. These represent connections and 
relationships between tissues, cells, genes, gene products (protein), networks and pathways. 
This information provides a higher level of understanding of phenomena and cellular 
processes in an organism. To date, gene expression profiling is the most widely used approach 
to construct gene networks from gene expression data. Gene expression data mainly come 
from publicly available databases. Due to increasing availability of high throughput data, 
especially, microarray data, a database has been developed to store and standardise the 
information for further analysis. Lists of existing public databases, internet-based platforms 
and software for networks/pathways analysis (construction, data mining, and visualisation) 
can be found in various sources such as Babu, (2008) and Tsui, Chari, Buys, & Lam, (2007). 
The knowledge of unknown gene function and transcriptional regulatory networks are not 
retrieved when using a pathway-based method. Therefore, integration with clustering methods 
may help to identify function of unknown genes assigned to the same function or pathway of 
known genes in the cluster (Cavalieri & De Filippo, 2005).  
 
Gene expression data from microarray technology is used extensively in genome wide 
analysis of cancer, for example, gene clustering and inferring gene networks. A number of 
methods, including machine learning and mathematical approaches have been used to 
construct gene networks from synthetic and experimental data. In addition, microarray data 
can be used to infer gene networks by using forward and reverse engineering methods. 
Reverse engineering or inferring gene networks is the process of reconstructing networks 
from experimental systems. A genetic network is an interaction between genes and its 
products which indicate the regulation between genes. Gene networks are often known as 
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gene regulatory networks and they are large-scale interactions and connections of the cell at 
mRNA level. However, these networks do not give the whole picture of regulatory networks. 
For example, networks inferred from time series gene expression data only describe a 
phenomenon in the form of: every time that gene A is downregulated (underexpressed), gene 
B is upregulated (overexpressed). Thus, an inferred network gives only part of the whole 
actual regulatory process; however, this is an important step that will lead to further 
investigation (Ferrazzi & Bellazzi, 2007).  
 
The aim of gene network inference is to retrieve interactive or dynamic networks from given 
data. Usually, the network can be represented as a graph where nodes represent genes and 
edges represent the relationship or interaction between connected genes. The relationship may 
indicate coexpression or coregulation of genes, which may share regulatory inputs, common 
pathways, biological function, location or process. Many studies on network inference have 
been carried out using artificial intelligence, statistical methods and mathematical methods, 
including Boolean networks, Differential equations, Neural Networks, and Stochastic models. 
A network/pathway database is another method currently used after microarray data analysis. 
Many studies start with the experimental process, then pre-process and analyse data to obtain 
differentially expressed genes and, finally, IPA or similar program is used to infer gene 
networks (Panetta, Evans, & Cheok, 2005; Phillip et al., 2005; Raponi et al., 2004; Winter et 
al., 2007).  
 
The main focus of this study is glucocorticoids-induced apoptosis in childhood leukaemia 
treated with prednisolone. Generally, the apoptosis mechanism is mediated through two major 
pathways: the intrinsic (mitochondrial) pathway and extrinsic (cell death receptor) pathway. 
Many researchers have reported that the apoptosis mechanism initiated by conventional 
anticancer drugs is via the intrinsic pathway (R. Kim et al., 2002). In addition, glucocorticoid-
induced apoptosis involves other pathways. Knowledge of the relationship and crosstalk 
between the apoptotic pathways and other pathways can increase the understanding of the 
apoptosis process. Defects in apoptotic pathways cause resistance in cancer cells during 
chemotherapy. The response to chemotherapy may be mediated by the involvement of 
pathways including p53-dependent and independent mechanisms (Min et al., 2006). Figure 
5.1 shows the relationship of chemotherapeutic drugs and other factors that together affect the 
intrinsic apoptosis process. After treatment, chemotherapeutic drugs induce apoptosis through 
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microtubule damage or the DNA damage pathway and, subsequently, these pathways connect 
with the intrinsic and extrinsic apoptosis pathways. The chemotherapeutic drug referred to in 
this study is prednisolone, which is a synthetic glucocorticoid intensively used to treat 
childhood leukaemia. Generally, it is commonly known that the effect of glucocorticoids is 
mediated by the glucocorticoid receptor (Bachmann et al., 2007; Costlow, Pui, & Dahl, 1982; 
Kofler, 2000; Tissing et al., 2003; Tonko et al., 2001). Thus, knowledge of GR gene networks 
can enhance the understanding of GC-induced apoptosis mechanisms. Only few studies have 
been conducted on GR gene networks and these were not based on time series microarray data 
(Donn et al., 2007; Miller, Komak, Webb, Leiter, & Thompson, 2007; Phillip et al., 2005; 
Webb et al., 2003). As mentioned previously, in Chapter 3, we found that ALL subtypes: T- 
and B-ALL have some common and distinct genes. The inferred networks are proposed as 
GC-induced apoptosis networks for T-and B-ALL separately. Nevertheless, many studies 
have focused on finding common networks and pathways for childhood ALL. Therefore, we 
combined all possible networks from our data analysis and included previously proposed 
networks from the literature. We used three different gene sets to infer gene networks: (i) 
genes selected in this study by Short Time series Expression Miner (STEM) clustering 
method (ii) gene selected from three pathways of relevance to the apoptosis process and (iii) 
genes reported in the previously mentioned study by Phillip et al. (2005). These gene sets 
were analysed mainly by using Ingenuity Pathway Analysis software (IPA), only the last gene 
set was further analysed with BiblioSphere Pathway Edition (BSPE) and Oncomine. Then, a 
comparison and combination among these networks was carried out and proposed as a GR 
gene network.  
 
The specific objective in this chapter is to understand behaviour of known genes from the 
apoptosis, p53 and NFB pathways. In addition, to study the effect of different tissues and 
chemotherapeutics drugs on the inferred GR gene network. Finally, to maximise use of 
publicly available pathway databases to identify GR gene networks. The outcome of this 














Figure 5.1:  The Integrated Apoptotic Pathways  
A schematic diagram showing some of the known components of the intrinsic and death receptor apoptotic 
programs that may modulate tumour development and therapy. An asterisk denotes components that are 
frequently mutated or aberrantly expressed in human cancers. Components in red inhibit apoptosis while those in 











The data used in this part is the same as that used in the previous chapter. Specifically, the 
secondary microarray dataset by Schmidt et al. (2006) is used. Raw data in the format of CEL 
files and normalised microarray data were obtained online from the Gene Expression 
Omnibus (GEO). Raw data were collected from 13 patients (three T-ALL patients and ten B-
ALL patients) at three time points: 0 hour, 6/8 hours, and 24 hours. 
 
5.2.2 Computational Methods 
 
Gene network analysis and recovery of key biological pathways in this study were conducted 
using three network/pathway tools, summarised as follows:  
(1) Ingenuity Pathway Analysis software (IPA) (Ingenuity® Systems, Redwood City, CA, 
USA, http://www.ingenuity.com). IPA is a web-based application that integrates a systems 
biology approach to solve various biological problems. The knowledge base of IPA comes 
from journal articles, textbooks and other data sources. This software has many applications; 
only functional analysis of genes and their networks have been used in this study. The p-value 
defines the significance of gene function in a network as well as gene to gene relation, and a 
p-value less than 0.05 signifies a statistically significant and non-random association. The 
right-tailed Fisher Exact Test is used to calculate the p-value. 
(2) The BiblioSphere Pathway Edition (BSPE) (Genomatix Software, Munich, Germany, 
http://www.genomatix.de). This software can be used to analyse gene relationship networks, 
which combines literature analysis (from Pubmed), gene annotation and promoter analysis. 
Statistics are performed to check over- or under-represented groups of genes by using Z-
score. The intensity of node (gene) varies from red to blue, denoting overexpression to 
underexpression, respectively. 
(3) The Oncomine (http://www.oncomine.org) is a knowledge-based database curated from 
existing literature of human cancer gene expression profiles and integrated data-mining 
platforms. The differentially expressed genes are analysed using t-statistics and corrected 
measure of significance by using false discovery rate. As of 22 June, 2009, there were 41 
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cancer types with 392 studies and 28,880 microarray experiments available for further 
analysis with integration of other 18 bioinformatics resources.  
 
5.3 Results and Discussion  
 
The aim of our study was to better understand the GC-induced apoptosis mechanism via two 
major GCs issues: GC-induced apoptosis genes and GR gene network. After identifying 
candidate GC-induced apoptosis genes in Chapter 3 and their network in Chapter 4, we 
focused on GR gene networks for childhood leukaemia in this chapter.  
 
5.3.1 Inferring GR gene networks from selected genes from three pathways 
(apoptosis, p53 and NFB) 
 
Generally, there are two main apoptosis signalling pathways: the extrinsic and the intrinsic 
Apoptosis is regulated by various death inducing signals and interplay of several initiator, 
regulator and executioner genes. After receiving the apoptotic stimulus, the biochemical 
reactions and signalling pathways lead to apoptosis through several molecules, for example, 
Bax (the prototypic pro-apoptotic protein), Apaf-1 (apoptotic protease-activating factor 1), 
and caspases 9. In addition, the molecular mechanism of apoptosis signalling pathways is 
activated through anti- and pro-apoptotic molecules: the Bcl-2 family. The Bcl-2 family of 
proteins is essential to induce the apoptosis process; it can be either pro-apoptotic such as 
BH3-only, BAD, Bax and Bim (Bcl-2L11) or anti-apoptotic such as Bcl-2, Bcl-xLand Bcl-w. 
 
We first selected five vital genes commonly referred to in the literature about extrinsic and 
intrinsic pathway to investigate their behaviour before and after treatment. From the extrinsic 
pathway, the five selected genes were: caspase 8 (cysteine-aspartic acid protease (caspase)), 
caspase 10, FADD (Fas-Associated protein with Death Domain), FAS (tumor necrosis factor 
receptor superfamily, member 6) and TRADD (tumour necrosis factor receptor type-1-
associated DEATH domain protein). The five selected genes from the intrinsic pathway 
were: Apaf-1 (apoptotic protease activating factor 1), Bad (bcl-2-associated death promoter), 
Bcl2 (B-cell CLL/lymphoma 2), caspase 3 and caspase 7.  
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None of these genes passed our criteria for finding differentially expressed genes. Their log 
ratios for the three time intervals (0-6, 6-24, and 0-24 hours) were relatively low, varying 
from 0.005 (mostly) up to 0.7. Only few genes with ratios above 0.9 were found in one out 
three patients for T-ALL and one or two out of ten patients (B-ALL). We can speculate from 
these results about why known apoptosis genes were not differentially expressed: (i) the  time 
frame for apoptosis process can vary, taking up to 96 hours; Thomson and Johnson (2003) 
studied the apoptosis time frame for gene regulation after CEM-C7 were exposed to 
dexamethasone. They indicated that 24 hours after treatment was still pre-apoptotic and a 
reversible process (Thompson & Johnson, 2003). Therefore, the selected data only 
represented the early stage of the GC-induced apoptosis mechanism. (ii) The selected 
threshold (two fold) may be too high, but the question still remains as to how low a threshold 
could be and still provide biologically statistically and meaningful differentially expressed 
genes. Overall, it was possible to conclude that ten of known vital genes from extrinsic and 
intrinsic apoptosis pathways were not yet activated within 24 hours after the treatment. 
 
Next, we looked into the inferred networks from the three related pathways (apoptosis, p53 
and NFB). We considered these three pathways because apoptosis is involved with multiple 
processes and pathways. Many studies reported that the GC-induced apoptosis process in 
ALL was mainly involved with the intrinsic pathway (Laane et al., 2007; Ploner et al., 2005; 
Schmidt et al., 2004). Thus, we selected only known genes from the intrinsic pathway; in 
addition, we focused on the Bcl2 family instead of caspases. The reason why we added two 
pathways (p53 and NFB) into our network analysis was because previous studies have 
shown their strong relationship with apoptosis pathways. In addition, p53 and NFB play an 
important role in cancer research. First, p53 is a transcription factor and a tumour suppressor 
protein which plays an important role in the control between apoptosis and survival. There are 
many positive and negative feedback loops involved with p53, as reviewed by Harris and 
Levine (Harris & Levine, 2005) and a recent review of p53 can be found in Batchelor, 
Loewer, and Lahav (2009). A recent study on crosstalk between p53 and apoptosis process 
can be found in Sun et al., (2009). Second, a model of GC-induced apoptosis in leukemic cells 
showed a connection between NFB and the GC-GR complex when it was translocated to the 
nucleus (Tissing et al., 2003).  
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Fifteen key genes from the three pathways (apoptosis (intrinsic pathways) and five each from 
p53 and NFB) were selected and highlighted in bold (Table 5.1) and detailed, as follows: 
 Intrinsic pathway: Apaf-1* (Apoptotic Peptidase Activating Factor), Bcl2 (B-cell 
CLL/lymphoma2), BAD (Bcl2-antagonist of cell death), BAX (Bcl2-associated x 
protein), and BCL2L1 (Bcl-2-like1). *Apaf-1 involved in both intrinsic and p53 
pathways (Soengas et al., 1999).  
 p53 pathway: Apaf-1*, CASP9 (Caspase 9, apoptosis-related cysteine peptidase), 
MDM2 (Transformed mouse 3T3 cell double minute 2, p53 binding protein), MYC, 
and TP53 (Tumour protein p53).  
 NFB pathway: NFB family (Nuclear Factor Kappa-light-chain-enhancer of activated 
B cells) consist of NFB1, NFB2, REL, RELA, and RELB. 
 
The total 15 genes mentioned above and two known genes (NR3C1 and AP-1) involved with 
the GC-induced apoptosis process (Tissing et al., 2003). AP1 (Activator Protein 1) consisted 
of proteins belonging to the c-Fos and c-Jun families. In this study we selected: FOS, FOSB, 
JUN, JUNB, and JUND. Therefore, a total of 20 genes was input into IPA. It revealed gene 
network (s) common to the three pathways, as shown in Table 5.1, indicating three possible 
gene networks. In the table, the genes from the list of 20 genes are highlighted in bold and 
others are added by IPA. We further analysed the three networks with expression values for 
20 genes from T-ALL data and the networks are shown in Figure 5.2. The generic network 
structures will be the same with B-ALL (data not shown). Only network number no.3 from 
IPA showed a gene connection with NR3C1: Akt, MDM2, MYC and TP53 or p53. The 
apoptosome (Apaf1, CASP9 and Cytochrome c) were found scattered in different networks 













Table 5.1: Selected gene lists from Apoptosis, p53 and NFB pathway 
 
ID Molecules in Network Score 
Focus 
Molecules Top Functions 
 1 
26s Proteasome, BAD, BCL2L1, BCR, Calcineurin 
protein(s), CASP9, Caspase, CD3, E2f, 
Glucocorticoid-GCR, Hat, Hsp90, IFN Beta, 
IFN&alpha;/&beta;, Ikb, IL12 (complex), MHC 
CLASS I (family), NF-kappaB (family), NFKB1, 
NFKB2, NFkB (complex), NfkB-RelA, NGF, 
peptidase, PRKAC, Proteasome, REL, 
REL/RELA/RELB, RELA, RELB, Rxr, SAA@, 
SWI-SNF, TCR, Ubiquitin 
 17  8 
Lymphoid Tissue Structure 




Ant, APAF1, BAX, BCL2, Cdc2, Creb, Cyclin A, 
Cyclin D, Cytochrome c, ERK, FOSB, Growth 
hormone, Gsk3, hCG, Hexokinase, HISTONE, Ige, 
IgG, Il12 (family), Il8r, JUN, JUN/JUNB/JUND, 
JUNB, JUND, LDL, MAP2K1/2, Mek, Pdgf, PDGF 
BB, Pias, Pkg, PP2A, Rb, STAT5a/b, Top2 
 15  7 
Behaviour, Nervous System 
Development and Function, 
Cancer 
 3 
14-3-3, Akt, ALP, Ap1, Arf, Calmodulin, Calpain, 
Cbp/p300, Ck2, ERK1/2, Fgf, FOS, Hsp70, IL1, 
Insulin, Interferon alpha, Jnk, Mapk, MDM2, MYC, 
NR3C1, P38 MAPK, PI3K, Pkc(s), PLA2, Ras, RNA 
polymerase II, Sapk, Shc, SNCA, STAT, Tgf beta, 
Thyroid hormone receptor, TP53, Vegf 
 12  5 
Inflammatory Disease, Renal 
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Figure 5.2: The three gene networks from Table 5.1  
 
Figures illustrated with expression values for T-ALL patients (colours indicate intensity 






In Figure 5.2, there was no direct connection between NR3C1 and NFB but after merging 
networks 1 to 3 (data not shown), three connections between NR3C1 and NFB were found, 
details of their connections follow: 
 NR3C1      NFB  (i) activation: GR protein is involved in activation of NFB (ii) 
inhibition: GR increases inhibition of NFB 
 NR3C1     NFB1 (i) expression:  in U2-OS cells, human GR alpha A protein is 
involved in expression of human NFB1 mRNA (ii) protein-protein interactions: 
binding of human p50 (NFB-p50) protein and human GR (NR3C1) protein occurs in 
cell extracts from COS cells. 
 NR3C1     NFB2 (i) expression:  in U2-OS cells, human GR alpha A protein is 
involved in expression of human NFB2 mRNA (ii) protein-protein interactions: 
binding of human NFB2 protein and human GR (NR3C1) protein occurs. 
 
The details of NFB connections given above, as well as overall results, showed that the 
inferred network from IPA only gave genes (from the literature) connected to the uploaded 
gene set without being limited to any specific cells/tissues/processes. Furthermore, we used 
input genes that we through could possibly be involved with the apoptosis process, the final 
inferred network gave a gene network based on literature from other studies that may or may 
be not involved with the apoptosis process. Nevertheless, the inferred network may give 
information for clinicians and scientists to use for further investigation.  
 
Although the IPA networks highlight generic gene network structures, gene connectivities in 
IPA have been rigorously validated from literature, therefore, the networks generated in this 
study may be useful for constructing a possible GR network, as discussed in section 5.3.3. 
Prior to final section, we study one more aspect: GR gene networks from previous studies. 
 
In the following section, three selected web-based knowledge network/pathway tools were 
used to construct a glucocorticoid receptor gene network based on prior studies. 
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5.3.2 Inferring GR gene networks using genes found vital in previous studies  
 
In this section we analysed gene networks based on genes from previous studies. 
Additionally, we investigated whether there was an effect from drugs or tissues on gene 
networks. We reviewed previous studies on GR network and found three studies: (i) Donn et 
al. (2007) (Figure 5.3a) and (ii) Miller et al. (2007) (Figure 5.3b) and (iii) Phillip et al. (2005) 
network (Figure 5.3c).  
 
We selected Phillip et al.‘s (2005) study for further investigation because our study was based 
on humans treated with prednisolone whereas the Phillip et al. (2005) study was in mouse 
livers treated with dexamethasone three hours before being sacrificed. Phillip et al. (2005) 
illustrated glucocorticoid receptor gene networks using data from two high-throughput 
technologies (microarray and genome wide location analysis (ChIP-on-Chip)). The 53 
overlapping probe sets (23 genes) between the two methods were used to create a GR gene 
network (in Figure 5.3c) using Ingenuity Pathway Analysis (Ingenuity Systems, 
http://www.ingenuity.com) (Phillip et al., 2005). We constructed a GR gene network based on 
Schmidt et al.‘s (2006) microarray data and pathway analysis (two selected network/pathway 
software (IPA and BSPE)) by using the 23 differentially expressed genes from for T-ALL and 
B-ALL. Our GR gene network was then compared with the three glucocorticoid networks 
mentioned above.  
 
The gene expression level of the selected 23 genes is shown in Table 5.2. We extracted the 
gene expression level of the 23 genes from Phillip et al. (2005), as these data were retrieved 
three hours after treatment; therefore, we extracted gene expression levels six or eight hours 
after treatment from the Schmidt data. One out of 23 genes (SERPINA1) was found 
differentially expressed in B-ALL only under our new criteria, as discussed in Chapter 3. 
Also, NR3C1 was found differentially expressed only in T-ALL. The Table 5.2 shows the 
average gene expression level for T- and B-ALL for the 23 genes.  Eight out of twenty three 
genes have the same expression pattern (up-regulation or down-regulation) between Phillip et 
al. (2005) and our study: CKS1B, FNTA, HSPCB, IGFBP1, MKNK2, NR3C1, and TXN 
(noted with * in Table 5.2).  
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Figure 5.3: Existing GR gene networks from three studies (Donn et al., 2007; Miller, Komak et al., 
2007; Phillip et al., 2005) 
 
a) Network analysis of the transcriptome response to glucocorticoid in human, primary T lymphoblasts. 
Induced genes are shown in red and repressed genes in green. Linking nodes not contained in the query set are 
shown in gray. Relationships involving changes in expression levels are coloured red (increase) and green 
(decrease). All other relationships are represented by a black line. Arrows indicate the orientation of the 
relationship (Donn et al., 2007). b) A signalling network links genes regulated by GCs in CEM cells. 
Ingenuity
® 
bioinformatics pathway analysis tool was used to connect a subset of 35 genes from the CEM 
signatory list based upon a database of published observations. Symbols for genes representing specific 
categories of cellular molecules as well as interactive relationships are depicted in the legend. Colour gradations 
are based upon gene regulation at the fold-change level. Red: induced gene; green: repressed gene. Fold-change 
data from CEM-C7–14 cells treated with Dex are presented as representative of the CEM signature (Miller, 
Komak et al., 2007). c) A Regulatory Network for the GR. Pathway analysis was seeded with the 53 
differentially expressed and GR-bound genes, plus the GR itself, as described in Materials and Methods. Genes 
in coloured, bold text were in the seed set, while all others were brought into the network by the pathway 
analysis program based on their known relationships to the genes in the seed set. Colour indicates induction (red) 


















Table 5.2: Comparison of gene expression between the original article by Phillipe et al. 
(2005) and our data for T-ALL and B-ALL patients 
 
 
Gene Article T-ALL B-ALL Gene Article T-ALL B-ALL 
ABCA1 -2.606 0.349 0.151 HSPCB* -1.466 -0.091 -0.313 
ADM 1.206 -0.046 0.583 IGFBP1* 9.689 0.019 0.058 
APOA2 1.291 -0.259 -0.089 MKNK2* 1.096 0.035 0.279 
BRD2 1.224 -0.132 0.107 NR3C1* 20 0.594 0.178 
B2M -1.383 0.427 -0.267 PCK1 1.248 -0.074 0.075 
CKS1B* -1.152 -0.242 -0.485 PSMA6 1.454 -0.158 -0.073 
DB1 -2.392 0.310 0.120 STUB1 -1.266 -0.041 0.132 
DDX5 1.454 0.038 -0.105 SERPINA1 -1.712 -0.564 1.098 
ETR101 -1.963 -0.191 0.451 TDE1 1.737 -0.020 -0.096 
FNTA* -1.297 -0.219 -0.097 TXN* -1.602 -0.316 -0.161 
GAS1 -1.796 0.218 -0.653 YWHAE* -1.195 -0.275 -0.372 
HMGCS2 2.239 -0.091 0.090     
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Networks were constructed with both- BSPE and IPA and results are shown in Figure 5.4 (a) 
and (b) for BSPE and Figure 5.4 (c) and (d) for IPA. IPA networks included gene, protein, 
enzyme, transcription factor, nuclear receptor, kinase and peptidase, while BSPE networks 
can be viewed as depicting gene-gene relations or gene-transcription factor relationships.  
 
Figures 5.4 a and b show gene networks of NR3C1 or GR from BSPE - Bibliographic 
relationships for differentially expressed gene profiles analyzed with the Genomatrix 
Bibliosphere software tool. Arrow heads indicate the type of functional relationship between 
the connected genes. The half line green (          ) connection means a gene encoding for a 
transcription factor is connected to a gene with the binding site for this transcription factor in 
its promoter, for example, NR3C1 and B2M or FNTA in Figure 5.4 a. A Genomatrix expert 
verified that gene-gene relationships are indicated by a blue circle in the centre of the 
connection line, e.g., NR3C1 and IGFBP1 in Figure 5.4 a. Red indicates up-regulated genes 
and blue indicates down-regulated genes during 0 to 6 hours of T-ALL and B-ALL patient. 
The colour intensity indicates the level of up- or down-regulation. 
 
Figure 5.4 c and d show gene networks of NR3C1 or GR from IPA. Even though the input 
probe sets are the same as those originally used in Phillip et al. (2005), we found different 
output gene names due to different species (human and mouse). Three genes from the original 
study were changed to different gene names: ETR101 to IER2, HSPCB to HSP90AB1, and 
TDE1 to SERINC3. 
 
Comparing results from BSPE and IPA, IPA found connections for all 23 genes but BSPE 
only found 14 connections. IPA added other relevant genes (12 genes) from databases to the 
network. IPA confirmed six connections found in BSPE: NR3C1 connects with ABCA1, 
B2M, FNTA, IGFBP1, STUB1, and TXN. In addition, the connections between and ABCA1 
and APOA2 from BSPE were also found in IPA. However, connections between B2M with 
ADM, CKS1B, SERPINA1 and ADM with HSP90AB1 found in BSPE were not found in 
IPA. In fact, these genes (ADM, CKS1B, SERPINA1, and HSP90AB1) and APOA2 were 
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Figure 5.4: GR gene network from; a) BSPE for T-ALL; b) BSPE for B-ALL; c) IPA for T-




We further investigated an effect of drugs and tissues on gene networks by identifying 
common genes. The GR network used in this study was inferred from blood sample data from 
patients treated with prednisolone and collected at, before treatment, and at 6/8 and 24 hours 
after treatment; whereas, Phillip et al.‘s (2005) samples were mice liver treated with 
dexamethasone and measured three hours before being sacrificed. In addition, Miller et al. 
(2007) used paediatric patient cell lines treated with dexamethasone and sampled at 20-24 
hours, while Donn et al. (2007) collected data from healthy adults treated with 
dexamethasone.  
 
 Same tissues and same drug (human and dexamethasone) 
Next, we directly compared the previously mentioned two exiting glucocorticoid networks 
from (i) Donn et al. (2007) and (ii) Miller et al. (2007). Four genes were found common 
between (i) and (ii): IL7R, FKBP5, PIK3R1 and TXNIP. NR3C1 and HDAC1 were added to 
network (i) by IPA but found in network (ii).  
 
 Different tissues and same drug (human vs mouse and dexamethasone) 
Finally, we compared network (i) Donn et al. (2007) and (ii) Miller et al. (2007) with network 
(iii) Phillip et al. (2005). There were two common genes between networks (ii) and (iii): 
NR3C1 was from both original sets while MYC was added to the network (ii) by IPA 
software and found in network (iii). ADM was the only common gene between network (i) 
and (iii).  
 
 Different tissues and drugs (human vs mouse and prednisolone vs dexamethasone) 
First, we compared the gene list from STEM (Table 4.4 and 4.5) and network (iii) Phillip et 
al. (2005). For B-ALL, there were six common genes (MYC, STAT5A, HLA-G, CASP3, 
NFKBIB, and HNF4A) and for T-ALL only three common genes were found (HNF4A, 
RELA, and TNF).  
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Some existing literature confirmed a relationship between common genes and the apoptosis 
process, specifically, in leukaemia, as follows: CASP3 (T. Liu et al., 2002), FKBP5 
(Kajiyama et al., 2009; Schmidt et al., 2006), HDAC (Rosato, Almenara, Dai, & Grant, 2003; 
Tsapis et al., 2007), HLA-G (Gros et al., 2006), IL7R (Karawajew et al., 2000), MYC 
(Ceballos et al., 2005), NFKBIB (Zhuang et al., 2004), PIK3R1 (Kharas et al., 2008), RELA 
(Dai, Rahmani, Dent, & Grant, 2005), STAT5A (Nosaka et al., 1999), TNF (Wen et al., 2000; 
Wuchter et al., 2001), and TXNIP (Z. Wang et al., 2005). No literature was found for HNF4A 
from a PubMed search using the key words ―HNF4A apoptosis leukaemia‖ 
(http://www.ncbi.nlm.nih.gov/sites/pubmed). 
 
It is possible to conclude from our results that the glucocorticoid response depends on the type 
of tissue, chemotherapeutic drugs and elapsed time after treatment. Another factor that can 
affect the final gene network result is the software selected. In our study, both software (BSPE 
and IPA) were based on curated connections from existing literature, however, we found 
differences in the inferred networks from the two methods. 
 
Since NR3C1 was likely to be the most common gene, this gene was further investigated 
using Oncomine - a cancer microarray database. This tool gives a visualisation of gene 
expression from many different studies at the same time. However, analysis of the network 
using Oncomine can only be done using the available datasets on the database because a user 
cannot upload their dataset. NR3C1 has been found differentially expressed in many types of 
cancer; for example, ovarian, prostate, breast and lymphoma. In leukaemia, NR3C1 has been 
found up- or down-regulated. Existing human leukaemia cancer datasets on Oncomine were 
analysed in relation to NR3C1 and the level of gene expression between normal cells, T-ALL 
and B-ALL is shown in Figure 5.5. There were 15 independent experiments/studies. Details 
of each experiment/study, including p-values, are shown in the table under Figure 5.5. 
Colours indicate different classes: class one (blue), class two (red), class three (green) and 
class four (yellow). Analysis no.1 was between normal bone marrow (left-hand side) and B-
ALL (right-hand side) while analysis no.7 showed expression between normal bone marrow 
(left-hand side) and T-ALL (right-hand side). Analysis no. 10 shows the differences 
expression of NR3C1 between males and females and analysis no. 15 shows the resistance 
and sensitivity to GCs. 
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                                                                                          Schmidt et al. (2006) (current study)                                                                        
Figure 5.5: Box-plot distribution of NR3C1 across 15 independent experiments/studies 




1 Anderson leukaemia   




2 Maser leukaemia T-ALL (18) 1e
-7 
3 Anderson leukaemia  class 1: B-ALL (87)  class 2: T-ALL (11) 1.1e
-5 
4 Holleman leukaemia  class 1: B-ALL (146)  class 2: T-ALL (27) 2.2e
-5 
5 Raetz leukaemia  class 1: T-ALL (9)  class 2: B-ALL (10) 7.3e
-5 
6 Bhojwani leukaemia  
class 1: Pre B-ALL (103)  class 2: T-ALL (10) 
3.1e
-4 
7 Anderson leukaemia class 1: Normal (6)  class 2: T-ALL (11) 0.002 
8 Schmidt leukaemia class 1: B-ALL (30)  class 2: T-ALL (9) 0.005 
9 Raetz leukaemia class 1: B-ALL (10)  class 2: T-ALL (10) 0.022 
10 Heuser leukaemia class 1: Female (18)  class 2: Male (17) 0.035 
11 Choi leukaemia class 1: healthy (6)  class 2: Adult T-ALL (41) 0.067 
12 Cario leukaemia  
class 1: Common (32)  class 2: Pre B-ALL (19) 
0.073 
13 Schmidt leukaemia ALL class 1: prior to treatment (14)  class 2: 
after 8 and 24 hours  
0.188 
14 Schmidt leukaemia ALL 
class 1: prior to treatment (13)  class 2: after 6 hours (9) class 
3: after 8 hours (4) class 4: after 24 hours (13) 
0.245 
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For B-ALL, there was strong evidence that NR3C1 is up-regulated and in T-ALL it appeared 
to be mainly down-regulated. In our study, we did not find NR3C1 differentially expressed in 
B-ALL (only 2/10 patients show that NR3C1 was differentially expressed: up-regulated). For 
T-ALL, NR3C1 was found differentially expressed (up-regulated) in 2/3 patients. We 
compared this with analysis no.14 which showed the expression from NR3C1 of Schmidt et 
al.‘s (2006) study whose data were used in our study. (Schmidt et al. (2006) combined B- and 
T-ALL subtypes into one group but we analysed subtypes separately). The level of expression 
of NR3C1 when compared before treatment (0 hour- blue box plot) indicated up-regulation 
after treatment (6 or 8 hours and 24 hours- red, green and yellow box plots). The results from 
Oncomine indicated that NR3C1 was differentially expressed with a p-value of only 0.245; 
this was confirmed by our study; altogether only four out of thirteen patients‘ expression 
value passed the criteria. Thus, the average NR3C1 gene expression value was definitely low 
and statistically insignificant. 
 
The next section is the final section in this chapter and focuses on combining all possible GR 
gene networks from the previous section and proposed the most intensive GR gene network. 
 
5.3.3 Proposed GR gene network  
 
We come to the last part, the most important finding, and the core of this study which is the 
possible GR gene network. In addition, we also combine previously known GR gene networks 
and GR gene network curated genes from the most relevant pathways. This gene network is a 
comprehensive network and it may provide a good base for scientists to select target genes for 
future research. 
 
Information from previous studies were combined and presented as a GR gene network that 
extended the existing network proposed by Phillip et al. (2005). These studies are: Miller et 
al. (2007), Donn et al. (2007), Phillip et al. (2005), and our selected gene networks of GC-
induced apoptosis genes based on NR3C1 gene, as shown in Figures 4.4, 4.5, 5.2 and 5.4 
(Figures 4.4 and 4.5 contain our GR gene networks based on gene clusters from STEM for B-
ALL and T-ALL, respectively; Figure 5.2 contains the GR gene networks based on apoptosis, 
p53, NFB genes; and Figure 5.4 shows the GR gene network we curated from IPA, based on 
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genes from the Phillip et al. (2005) study). Gene lists from these six gene network were used 
to develope the gene network on the CellDesigner

 program (Funahashi et al., 2008) which 
can be freely downloaded from http://www.celldesigner.org/. The result is shown in Figure 
5.6. Most figures generated by IPA program have nodes presented in several shapes, for 
example, cytokine (   ), growth factor (    ), enzyme (  ), and kinase (   ). These network shapes 
not exist in CellDesigner

. Therefore, we replaced most of the components (nodes) from IPA 
as a gene node (    ) in CellDesigner

, only transmembrane receptor (   ) and complex or 
group (    ) nodes retained their representation as receptor and complex node, respectively.  
 
Common genes were found in more than two networks, for example, ABAC1, ADM, B2M, 
DDX5, FKBP5, HDAC, MYC, PIK3R1, SERPINA1, TNF, TXN and YWHAE. This 
possible GC network in childhood leukaemia was curated from literature-based knowledge 
from many experiments on different tissues/organism and conditions. A future research topic 
is to verify the gene connections; specifically, for childhood leukaemia.  
 
All the methods in our study used hand/manual literature curated networks from existing 
databases as a part of network construction based on co-occuring terms. Therefore, the 
proposed network may be used with caution as the networks created from databases may have 
some incorrectly incorporated gene pairs (no relationship or incorrect relationship). Jessen et 
al. (2001) pointed out possible errors from gene symbols and short names; for example, 
different symbols have been used for different species and cell lines and short names refer to 
something else other than  gene names (Jenssen, Lægreid, Komorowski, & Hovig, 2001) 
 



















After identifying the set GC-regulated genes in Chapter 3, in this chapter, we focused on 
finding GR gene networks in childhood leukaemia. We constructed the gene network based 
on three aspects: GR gene networks from GC-induced apoptosis genes after using the STEM 
clustering method (illustrated in Chapter 4), GR gene networks from relevant pathways 
(apoptosis, p53 and NFB) and GR gene networks using genes from previous study (Phillip et 
al. (2005)).   
 
We investigated how known genes in known pathways involved in the apoptosis process 
behaved in our selected dataset. All the selected genes had expression levels under the 
threshold ( two fold) and relatively small changes in expression. This led to our conclusion 
that these known genes may not yet be active 24 hours after treatment or small subtle changes 
in gene expression should be considered in the process of selecting differentially expressed 
genes. When we further investigated gene connections from the three pathways given by the 
IPA program, we found that even the selected gene (NFB), known in the literature to be 
related to GC-induced apoptosis process, did not show up in one of the three networks from 
three pathways. Tissing et al. (2003) showed a direct connection between GR (NR3C1) and 
NFB in leukaemia. These two genes are also vital genes in the three selected pathways. 
However, no direct connection was found between these two in any of the three gene 
networks based on the 20 genes from the three pathways. When the three networks were 
combined, however, connection between GR and NFB was reinstated by IPA, possibly 
indicating that the connection come from the combined activity of several functions 
represented by these networks. Another possibility is that IPA database is from a variety of 
cells/tissues/diseases/processes, therefore, may not highlight connections specific to a 
particular disease situation. Therefore, inferred networks need further study in relation to a 
specific biology process. However, the inferred gene networks from IPA still a good base to 
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Network no. 3 (Figure 5.2) was used to add to the final gene network with the connection 
between NR3C1 with other 34 genes including: 14-3-3, Akt, ALP, Ap1, Arf, Calmodulin, 
Calpain, Cbp/p300, Ck2, ERK1/2, Fgf, FOS, Hsp70, IL1, Insulin, Interferon alpha, Jnk, 
Mapk, MDM2, MYC, P38 MAPK, PI3K, Pkc(s), PLA2, Ras, RNA polymerase II, Sapk, Shc, 
SNCA, STAT, Tgf beta, Thyroid hormone receptor, TP53, Vegf. 
 
The GR gene network was elucidated from IPA based on the gene list of Phillip et al. (2005) 
(Figure 5.3c) but this study used a different chemotherapeutic agent (dexamethasone) and 
mouse liver tissues. The comparison of networks between the study of Phillip et al. (2005) 
and our study showed only a few overlapping genes. Few overlapping genes were also found 
when our network was compared with other two recently proposed GR gene networks. This 
leads to the conclusion that GR networks may depend on chemotherapeutic agents and tissue 
type. In this study, we utilised the strengths of three existing network/pathway tools to 
improve the understanding of GC-induced apoptosis through GC-regulated genes and GR 
gene networks. IPA is considered to be the best tool to visualise and create pathways and view 
networks while BSPE can add more details on transcription factor levels. Oncomine was used 
because it is a cancer database, so it systematically compares and links with other cancer 
databases. The only limitation is that it does not allow users to upload their own datasets. As 
there are many available tools for scientists to choose from, using different software to create 
gene networks can cause variation in the proposed gene networks. The key question for 
further research is how to verify gene networks from differing sources. 
 
Finally, we proposed a GC-induced apoptosis network with the main focus on GR or NR3C1 
genes. We combined three existing GR gene networks from previous studies (Donn et al. 
(2007), Miller et al. (2007) and Phillip et al. (2005)) with our three inferred gene networks 
from the selected genes (Figures 4.4, 4.5, 5.2 and 5.4) using CellDesigner

 program. This 
network is a starting point for scientists to conduct further investigations.   
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    Chapter 6 
Summary, Conclusions and Future Directions 
In this thesis, glucocorticoid-induced apoptosis genes and glucocorticoid receptor (GR) gene 
networks were identified in order to increase an understanding of the underlying biological 
mechanisms of GC-induced apoptosis in childhood leukaemia. The dataset used in this study 
was retrieved from the original study by Schmidt el al. (2006). Differentially expressed genes 
were identified according to the following criteria: log-ratio and number of patients. 
Thereafter, these genes were used to find gene clusters using four emergent clustering 
methods: Self organising map (SOM), Emergent self organising maps (ESOM), Short time 
series expression miner (STEM) and Fuzzy clustering by local approximations of 
memberships (FLAME). Finally, these genes were used for gene network construction 
through selected network/pathway knowledge-based databases.  
 
We extended the investigation further from the original Schmidt et al. (2006) study. 
Specifically, new criteria were proposed to select novel genes in B-ALL and T-ALL subtypes 
separately and more genes were found than in the original research that combined the two 
subgroups in the analysis. The relationship between GC-induced apoptosis and GR gene 
network was illustrated. From short time series data, we defined novel genes and elucidated 
the gene network which we believe expands the current knowledge about GC-induced 
apoptosis in childhood leukaemia. A previously proposed GR gene network from liver tissue 
was updated in this study for clinical tissues. Finally, we proposed GC-induced apoptosis 
based on the NR3C1 gene network which lead to an understanding of the underlying 
mechanism and will lead to better clinical treatment. The following section presents a 
summary of what we discovered and contributions of this research, as well as future research 
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6.1 Summary 
 
We started with an extensive literature review, which was published and presented in Chapter 
1. This review focused on the existing research on the use of machine learning approaches to 
investigate childhood leukaemia. Even though childhood therapy achieves a highly successful 
survival rate, there are still many children who face severe side effects and failure from 
treatments. Therefore, chemotherapeutic treatment for childhood acute lymphoblastic 
leukaemia was the main focus in this study. The first aim of this study was to identify GC-
induced apoptosis genes in childhood leukaemia, starting from a set of genes proposed in a 
previous study. The previous study showed little agreement with findings from other studies 
(a few or no common genes) (Schmidt et al., 2006). Different gene sets have been reported 
from previous studies that used different drugs and tissues, as mentioned in Chapter 3. 
Experiments based on a clinical setting are extremely rare, difficult and expensive to carry 
out, so most studies used in vitro experiments and cell lines instead. We used a dataset from 
Schmidt et al. (2006); the most prominent dataset because it used gene expression data 
collected from childhood leukaemia patients at two time points after treatment. We analysed 
this dataset with specific objectives and the finding were reported as follows. 
 
The first specific objective of this study is to identify GC-regulated candidate genes. 
Objectives: 
(1) How reproducible or robust are the original authors‘ result?  
(2) Do different platforms (software) available to normalise data have an effect on the final 
gene sets? 
(3) Do leukaemia subtypes: T and B-ALL produce similar differentially expressed gene sets? 
Findings: 
We found that the selected dataset is reproducible and robust. In addition to the R software 
used by Schmidt et al. (2006), we applied Matlab and RMExpress to normalise raw data. 
Different software platforms produced slightly different sets of differentially expressed genes. 
Among the differentially expressed genes, there are some genes that are common between 
subtypes and some genes are found only in each subtype? 
 138 
The analysis process started using robust-multi array average (RMA) to normalise the raw 
dataset (from B-and T-ALL patients). Next, we identified differentially expressed genes using 
the same criteria ((i) log ratio of 0.7 or higher (ii) log ratio of 1.0 or higher, for at least six 
out of thirteen patients) as in the original research; we found more differentially expressed 
genes than the ones reported in the original research. Then, we investigated the proposed 
novel gene set (22 genes) in the original research. Most genes were found for B-ALL only 
(11/22 genes), while only three were found in T-ALL, and the remaining eight genes were 
found in both subtypes. The original authors (Schmidt et al. (2006)) assumed the commonality 
of the two subtypes (T-ALL and B-ALL), whereas there is a discrepancy between them. 
Therefore, we proposed new criteria for the two subtypes separately (log ratio of  1.0 for five 
out of ten B-ALL patients and two out of three T-ALL patients and new gene sets was 
reported. For T-ALL, there were 237 probe sets (203 unique probe sets after removing 
repeats) and for B-ALL there were a total of 257 probe sets (207 unique probe sets) for three 
time intervals. We combined these two gene sets from T- and B-ALL. This set contained 380 
unique probe sets (only 24 probe sets were common to T-ALL and B-ALL, of which three 
probes were not found in the original paper). In the next step, we deleted cell cycle genes 
from this list by using known cell cycle genes from KEGG, Cell cycle database, and the 
original article. After deleting cell cycle genes, T-ALL contained 222 probe sets (172 unique 
probe sets) and B-ALL contained 190 probe sets (155 unique probe sets) for the three time 
intervals. After combining the gene lists from the two subtypes, the final set had 327 unique 
probe sets (304 genes) responsive to GCs (19 probe sets were common to T-ALL and B-
ALL). Thereafter, we compared the new gene list with GC responsive gene reported in other 
previous research, even so, only few overlapping genes were found. 
 
The second specific objective is to identify group of GCs-induced apoptosis genes that 
may have similar functions.  
(1) Do gene clusters differ when analysed by general clustering methods as opposed to using 
clustering methods specifically designed for short time series data?  
The second aim was achieved by processing the new gene set through four different emergent 
clustering methods to identify genes with similar expression. SOM and ESOM are good at 
visualising how genes are organised in terms of distance and density, respectively. Both 
clustering methods provided a clear overview of the expression patterns of genes. However, 
SOM clusters may not be consistent due to the instability of neural gas, the method used in 
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this study to cluster neurons on the trained map as it produces unclear cluster boundaries. For 
ESOM, similar issues are known found true in this study. In addition, its number of clusters 
needs to be pre-defined by the user. Therefore, clusters from both SOM and ESOM methods 
were not used in further comparisons.  
 
STEM is a clustering approach that combines temporal characteristics with statistical 
significance analysis into cluster analysis to reduce possible networks that can happen by 
chance. Gene clusters from STEM were selected and used for gene network analysis in the 
second part of this research. The FLAME clustering method can be used to find clusters 
without predefined groups as it considers all possible clusters. The result from FLAME was 
useful to verify clusters from STEM. Clusters had to be compared manually for each patient. 
STEM and FLAME identified similar gene clusters. As more and more data are collected 
from many patients, the challenge is to develop data analysis tools which can analyse multiple 
samples (patients) at a time with respect to genes and their temporal patterns. We also showed 
the effect of distance measure on the final gene cluster. Therefore, prior knowledge needs to 
be incorporated with the selection of distance measure that is appropriate for a specific 
dataset.  
 
Next, we compare gene clusters from both methods with known gene functional clusters from 
the Database for Annotation, Visualisation and Integrated Discovery (DAVID). The results 
lead to the finding that only some genes from the same cluster have similar gene function (as 
they were found in the same gene functional cluster in DAVID). But there was more than one 
function for each cluster. How to assign genes to their right function can be a future research 
topic. 
 
The third specific objective is to construct gene networks of proposed GC-induced 
apoptosis genes.  
Findings 
In regard to objective one, we inferred gene networks of GC-induced apoptosis gene sets 
using IPA software to find the common (dominant) genes between the three time intervals. 
The connection between these gene networks with GR was displayed. We proposed GC-
induced apoptosis gene networks for T- and B-ALL separately. It was found from IPA that 
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the main function of the input genes in T-ALL was involved with cell death while the 
function of B-ALL was involved with cell cycle processes. We found a different time-lag 
(time-delay) response to treatment between these two subtypes.  
 
The fourth specific objective is to elucidate glucocorticoid receptor (GR) gene network. 
The objective and specific findings were defined as follows:  
 (1) To investigate the behaviour of selected known genes from the two main apoptosis 
pathways (extrinsic and intrinsic). 
(2) To illustrate GR gene networks based on selected genes from previously proposed 
glucocorticoid receptor gene networks by Phillip et al. (2005). 
(3)  To elucidate GC-induced apoptosis network with emphasis on GR or NR3C1 gene. 
Findings 
To answer the first sub-objective, we indicated that the gene expression level of selected 
known genes from the two main apoptosis pathways (extrinsic and intrinsic). Thereafter, we 
constructed an interplay network between three selected pathways (apoptosis, p53 and 
NFB). We selected a limited number of genes which have previously been defined in 
relevant literature as known genes in apoptosis, p53 and NFB pathways. The inferred 
network showed possible gene connections that were created by IPA, which is curated from 
journal articles, on different cell/tissue/process/disease studies may be not highlight the 
specific process. For example, the relationship between NR3C1 and NFB identified by IPA 
was not included in the Tissing et al. (2003) study which also mentioned the relationship 
between these two genes in the GC-induced apoptosis process. However, the inferred gene 
networks from IPA and their gene connection have been rigorously validated from the 
literature. Therefore, the networks generated by IPA may be useful for constructing a possible 
GC gene network with focus on GR. 
 
For the second sub-objective, we extracted the same genes that were used in the Phillip et al. 
(2005) study from Schmidt et al.‘s (2006) dataset. This led to the finding that different 
chemotherapeutic agents (prednisolone and dexamethasone), tissues (blood and liver), species 
(human and mouse) and time (6/8 hours and three hours after treatment) may have an effect 
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on the final candidate genes. In the final objective, we manually combined gene networks: 
three existing networks (Donn et al. (2007), Miller et al. (2007) and Phillip et al. (2005)) and 
our inferred network from STEM, three relevant pathways and Phillip et al. (2005) gene set to 
retrieve the possible GC-induced apoptosis network.  
 
We used three databases: Ingenuity Pathway Analysis software (IPA), the BiblioSphere 
Pathway Edition (BSPE) and the Oncomine. The main pathway analysis tool used with all 
input gene sets was IPA, whereas, BSPE was only used with the gene set from previous study 
(Phillip et al. (2005)).  
 
For the final sub-objective, we manually curated the GC-induced apoptosis network with 
emphasis on GR or NR3C1 gene from selected studies and our own investigations. This 
proposed GR gene network is far from being complete but it may be a starting point for 
further investigation and may be added to future networks modelling. 
 
We concluded, after gene expression data analysis, the following: 
 (i) ALL subtypes share some common molecular profiling: however, they have distinct 
patterns; although this was based on a small sample size, this issue should be taken into 
account.  
(ii) While different sample types: cell lines, clinical samples and mice treated with different 
chemotherapeutic drugs may share common response, there still have unique patterns and the 









Glucocorticoids are used intensively in the treatment of childhood acute lymphoblastic 
leukaemia. GCs induce apoptosis in immature lymphoid cells. However, molecular 
mechanism of GC-induced apoptosis has not been clearly defined. This study focused on 
extending the understanding of the underlying mechanism of GC-induced apoptosis process in 
childhood leukaemia. This goal was accomplished by using short time series clustering 
methods and web-based knowledge network/pathway tools. In this study, glucocorticoid 
treated childhood leukaemia short time series gene expression profiles were used (i) to 
identify GC-induced apoptosis genes and (ii) to infer GR gene networks. Even though there 
were many issues to extend this study in future research, we hope the gene lists and gene 
networks identified in this study will add new knowledge to the field and will lead to further 
experiments and clinical trials in order to increase the survival rate and reduce side effects in 




In this thesis, we addressed the problem of understanding the glucocorticoid-induced 
apoptosis mechanism in childhood leukaemia. The following summarises the contributions of 
the thesis. 
 The original study from which we retrieved the dataset identified only novel genes 
involved with GC-induced apoptosis process. The expensive costs and difficult 
processes involved with data collection still exist in this research field. The selected 
dataset is invaluable as an extremely rare time series dataset from clinical samples.  My 
contribution is extending the data analysis of this dataset to further analyse gene 
networks which may shed light on understanding the GC-induced apoptosis mechanism 
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 We have used short time series clustering to discover relationships among selected 
differentially expressed genes in order to find similar gene functions based on emergent 
clustering methods. The results have helped with understanding how four emergent 
clustering methods work with short time series data from childhood ALL and produced 
novel and consistent GC-regulated gene sets that will be extremely useful in clinical 
settings, in understanding GC gene networks and in identifying new drug targets. 
 The work focused on using identified gene sets to elucidate networks based on prior 
knowledge by incorporating some manually curated networks/pathways from the 
relevant literature. This has produced the gene network of GC-induced apoptosis in 
relation to the most important GC-regulated genes. 
 GC-induced apoptosis genes which have been reported in this study are from various 
tissues treated with different drugs, resulting in only small numbers of overlapping 
genes. My contribution to this work is in the investigation and confirmation of the effect 
of subtypes, samples sources, and chemotherapeutic drugs to the final novel genes or 
selected differentially expressed genes.  
 
6.4 Future Research 
 
Biomedical informatics research is an emerging field, still in its infancy, with much on-going 
research. There are various directions in which to consider further research. We indicate the 
specific points that are of prime importance. 
 
6.4.1 Computational methods 
 Integration of ‘omics’ data.  
This research field requires systematic analysis in order to uncover the whole picture of the 
GC-induced apoptosis mechanism. Gene expression profiles may not provide a complete 
whole insight into GC-induced apoptosis mechanisms because the changes in gene expression 
may not always refer to a simultaneous change in protein expression (Carroll et al., 2005). 
Therefore, integrating other high throughput proteomic, splicing, or other newer techniques 
with gene expression profiles may provide true insight into GC-induced apoptosis process. In 
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addition, gene networks are constructed based on different sources; in this research 
glucocorticoid receptor gene networks were constructed based on microarray data. In future, a 
combination of various data sources including transcription factor binding information, 
protein-protein interaction, ChIP (Chromatin Immunoprecipitation) on chip and other high 
throughput technology data will increase the reliability, provide more understanding and 
insight, and unravel the sophisticated and complex nature of gene networks. 
 Selection of normalisation process 
The normalisation process has an effect on inferring gene networks, and more details can be 
found in Lim et al. (2007). In addition, normalisation affects array-to-array precision and 
accuracy (Stafford & Tak, 2008). As there is no definitive conclusion on the best 
normalisation process, using different normalisation methods to analyse the dataset, as used in 
our study, then comparing results might be another way to verify differentially expressed 
genes. In addition, it is interesting to study further what cuase the different results when using 
different software but same normalisation method. 
 Criteria for selection of differentially expressed genes  
Differentially expressed genes are selected from a comparison between a target sample and 
control sample (e.g. no treatment/after treatment) as log ratio (base two) of target to control 
gene expression, which is called a fold change. The selection of statistical methods affects the 
selection of novel gene lists. Differentially expressed genes in this study were selected based 
on the fold change method which considered genes above a fold change cut-off as significant 
genes. Fold change has been criticised for its propensity to variation or unreliability. This 
method does not take into account the variability of inter-experiment noise and outliers. 
Genes with large fold ratios may probably come from high variability; consequently, genes 
with more than two fold changes may not always be significant genes. Several statistical 
methods have been developed to improve the outcome and reduce system variability. Further 
analysis should apply these statistical methods and compare the results in order to verify the 
novel genes. The decision on which method to use should be based on the nature of the target 
biological system; for example, the modified t-test is suitable for gene expression that changes 
according to the underlying noise, and fold-change is suitable for gene expressions that have 
large absolute changes (Tibshirani & Witten, 2007). A comparison of ten gene selection 
methods with several cancer data can be found in Jeffery et al., (2006). Apart from the 
existing methods, there are new methods under development or recently published in relevant 
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bioinformatics journals for public use; for example, FCPC methods, based on gene-to-gene 
correlation and principal component analyses (Qin, Feng, Harding, Tsai, & Zhang, 2008). 
 Selection of short time series clustering method 
Although gene clustering is the most common, important and essential method in microarray 
data analysis, the issue still remains as to which of the available methods should be selected 
and the choice of the corresponding parameters to generate clusters for selected data in order 
to reveal data structure and characteristics. For analysis of short time series data, STEM is one 
of a possible number of clustering methods. This field is still at an early stage; suitable 
approaches are being developed in order to capture the nature of short time series data, such 
as TA-clustering (Temporal Abstractions) (Sacchi et al., 2005). A comparison of three 
existing methods for analysing time series gene expression data can be found in Di Camillo, 
Toffolo, Nair, Greenlund, and Cobelli (2007). There is still no one method for all data; 
therefore, further study should consider cluster validity in order to evaluate/validate clusters. 
Currently, there are a number of cluster validation techniques available (Bolshakova & 
Azuaje, 2003; Bolshakova, Zamolotskikh, & Cunningham, 2006). 
 Selection of network/Pathway analysis tools 
Networks/Pathways analysis is still in its infancy; new tools are under development or are 
currently being released. Most new tools are free and user-friendly with web access; 
furthermore, these tools increase the capability and stability in handling the large datasets 
from existing databases, generating heterogeneous and complex cellular networks, and 
analysing noisy and incomplete gene expression data. Examples of these new tools are: Gene 
Network Generator (GeNGe) (Hache, Wierling, Lehrach, & Herwig, 2009), GraphWeb 
(Reimand, Tooming, Peterson, Adler, & Vilo, 2008), Network Analysis Tool (NeAT) (Brohee 
et al., 2008) and VisANT (Hu et al., 2009; Hu, Snitkin, & DeLisi, 2008). In addition, there are 
software/tools designed specifically for time series data including JCell- a java-based tool to 
reconstruct gene networks from time series gene expression data (Spieth, Supper, Streichert, 
Speer, & Zell, 2006). A more comprehensive list of network visualisation and analysis tools 
can be found in S. Zhang, Jin, Zhang, and Chen (2007). In addition, reverse engineering using 
network/pathway tools or other methods (such as neural networks and genetic algorithm) 
along with mathematical modelling will help to complete the whole picture of selected study 
process. Each method has different approaches and these differences will provide different 
perspectives that complement each other which may lead to better understanding of complex 
processes. 
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6.4.2 Biology of Childhood Leukaemia 
 Subtypes of T-and B-ALL 
Childhood leukaemia can be divided into at least six prognostic subtypes under T- and B-cell 
precursor: T-ALL, TEL-AML1, E2A-PBX1, BCR-ABL, MLL gene arrangement and 
hyperdiploidy> 50 chromosomes (Pui, 2004; Ross et al., 2003; Yeoh et al., 2002). 
Furthermore, they can be divided into good-, standard-, high- or very high-risks groups (Moos 
et al., 2002). These issues should be taken into account in order to understand the underlying 
GC-induced apoptosis in each subtype and risk groups. 
 Different chemotherapeutic agents 
Gene expression profiles from patients (clinical samples) were shown to be different from 
their cell line samples in the case of chronic myeloid leukaemia and acute myeloid leukaemia 
(Leupin et al., 2006). In GC-induced apoptosis gene studies on acute lymphoblastic 
leukaemia, there has been an extrapolation from leukemic cell lines to clinical samples with 
various chemotherapeutics.  As a consequence, two main points are of concern: (i) there are 
many synthetic glucocorticoids as well as other antileukaemic drugs that have been used; for 
example, L-asparaginase (L-asp), daunorubicin, and some that have been tested in clinical 
trials, such as clofarabine, nelarabine and forodesine (Pui, Robison, & Look, 2008) (ii) there 
is still no conclusion on how chemotherapy drugs may vary in effect on the treatment and the 
GC-induced apoptosis process. Cheok et al. (2003) suggested that the changes in gene 
expression are treatment-specific, in addition, different leukaemia subtypes share common 
responses to antileukaemic agents. However, this conclusion is for specific antileukemic 
agents (mercaptopurine and methotrexate). The degree of sharing is still in question; from 
previous studies, there is only a small number of overlapping genes between cell lines and 
clinical samples. Moreover, samples from clinical settings with different drug treatments give 
distinct gene sets.  
 Relevant Pathways 
Unravelling the underlying mechanism of the glucocorticoid-induced apoptosis signalling 
pathway for specific cell types is still in its infancy. GCs are involved with several signalling 
pathways, which are not all included in this study. For example, the cAMP/protein kinase A 
(PKA) and the mitogen-activated protein kinase MAPKs pathways, which include extra-
cellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p58 (Miller, 
Garza, Johnson, & Thompson, 2007). Twelve molecules and pathways  associated with GCs 
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have been reported by Herr et al. (2007) including mitochondria, death receptor signalling, 
Bcl-2-family, Caspases, c-myc, IB, Granzyme A, TDAG8, Lysosomes, Proteasomal 
degradation, Stress pathway and other modulators, such as IL-6 and T-cell receptor. New 
discoveries in biology for each individual pathway may be combined to increase the 
completeness of pathways/networks; for example, the ubiquitin-proteasome pathway, which is 
the main pathway involving degradation of intracellular protein in eukaryotes and controls the 
regulation of apoptosis process. Manual collection is a painful task to cover all information in 
the literature; therefore existing databases will help to gather most of the information. 
However, the final networks/pathways still need to be verified and validated. The 
combination of forward modelling using mathematical techniques with reverse engineering 

















     Appendix A 
A.1 Comparing genes from original author with our data analysis 
The original author proposed 128 probe sets (104 genes) as follows: 
Subset # of probe sets # of genes 
Table S2A Induced (early response: 6/8 hours) 25 19 
Table S2B Repressed (early response: 6/8 hours) 37 30 
Total 62 49 
Table S2C Induced (late response: 24 hours) 28 24 
Table S2D Repressed (late response: 24 hours) 38 31 
Total 66 55 
 
We reanalysed the dataset from original authors using the same method and criteria. Then we 
compared number of patients that passed the criteria in the original authors‘ data analysis and 
our data analysis. In Tables A.1.1-1.4, we highlighted in grey colour when the number of 
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A.1.1 Comparison of the number of patients who passed selection criteria in 













208078_s_at SNF1LK 9 10 208078_s_at 9 10 
226733_at PFKFB2 10 9 226733_at 10 9 
204560_at FKBP5 8 9 204560_at 8 10 
224856_at FKBP5 7 9 224856_at 7 10 
228854_at ZBTB16 8 9 228854_at 7 9 
224840_at FKBP5 7 8 224840_at 7 8 
203761_at SLA 7 11 203761_at 7 11 
202887_s_at DDIT4 8 11 202887_s_at 8 11 
203760_s_at SLA 8 10 203760_s_at 8 10 
210001_s_at SOCS1 6 9 210001_s_at 6 9 
221756_at MGC17330  6 9 221756_at 6 9 
228434_at BTNL 9 8 228434_at 9 8 
209992_at PFKFB2 6 8 209992_at 7 8 
232069_at   7 7 232069_at 7 7 
201369_s_at ZFP36L2 6 9 201369_s_at 6 9 
236450_at   6 9 236450_at 7 10 
232164_s_at EPPK1 7 7 232164_s_at 7 7 
202833_s_at SERPINA1 7 5 202833_s_at 7 5 
232165_at EPPK1 7 5 232165_at 7 4 
206637_at P2RY14 7 7 206637_at 7 7 
208438_s_at FGR 6 5 208438_s_at 6 5 
208949_s_at LGALS3 7 5 208949_s_at 6 5 
211429_s_at MYCPBP 6 3 211429_s_at 6 4 
229985_at BTNL9 7 8 229985_at 6 9 






















A.1.2 Comparison of the number of patients who passed selection criteria in 














207165_at HMMR      9 11 207165_at 9 11 
207828_s_at CENPF 9 11 207828_s_at 8 11 
201291_s_at TOP2A 10 10 201291_s_at 10 10 
219918_s_at ASPM 9 11 219918_s_at 9 11 
203764_at DLG7      10 10 203764_at 9 10 
202870_s_at CDC20    9 11 202870_s_at 10 11 
201292_at TOP2A    9 11 201292_at 9 11 
204962_s_at CENPA 9 10 204962_s_at 10 9 
202954_at UBE2C     7 10 202954_at 7 10 
228273_at FLJ11029 6 11 228273_at 6 11 
209709_s_at HMMR 9 10 209709_s_at 9 10 
225834_at         11 9 225834_at       10 9 
223381_at       CDCA1 7 11 223381_at       8 10 
202705_at       CCNB2 8 10 202705_at       7 10 
235574_at       GBP4 8 9 235574_at       8 11 
204444_at       KIF11 6 10 204444_at       6 10 
214710_s_at CCNB1 8 11 214710_s_at 8 11 
218542_at C10orf3 8 10 218542_at 8 10 
204709_s_at KIF23 7 7 204709_s_at 7 8 
209714_s_at CDKN3 8 8 209714_s_at 7 8 
218755_at KIF20A 8 9 218755_at 8 10 
1555758_a_at CDKN3 9 9 1555758_a_at 9 10 
219148_at TOPK 6 9 219148_at 6 9 
212022_s_at MKI67 7 8 212022_s_at 7 8 
212023_s_at MKI67 8 9 212023_s_at 9 9 
206364_at KIF14 7 9 206364_at 7 9 
202095_s_at BIRC5 8 11 202095_s_at 5 11 
212020_s_at MKI67 6 8 212020_s_at 7 7 
222958_s_at DEPDC1 8 7 222958_s_at 8 7 
205046_at CENPE 7 7 205046_at 7 6 
228071_at GIMAP7 7 3 228071_at 7 3 
204822_at TTK 7 9 204822_at 7 10 
204641_at NEK2 6 8 204641_at 8 7 
220359_s_at ARPP-21 7 5 220359_s_at 7 6 
228729_at CCNB1 6 8 228729_at 7 10 
203554_x_at PTTG1 7 10 203554_x_at 7 10 
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A.1.3 Comparison of the number of patients who passed selection criteria in 
Table S2C from original article (left) and reproduced (right) in our study  
 









224325_at FZD8 4 8 224325_at 5 7 
235735_at TNFSF8 5 12 235735_at 5 11 
233921_s_at MAD1L1 5 8 233921_s_at 5 7 
236512_at SESN1 3 9 236512_at 3 10 
202917_s_at S100A8 5 6 202917_s_at 5 6 
204150_at STAB1 5 8 204150_at 5 8 
234989_at TncRNA 4 8 234989_at 4 8 
244357_at LOC64744        3 9 244357_at 3 9 
205786_s_at ITGAM 3 8 205786_s_at 3 8 
225685_at CDC42EP3  3 10 225685_at 3 10 
209286_at CDC42EP3  4 9 209286_at 4 9 
201012_at ANXA1 5 4 201012_at 5 4 
204232_at FCER1G 5 6 204232_at 5 5 
219230_at FLJ10970 4 8 219230_at 4 8 
209288_s_at CDC42EP3  4 10 209288_s_at 4 10 
38487_at STAB1 5 8 38487_at 6 8 
1556472_s_at SCML4 5 7 1556472_s_at 5 7 
213975_s_at LYZ 4 4 213975_s_at 4 4 
242551_at   3 9 242551_at 3 8 
210538_s_at BIRC3 4 6 210538_s_at 4 5 
222281_s_at   5 9 222281_s_at 5 9 
227405_s_at FZD8 3 8 227405_s_at 3 7 
203535_at S100A9 4 5 203535_at 4 5 
214414_x_at HBA1 5 5 214414_x_at 4 5 
244358_at   4 7 244358_at 5 7 
1569477_at FOXO3A 5 8 1569477_at 4 8 
241893_at   1 8 241893_at 1 8 



















A.1.4 Comparison of the number of patients who passed selection criteria in 














210052_s_at TPX2 5 9 210052_s_at 4 9 
1554696_s_at TYMS 5 10 1554696_s_at 5 9 
222680_s_at RAMP 4 10 222680_s_at 5 9 
209642_at BUB1 5 8 209642_at 5 9 
219306_at KNSL7 5 9 219306_at 6 9 
218663_at HCAP-G 5 10 218663_at 5 9 
205394_at CHEK1 2 10 205394_at 3 9 
212141_at MCM4 4 9 212141_at 3 9 
220651_s_at MCM10 3 11 220651_s_at 2 11 
202503_s_at KIAA0101 1 10 202503_s_at 1 10 
1554037_a_at ZBTB24 4 6 1554037_a_at 4 5 
242870_at KIAA1238 5 4 242870_at 4 4 
1560610_at FLJ37673 5 7 1560610_at 5 7 
203213_at CDC2 4 10 203213_at 6 11 
203214_x_at CDC2 5 9 203214_x_at 6 9 
219978_s_at NUSAP1 4 9 219978_s_at 5 7 
1554768_a_at MAD2L1 5 9 1554768_a_at 5 10 
204146_at RAD51AP1 4 10 204146_at 4 9 
210559_s_at CDC2 4 9 210559_s_at 3 10 
212281_s_at MAC30 3 8 212281_s_at 3 9 
212949_at BRRN1 3 9 212949_at 3 9 
228033_at E2F7 3 10 228033_at 3 9 
213599_at OIP5 4 11 213599_at 4 9 
218039_at NUSAP1 3 10 218039_at 5 10 
204768_s_at FEN1 2 8 204768_s_at 2 8 
204825_at MELK 4 9 204825_at 4 9 
212142_at MCM4 3 7 212142_at 3 7 
212282_at MAC30 2 9 212282_at 1 9 
218782_s_at ATAD2 1 8 218782_s_at 1 9 
219990_at FLJ23311 3 9 219990_at 4 9 
235609_at BRIP1 3 9 235609_at 2 9 
204127_at RFC3 3 7 204127_at 1 7 
222740_at ATAD2 1 10 222740_at 2 10 
204126_s_at CDC45L 2 10 204126_s_at 2 10 
209773_s_at RRM2                  0 8 209773_s_at 1 8 
218585_s_at RAMP                   0 9 218585_s_at 0 10 
221521_s_at Pfs2 3 9 221521_s_at 4 9 
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A.2  Extra probe sets from our data analysis 
After repeating the analysis of original authors‘ microarray data, we found that the two 
subtypes should be separated in the data analysis. We separated patients (T- and B-ALL) and 
proposed new criteria: log ratio of  1 or higher for at least five out of ten B-ALL patients and 
two out of three T-ALL patients. We also extended the analysis to response between 6 and 24 
hours. The results are shown in the following tables with details of probe sets at each time 
point:  
 0-6 hours 6-24 hours 0-24 hours 
 Induced Repressed Induced Repressed Induced Repressed 
T-ALL 19 10 59 51 58 40 
B-ALL 24 23 16 13 73 108 
 
A.2.1 Extra probe sets found in this study for B-ALL at each time point 
B-ALL 
0-6 hours 6-24 hours 
Induced Repressed Induced Repressed 
1556472_s_at 201291_s_at 1564077_at 1554696_s_at 
202833_s_at 201292_at 1565599_at 201291_s_at 
202908_at 202870_s_at 202917_s_at 201292_at 
202917_s_at 202954_at 204150_at 201890_at 
203761_at 203708_at 206637_at 202503_s_at 
204232_at 203764_at 209286_at 209773_s_at 
204560_at 204709_s_at 228854_at 210559_s_at 
205681_at 204962_s_at 228964_at 211430_s_at 
205883_at 205046_at 233223_at 217022_s_at 
206637_at 206364_at 235735_at 218542_at 
208078_s_at 207165_at 236450_at 218585_s_at 
208438_s_at 207828_s_at 240665_at 220651_s_at 
208949_s_at 209642_at 241893_at 235609_at 
211429_s_at 209709_s_at 242551_at   
219607_s_at 211302_s_at 244357_at   
223194_s_at 217373_x_at 244414_at   
224856_at 218755_at   
226733_at 219918_s_at   
227265_at 222326_at   
228854_at 222958_s_at   
232069_at 223381_at   
232164_s_at 228071_at   
232165_at 235574_at   






Induced Induced Repressed Repressed Repressed 
1553906_s_at 227405_s_at 1554696_s_at 209709_s_at 227921_at 
1560706_at 227611_at 1554733_at 209773_s_at 228033_at 
1564424_at 227762_at 1554768_a_at 210052_s_at 228273_at 
1564525_at 228434_at 1555758_a_at 210334_x_at 228729_at 
1565752_at 228697_at 1556598_at 210559_s_at 229490_s_at 
1569225_a_at 228854_at 1557910_at 210948_s_at 235088_at 
202908_at 229958_at 1560610_at 211341_at 235287_at 
202917_s_at 229985_at 1565602_at 212020_s_at 235574_at 
203543_s_at 232164_s_at 201013_s_at 212021_s_at 235609_at 
203695_s_at 232583_at 201014_s_at 212022_s_at 236641_at 
203760_s_at 233921_s_at 201291_s_at 212023_s_at 241926_s_at 
203761_at 234989_at 201292_at 212141_at 242787_at 
204150_at 235735_at 201577_at 212142_at  
204560_at 236450_at 201890_at 212279_at  
205033_s_at 236512_at 202095_s_at 212281_s_at  
205099_s_at 236931_at 202345_s_at 212282_at  
205786_s_at 240019_at 202503_s_at 212949_at  
205883_at 240038_at 202589_at 213599_at  
206618_at 240665_at 202705_at 214452_at  
206637_at 241893_at 202870_s_at 214710_s_at  
207697_x_at 242551_at 202954_at 215117_at  
208078_s_at 244026_at 203213_at 218039_at  
209286_at 244357_at 203214_x_at 218355_at  
209288_s_at 244697_at 203362_s_at 218542_at  
210001_s_at 38487_at 203554_x_at 218585_s_at  
210146_x_at  203612_at 218662_s_at  
210448_s_at  203755_at 218663_at  
212771_at  203764_at 218755_at  
212912_at  203968_s_at 219148_at  
215528_at  204026_s_at 219306_at  
215602_at  204126_s_at 219493_at  
218638_s_at  204128_s_at 219918_s_at  
219230_at  204146_at 219978_s_at  
221756_at  204444_at 219990_at  
222062_at  204641_at 220085_at  
222281_s_at  204709_s_at 220448_at  
223027_at  204822_at 220651_s_at  
223028_s_at  204825_at 221258_s_at  
223194_s_at  204962_s_at 221521_s_at  
224325_at  205393_s_at 221591_s_at  
224840_at  205394_at 222037_at  
224856_at  206102_at 222680_s_at  
225207_at  206364_at 222740_at  
225239_at  207165_at 223229_at  
225685_at  207828_s_at 223381_at  
225949_at  209172_s_at 223556_at  
226733_at  209642_at 225834_at  
226982_at  209714_s_at 226980_at  
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A.2.2 Extra probe sets found in this study for T-ALL at each time point 
T-ALL 
0-6 hours 6-24 hours 
Induced Repressed Induced Induced Repressed Repressed 
1555372_at 1555745_a_at 1552439_s_at 226530_at 1552742_at 242829_x_at 
1559975_at 203395_s_at 1553338_at 226632_at 1552921_a_at 242894_at 
1562230_at 204115_at 1556682_s_at 226811_at 1552925_at 243649_at 
209992_at 204700_x_at 1557961_s_at 230690_at 1555372_at 244523_at 
215447_at 205094_at 201061_s_at 231005_at 1557257_at  
226733_at 205863_at 201694_s_at 235384_at 1558143_a_at  
227062_at 210279_at 202917_s_at 238999_at 1559119_at  
228434_at 212998_x_at 202975_s_at 240336_at 1561973_at  
230175_s_at 219918_s_at 202976_s_at 243398_at 1562230_at  
231437_at 225834_at 203395_s_at 243904_at 1569600_at  
232231_at   203502_at 244447_at 201761_at  
232744_x_at   203535_at 38671_at 201890_at  
235213_at   203574_at  202503_s_at  
235412_at   203936_s_at  202643_s_at  
235735_at   204018_x_at  204146_at  
237009_at   204081_at  204285_s_at  
241819_at   204115_at  204444_at  
242210_at   204419_x_at  204768_s_at  
242248_at   204848_x_at  205024_s_at  
  205033_s_at  205347_s_at  
  205262_at  205559_s_at  
  205653_at  209522_s_at  
  205780_at  209773_s_at  
  205863_at  210001_s_at  
  205950_s_at  210034_s_at  
  206390_x_at  210356_x_at  
  206655_s_at  212195_at  
  209301_at  213459_at  
  209458_x_at  214805_at  
  210314_x_at  215330_at  
  210384_at  216834_at  
  210982_s_at  218585_s_at  
  211560_s_at  218782_s_at  
  211699_x_at  220651_s_at  
  211745_x_at  222018_at  
  211899_s_at  222303_at  
  212235_at  222680_s_at  
  213515_x_at  223570_at  
  213817_at  226287_at  
  213975_s_at  229882_at  
  214146_s_at  232344_at  
  215894_at  234150_at  
  217414_x_at  236439_at  
  217478_s_at  236528_at  
  219672_at  239504_at  
  222164_at  241403_at  





Induced Induced Repressed Repressed 
1553338_at 215150_at 1554696_s_at 222740_at 
1557961_s_at 215447_at 201291_s_at 223062_s_at 
1569153_at 215679_at 202503_s_at 223475_at 
200665_s_at 215894_at 202870_s_at 223570_at 
201060_x_at 216067_at 204127_at 223666_at 
201061_s_at 219049_at 204285_s_at 224797_at 
202975_s_at 220585_at 204439_at 225285_at 
202976_s_at 221756_at 204695_at 225655_at 
203949_at 221757_at 204768_s_at 226013_at 
204081_at 225202_at 204836_at 226677_at 
204419_x_at 225328_at 205347_s_at 228190_at 
205033_s_at 226530_at 205552_s_at 228273_at 
205857_at 227309_at 205898_at  
206390_x_at 228854_at 206102_at  
206655_s_at 230690_at 206749_at   
206828_at 231332_at 207826_s_at   
208078_s_at 232431_at 208782_at  
209771_x_at 232744_x_at 210052_s_at  
210244_at 235343_at 212141_at  
210971_s_at 235412_at 214710_s_at  
212364_at 235568_at 216510_x_at  
212365_at 235735_at 218585_s_at  
213093_at 237324_s_at 219918_s_at  
213515_x_at 238342_at 222036_s_at  
214146_s_at  222680_s_at  
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